Prevention / treatment of pseudomonas aeruginosa infection
By developing novel methylated rhamnosose-containing glycan and protein-glycan conjugates, combined with selective antibodies, the existing antibiotic-resistant Pseudomonas aeruginosa vaccine and high-cost treatment have been solved, and the problem of the existing antibiotic-resistant Pseudomonas aeruginosa vaccine and high-cost treatment has been achieved. Effective prevention and treatment of Pseudomonas aeruginosa.
Patent Information
- Application Number
- CN202380036901.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-07
- Filing Date
- 2023-03-07
- Publication Date
- 2024-12-06
AI Technical Summary
The existing antibiotic-resistant Pseudomonas aeruginosa vaccine has not yet been launched, and antibody treatments for surface carbohydrate targets have problems of inefficiency and high cost. The existing sugar conjugate vaccine has not been approved for human use.
Develop novel methylated rhamnosose-containing glycan and protein-glycan conjugates as antigens, combining selective antibodies for the treatment and prevention of Pseudomonas aeruginosa infection, and to form a vaccine by conjugating with carrier proteins, And use these antigens and antibodies to improve immune response in subjects.
Effective prevention and treatment of Pseudomonas aeruginosa was achieved, new antibiotic alternatives were provided, treatment costs were reduced, and immune responses were improved.
Smart Images

Figure CN119095871A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to the identification and synthesis of novel methylated rhamnose-containing glycans, protein-glycan conjugates and their use as antigens and vaccines. Antibodies that selectively bind to the glycans and glycoconjugates are also disclosed. The use of these glycans, glycoconjugates, corresponding compositions and antibodies in the treatment and prevention of Pseudomonas aeruginosa infections is disclosed. Background Art
[0002] In recent years, large pharmaceutical companies have moved away from antibiotic research, in part because of the high risks and costs associated with development compared to the potential rewards [1]. An alternative to new antibiotics is the development of vaccines to prevent infections caused by antibiotic-resistant bacteria [2]. No vaccines against antibiotic-resistant P. aeruginosa are yet to be marketed, although some are in clinical trials [3-5].
[0003] P. aeruginosa has a wide range of glycans on its surface. Therefore, glycoconjugate vaccines have been explored [5-7], although none of these vaccines have been approved for human use [5].
[0004] In addition to vaccine approaches, the therapeutic potential of antibodies against surface carbohydrate targets is also a consideration. Current examples of this approach include targeting Psl by Medimmune and targeting LPS O-antigen by Aridis [8-11]. Medimmune's bispecific antibody approach has not advanced beyond Phase 1 trials
[12] ; however, the potential of DNA-encoded mAb therapy (DMab) shows promise and may alleviate the high cost of direct mAb therapy
[13] . These studies suggest that antibodies against Pseudomonas aeruginosa may have therapeutic applications. Summary of the invention
[0005] The present disclosure generally relates to compounds and compositions and vaccines comprising novel isolated or synthesized Pseudomonas aeruginosa glycan antigens, optionally linked to a carrier protein in the form of a glycoconjugate. Antibodies that selectively bind to Pseudomonas aeruginosa glycans or glycoconjugates are also provided. Uses and methods of treatment are also disclosed, as well as methods of increasing and utilizing immune responses in subjects.
[0006] In one aspect, the present invention provides an antigenic compound comprising an oligosaccharide portion of formula A:
[0007] α-Rha3OMe(-4α-Rha3OMe) n -Formula A
[0008] wherein n is 1-5, preferably 2-4, and wherein the 2-position in each Rha3OMe sugar moiety is independently substituted with -OAc or -OH.
[0009] In one aspect, the present invention provides an antigenic compound comprising an oligosaccharide portion of formula A1:
[0010] α-Rha3OMe(-4α-Rha3OMe) n -X-type A1
[0011] wherein n is 1-5 (preferably 2-4), and X is -H or -(4α-Man3OMe) m - a connecting handle; and m is 0, 1 or 2, preferably 0 or 1; wherein the 2-position in each Rha3OMe sugar moiety is independently substituted by -OAc or -OH.
[0012] In one aspect, the invention provides antigenic compounds wherein the linker handle is -(CH2) z NH2 or 2-glyceraldehyde, wherein z is an integer selected from the group consisting of 1 to 5. In one aspect, when m is 0, the linking handle is -(CH2)2NH2, -(CH2)3NH2 or -(CH2)3NH2.
[0013] In one aspect, if m is 1 or 2, the linking handle is 2-glyceraldehyde.
[0014] In one aspect, the invention provides an antigenic compound selected from the group consisting of:
[0015] α-D-Rha3OMe-4-(α-D-Rha3OMe-4)4-4-α-D-Man3OMe-2-glyceraldehyde-1d(OS2);
[0016] 3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside (pentasaccharide);
[0017] 3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-Methyl-α-D-rhamnopyranoside (tetrasaccharide)
[0018] 3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside (trisaccharide)
[0019]
[0020] In one aspect, the present invention provides an antigenic compound comprising a linker for attachment to a carrier protein and having formula A2:
[0021] α-Rha3OMe(-4α-Rha3OMe) n -X-Connector Type A2
[0022] Where n is 1-5, and X is -(4α-Man3OMe) m -(Connecting handle) p -; wherein m is 0, 1 or 2, preferably 0 or 1; and p is 0 or 1; and wherein the 2-position in each Rha3OMe sugar moiety is independently substituted with -OAc or -OH
[0023] In one aspect, the invention provides an antigenic compound comprising a conjugate of the antigenic compound conjugated to a carrier protein.
[0024] In one aspect, the conjugate has the formula
[0025] α-Rha3OMe(-4α-Rha3OMe) n -X-(Connector) q -Carrier protein formula A3
[0026] wherein n is 1-5 (preferably 2-4), and X is -(4α-Man3OMe) m -(Connecting handle) p -; wherein m is 0, 1 or 2, preferably 0 or 1; and p is 0 or 1; and q is 0 or 1; and wherein the 2-position in each Rha3OMe sugar moiety is independently substituted with -OAc or -OH.
[0027] In one aspect, the carrier protein of the present invention comprises CRM197, tetanus toxoid (TT), Pseudomonas aeruginosa protein, human serum albumin (HSA), bovine serum albumin (BSA), diphtheria toxin B fragment (DTFB), DTFB C8, diphtheria toxoid (DT), C fragment of TT, pertussis toxoid, cholera toxoid, Escherichia coli LT, Escherichia coli ST, or exotoxin from Pseudomonas aeruginosa. In one aspect, the carrier protein is CRM197, TT or Pseudomonas aeruginosa protein.
[0028] In one aspect, the invention provides a pharmaceutical composition comprising a compound or conjugate described herein; and a pharmaceutically acceptable diluent, carrier or excipient. In one aspect, the pharmaceutical composition is a vaccine.
[0029] In one aspect, the invention provides a method of enhancing an immune response in a subject, comprising administering to the subject: a compound, conjugate, or pharmaceutical composition described herein.
[0030] In one aspect, the invention provides a method of preventing a Pseudomonas aeruginosa infection in a subject, the method comprising administering to the subject: a compound, conjugate, or pharmaceutical composition described herein.
[0031] In one aspect, the invention provides a compound, a conjugate, a vaccine or a pharmaceutical composition for use in preventing Pseudomonas aeruginosa infection.
[0032] In one aspect, the invention provides an antibody or antigen-binding fragment thereof that selectively binds to a compound or conjugate described herein, LPS of Pseudomonas aeruginosa, and or cells of Pseudomonas aeruginosa, wherein optionally, the antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.
[0033] In one aspect, the present invention provides an antibody or antigen-binding fragment thereof that selectively binds to an isolated oxidized A-band terminal epitope antigen (OS2), wherein optionally, the antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.
[0034] In one aspect, the invention provides an antibody or antigen-binding fragment thereof described herein that is a chimeric or humanized antibody.
[0035] In one aspect, the present invention provides an antibody or an antigen-binding fragment thereof, wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain variable region, the heavy chain variable region comprising a variable heavy chain CDR1, a variable heavy chain CDR2 and a variable heavy chain CDR3,
[0036] ● wherein the variable heavy chain CDR1 comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 10 and SEQ ID NO: 19;
[0037] ● wherein the variable heavy chain CDR2 comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 11 and SEQ ID NO: 20; and
[0038] ●Wherein, the variable heavy chain CDR3 comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, SEQ ID NO:12 and SEQ ID NO:21.
[0039] In one aspect, the present invention provides an antibody or antigen-binding fragment thereof, comprising a light chain variable region, the light chain variable region comprising a variable light chain CDR1, a variable light chain CDR2 and a variable light chain CDR3,
[0040] ● wherein the variable light chain CDR1 comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 6, SEQ ID NO: 15 and SEQ ID NO: 24;
[0041] ● wherein the variable light chain CDR2 comprises an amino acid sequence selected from the group consisting of: GTS and RVS; and
[0042] ●Wherein, the variable light chain CDR3 comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:7, SEQ ID NO:16 and SEQ ID NO:25.
[0043] In one aspect, the present invention provides an antibody or antigen-binding fragment thereof comprising a combination of a heavy chain variable region (VH) and a light chain variable region (VL), wherein the combination is selected from the group consisting of:
[0044] ● a VH comprising the amino acid sequence of SEQ ID NO: 4 and a VL comprising the amino acid sequence of SEQ ID NO: 8;
[0045] ● a VH comprising the amino acid sequence of SEQ ID NO: 13 and a VL comprising the amino acid sequence of SEQ ID NO: 17; and
[0046] ● A VH comprising the amino acid sequence of SEQ ID NO:22 and a VL comprising the amino acid sequence of SEQ ID NO:26.
[0047] In one aspect, the invention provides an antibody or antigen-binding fragment thereof for use in treating a Pseudomonas aeruginosa infection.
[0048] In one aspect, the present invention provides an antibody or antigen-binding fragment thereof for use in diagnosing a Pseudomonas aeruginosa infection.
[0049] In one aspect, the invention provides a method of treating a Pseudomonas aeruginosa bacterial infection in an animal comprising administering to the animal an antibody or antigen-binding fragment thereof described herein.
[0050] In one aspect, the invention provides a method for diagnosing a Pseudomonas aeruginosa bacterial infection in an animal, comprising contacting a test sample with an antibody or antigen-binding fragment thereof described herein, and detecting specific binding thereto.
[0051] In one aspect, the present invention provides a synthetic method for preparing a compound of formula A1, wherein m is 0, the method comprising:
[0052] ● deprotecting the anomeric portion of the 3-O-methylated rhamnopyranoside to form 3-O-methylated rhamnopyranose;
[0053] ● acetylation of 3-O-methylated rhamnopyranose to form acetylated 3-O-methylated rhamnopyranoside;
[0054] ● partially deprotecting the O-4 of the acetylated 3-O-methylated rhamnopyranoside to form a deprotected acetylated 3-O-methylated rhamnopyranoside;
[0055] ● coupling the O-4 deprotected acetylated 3-O-methylated rhamnopyranoside to form the acetylated 3-O-methylated oligosaccharide;
[0056] ● deprotecting the O-4 of the acetylated 3-O-methylated oligosaccharide to form an O-4 deprotected acetylated 3-O-methylated oligosaccharide; and
[0057] • Deacetylation of the partially deprotected acetylated 3-O-methylated oligosaccharide to form a compound of formula A1.
[0058] In one aspect, the present invention provides a synthetic method for preparing a compound of formula A1, wherein X is a linker, the method comprising the following steps:
[0059] glycosylation of an activated O-3 methylated rhamnopyranoside intermediate at 1-O with a linker handle comprising a protected amine, wherein the activated monorhamnopyranoside intermediate comprises a protecting group at glycosylation site 4-O, and forming a protected 1-O glycoside intermediate;
[0060] ● Removal of the protecting group from 4-O and formation of a deprotected 1-O glycoside intermediate;
[0061] ● coupling the deprotected 1-0 glycoside intermediate to an activated O-3 methylated rhamnopyranoside intermediate, wherein the activated rhamnopyranoside intermediate comprises a protecting group at 4-0, and forming a protected methylated disaccharide, trisaccharide, tetrasaccharide or pentasaccharide; and
[0062] • Removal of all protecting groups from a protected oligosaccharide, wherein the oligosaccharide is preferably a trisaccharide, a tetrasaccharide or a pentasaccharide. BRIEF DESCRIPTION OF THE DRAWINGS
[0063] Figure 1 The structures of some of the isolated compounds described herein are shown.
[0064] Figure 2 The band-A polysaccharide obtained from LPS by alkali treatment (lower trace) and its NaIO4 oxidation product OS1 (upper trace) are shown. 1 H NMR spectrum. * Marks impurities, R-rhamnose H-1 from rhamnose repeating unit, Rm-anomeric signal of 3-OMe-Rha.
[0065] Figure 3 Shown is an overlay of the gCOSY (70% grey), TOCSY (50% grey) and ROESY (black) spectra of A-PS isolated from the Pseudomonas aeruginosa PAO1 wzy mutant by mild acid hydrolysis of LPS (anomeric region).
[0066] Figure 4 The positive ion mode ESI-MS spectrum of OS1 is shown. The two peaks marked at m / z 1117.8 and 1122.6 correspond to the ammonium and sodium adducts of Rha5Man1 tetrasaccharide alcohol-1d1Me6.
[0067] Figure 5A and 5B The L-monosaccharides recorded in CD3OD are shown. Figure 5A ) and D-monosaccharides ( Figure 5B )of 1 H-NMR spectrum.
[0068] Figure 6 GC-MS traces of derivatized octyl glycosides of OS1 and standards are shown.
[0069] Figure 7 Shown is the structure of the Pseudomonas aeruginosa A-banded 3-O-methyl D-rhamnan pentasaccharide tip attached to 3-O-methyl D-mannose and glyceraldehyde prior to conjugation to CRIM.
[0070] Fig. 8A , 8B , 8C and 8D show BSA ( Fig. 8A )、BSA-3-O-methyl rhamnose conjugate ( Figure 8B )、CRM( Figure 8C ) and CRM-3-O-methyl rhamnose conjugate ( Fig.8D ) by MALDI-MS analysis.
[0071] Fig. 9A and Fig. 9B ELISA titrations of D56 sera from mice immunized with CRM-3-O-methylrhamnan conjugate (M1-M6) are shown, upper curves versus BSA-3-O-methylrhamnan conjugate, lower curves versus PAO1 wt LPS, IgM antibodies on the left, IgG antibodies on the right ( Fig. 9A ), or ELISA titration of D72 sera from rabbits immunized with CRM-3-O-methylrhamnan conjugate (R1-R2), left relative to PAO1 wt LPS and right relative to BSA-3-O-methylrhamnan conjugate ( Fig. 9B ).
[0072] Fig.10 Shown are ELISA analyses of binding of hybridoma supernatants containing 1B1, 3B8 and 3C4 mAbs (used neat) to purified LPS antigen of P. aeruginosa strains PAO1wt, PAO1(wzy::Gm)(Δpa5457) and PAO1(wzy::Gm)(Δpa5458).
[0073] Fig.11A , 11B and 11C show 1B1( Fig.11A )、3B8( Fig. 11B ) and 3C4( Fig. 11C ) ELISA analysis of binding of purified monoclonal antibodies (mAbs) (all at 100 μg / ml) to killed whole cells of Pseudomonas aeruginosa strains NRCC #6678, 6668-70, 6954-60 and negative control strains M. catarrhalis 6541 and N. meningitidis 6263 (see Table 1 for full details of the strains).
[0074] Fig.12 The purified mAbs (all at 100 μg ml) of 3C4 (panel A), 3B8 (panel B), and 1B1 (panel C) are shown. -1 ) and whole cell ELISA analysis of killing of clinical isolates of Pseudomonas aeruginosa strains NRCC #6678, 6944-53 (see Table 1 for full details of the strains).
[0075] Fig.13A and 13B Pseudomonas aeruginosa strain PAO1 BAA-47 ( Fig.13A ) and Pseudomonas aeruginosa strain 537 ( Fig. 13B ) of the opsonophagocytic assay titration curves of mAbs 1B1 (solid line), 3B8 (dashed line) and 3C4 (dotted line).
[0076] Fig.14AShown is a competition ELISA between mAbs 1B1 and 3C4 for purified PAO1 LPS. mAb 1B1 was titrated onto an ELISA plate coated with PAO1 LPS at the dilution shown on the x-axis. The plate was washed and mAb 3C4 was added at a constant concentration (62.5 μg / ml). A second mAb specific for mAb 3C4 was added and the absorbance was measured after adding a colorimetric reagent (line with square markers). The absorbance obtained when 3C4 was added to the plate without 1B1 competition is shown by the line with triangle markers.
[0077] Fig. 14B Shown is a competition ELISA between mAbs 3B8 and 3C4 for purified PAO1 LPS. mAb 3B8 is titrated onto an ELISA plate coated with PAO1 LPS at a concentration shown on the x-axis. The plate is washed and mAb 3C4 is added at a constant concentration (62.5 μg / ml). A second mAb specific to mAb 3C4 is added and absorbance is measured after adding a colorimetric reagent (line with square marks). The absorbance obtained when 3C4 is added to the plate without 3B8 competition is shown by a line with a triangle mark.
[0078] Fig.15A , 15B and 15C show mAbs 1B1 ( Fig.15A )、3C4( Fig. 15B ) and 3B8( Fig. 15C ) with LPS (left sub-figure; square markers-Pseudomonas aeruginosa PAO1 BAA-47, inverted triangle markers-Pseudomonas aeruginosa (wzy::Gm) (Δpa5458), diamond markers-Neisseria meningitidis galE / lpt3 and circle markers-PBS control) or synthetic oligosaccharides representing terminally methylated rhamnosaccharides (right sub-figure; solid circle markers-pentasaccharides, hollow square markers-tetrasaccharides, hollow circle markers-trisaccharides, inverted triangle markers-disaccharides, diamond markers-disaccharides with linkers, triangle markers-L monomers, solid square markers-D-monomers) inhibition ELISA against Pseudomonas aeruginosa PAO1 BAA-47 LPS. As shown on the x-axis, serial dilutions of LPS or synthetic oligosaccharides were combined with 10 μg / ml mAb in equal volumes. After 1 h incubation, 100 μl of the inhibition mixture was added to the PAO1 BAA-47 LPS-coated plate. A secondary mAb specific for the primary mAb is added and the absorbance is measured after the addition of the colorimetric reagent. The absorbance obtained when the mAb is no longer inhibited by additional LPS or synthetic oligosaccharides is equal to the inhibition rate by PBS.
[0079] Fig.15D , 15Eand 15F showed mAbs 1B1 ( Fig.15D )、3C4( Fig.15E ) and 3B8( Fig.15F ) with LPS (left panel; square markers-Pseudomonas aeruginosa PAO1 BAA-47, inverted triangle markers-Pseudomonas aeruginosa (wzy::Gm) (Δpa5458), diamond markers-Neisseria meningitidis galE / lpt3 and circle markers-PBS control) or synthetic oligosaccharides representing terminally methylated rhamnosaccharides (right panel; solid circle markers-pentasaccharides, hollow square markers-tetrasaccharides, hollow circle markers-trisaccharides, inverted triangle markers-disaccharides, diamond markers-disaccharides with linkers, triangle markers-L-monomers, blue-D-monomers) against inhibition ELISA of Pseudomonas aeruginosa PAO1 BAA-47 whole cells. As indicated on the x-axis, serial dilutions of LPS or synthetic oligosaccharides were combined with 10 μg / ml mAb in equal volumes. After 1 h incubation, 100 μl of the inhibition mixture was added to the plate coated with PAO1 BAA-47 whole cells. A secondary mAb specific for the primary mAb is added and the absorbance is measured after the addition of the colorimetric reagent. The absorbance obtained when the mAb is no longer inhibited by additional LPS or synthetic oligosaccharides is equal to the inhibition rate by PBS.
[0080] Fig.16 SPR sensorgrams showing binding of synthetic oligosaccharides to a high density 1B1 IgM surface are provided. Various concentration ranges of synthetic oligosaccharides (see Experimental) were flowed over IgM 1B1 and an irrelevant IgM, FN 4F1. Kinetics and affinities are reported in Table 5. Mcat lgt2 / 4: Control oligosaccharide.
[0081] Fig.17 The disaccharide of the compound is shown 1 H NMR spectroscopy (600 MHz, CD3OD).
[0082] Fig.18 The trisaccharide of the compound is shown 1 H NMR spectrum (500 MHz, CD3OD).
[0083] Fig.19 The tetrasaccharide of the compound is shown 1 H NMR spectrum (500 MHz, CD3OD).
[0084] Fig. 20 The pentasaccharide of the compound is shown 1 H NMR spectroscopy (600 MHz, CD3OD).
[0085] Fig.21 The disaccharide of the compound is shown 1H NMR spectrum (600 MHz, D2O).
[0086] Fig. 22 A reaction scheme for the synthesis of D-monosaccharides is shown (Scheme 1).
[0087] Fig.23 A reaction scheme for the synthesis of L-monosaccharides is shown (Scheme 2).
[0088] Fig.24 A reaction scheme for the synthesis of 3-O-methyl D-rhamnose oligosaccharides is shown (Scheme 3).
[0089] Fig.25 A reaction scheme for the addition of an aminoethyl linker to a disaccharide is shown (Scheme 4).
[0090] Fig.26A SDS-PAGE (left) and (right) of HSA (lane 2) and HSA-3-O-methylrhamnose pentasaccharide conjugate (two concentrations, lanes 3 and 4) are shown. Fig.26B Western blot analysis (with mAb 1B1; right) is shown. Molecular weight markers are shown in lane 1.
[0091] Figure 27 shows MALDI-MS analysis of a) HSA, b) HSA-3-O-methylrhamnan pentasaccharide conjugate.
[0092] Fig.28A , 28B , 28C, 28D, 28E, 28F, 28G and 28H show ELISA for the ability of sera from mice immunized with the synthetic conjugate to recognize P. aeruginosa LPS. Titrations of IgM and IgG antibodies at different time points are shown.
[0093] Fig.29 ELISA of antisera derived from synthetic oligosaccharide conjugates with killed whole cells is shown.
[0094] Fig.30 Reaction schemes for the synthesis of trisaccharides, tetrasaccharides, and pentasaccharides including a connecting handle and an optional linker are shown.
[0095] Fig.31A The NMR of 3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(2,2-dimethoxybutylcarbonyl)amino]ethyl 3-O-methyl-α-D-rhamnopyranoside (S22) is shown. 1 H NMR, 600 MHz, CD3OD.
[0096] Fig.31BThe NMR of 3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(2,2-dimethoxybutylcarbonyl)amino]ethyl 3-O-methyl-α-D-rhamnopyranoside (S23) is shown. 1 H NMR, 600 MHz, CD3OD.
[0097] Fig.32 The NMR of 3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(2,2-dimethoxybutylcarbonyl)amino]ethyl 3-O-methyl-α-D-rhamnopyranoside (S24) is shown. 1 H NMR, 600 MHz, CD3OD.
[0098] Fig.33 mAb 1B1 was co-administered with LPS (left graph; P. aeruginosa PAO1 BAA-47 (wt); N. meningitidis galE / lpt3; PBS control) or synthetic oligosaccharides with linkers representing terminally methylated rhamnosaccharides (right graph; pentasaccharides; tetrasaccharides; trisaccharides; PBS control). Inhibition ELISA against P. aeruginosa PAO1 BAA-47 (wt) LPS. Serial dilutions as indicated on the x-axis.
[0099] Fig.34A . Before CRM-oligosaccharide conjugate immunization, recognition relative to BSA-oligosaccharide conjugates was determined by ELISA using pre-immune mouse serum IgM (1:40 dilution). Mouse MRha3V 1-5 will receive trisaccharide CRM conjugates, mouse MRha4V6-10 will receive tetrasaccharide CRM conjugates, and mouse MRha5V 11-15 will receive pentasaccharide CRM conjugates.
[0100] Fig.34B . Prior to CRM-oligosaccharide conjugate immunization, recognition relative to Pa wt LPS was determined by ELISA using pre-immune mouse serum IgM titration. Mouse MRha3V 1-5 will receive trisaccharide CRM conjugates, mouse MRha4V 6-10 will receive tetrasaccharide CRM conjugates, and mouse MRha5V 11-15 will receive pentasaccharide CRM conjugates.
[0101] Fig.35A.After immunization with CRM-oligosaccharide conjugates, recognition relative to BSA-trisaccharide conjugates was determined by ELISA using terminal bleed mouse serum IgM titration. Mouse MRha3V 1-5 received trisaccharide CRM conjugates, mouse MRha4V 6-10 received tetrasaccharide CRM conjugates, and mouse MRha5V 11-15 received pentasaccharide CRM conjugates.
[0102] Fig.35B .After immunization with CRM-oligosaccharide conjugates, recognition relative to BSA-tetrasaccharide conjugates was determined by ELISA using terminal bleed mouse serum IgM titration. Mouse MRha3V 1-5 received trisaccharide CRM conjugates, mouse MRha4V 6-10 received tetrasaccharide CRM conjugates, and mouse MRha5V 11-15 received pentasaccharide CRM conjugates.
[0103] Fig.35C . Recognition relative to BSA-pentasaccharide conjugates was determined by ELISA using terminal bleed mouse serum IgM titration following CRM-oligosaccharide conjugate immunization. Mouse MRha3V 1-5 received trisaccharide CRM conjugates, mouse MRha4V 6-10 received tetrasaccharide CRM conjugates, and mouse MRha5V 11-15 received pentasaccharide CRM conjugates.
[0104] Fig.35D . Recognition relative to LPS was determined by ELISA using terminal bleed mouse serum IgM titration after CRM-oligosaccharide conjugate immunization. Mouse MRha3V 1-5 received a trisaccharide CRM conjugate, mouse MRha4V 6-10 received a tetrasaccharide CRM conjugate, and mouse MRha5V 11-15 received a pentasaccharide CRM conjugate.
[0105] Fig.36A . Before immunization with CRM-oligosaccharide conjugates, recognition of the conjugates relative to BSA-oligosaccharide conjugates was determined by ELISA using pre-immune mouse serum IgM (1:40 dilution). Mice MRha3V 1-5 will receive trisaccharide CRM conjugates, mice MRha4V6-10 will receive tetrasaccharide CRM conjugates and mice MRha5V 11-15 will receive pentasaccharide CRM conjugates.
[0106] Fig.36B . Prior to CRM-oligosaccharide conjugate immunization, recognition relative to Pa wt LPS was determined by ELISA using pre-immune mouse serum IgG titration. Mouse MRha3V 1-5 will receive trisaccharide CRM conjugates, mouse MRha4V 6-10 will receive tetrasaccharide CRM conjugates, and mouse MRha5V 11-15 will receive pentasaccharide CRM conjugates.
[0107] Fig.37A .After CRM-oligosaccharide conjugate immunization, recognition relative to BSA-oligosaccharide and Pa wt LPS was determined by ELISA using final bleeding mouse serum IgG (1:20 dilution) as indicated. Mouse MRha3V 1-5 received trisaccharide CRM conjugates, mouse MRha4V 6-10 received tetrasaccharide CRM conjugates, and mouse MRha5V 11-15 received pentasaccharide CRM conjugates. Preimmune serum (Pre) was included as a negative control, and mAb 3C4 (isotype IgG2b) was included as a positive control for Pa wt LPS.
[0108] Fig.37B .After CRM-oligosaccharide conjugate immunization, ELISA was used to determine recognition of LPS relative to Pa wt, Pa wzy5457, Pa wzy5458, and Nm wt (negative control) using pooled pre-immune and final bleed mouse serum IgG (1:40 dilution) as indicated. Mouse MRha3V 1-5 received trisaccharide CRM conjugates, mouse MRha4V 6-10 received tetrasaccharide CRM conjugates, and mouse MRha5V 11-15 received pentasaccharide CRM conjugates. Pre-immune serum (Pre) was included as a negative control.
[0109] Fig.38A . Recognition relative to BSA-oligosaccharide conjugates was determined by ELISA using pre- and post-immune (D70) rabbit sera (1:500 and 1:1500 dilutions) before and after immunization with CRM-oligosaccharide conjugates. Rabbit RRha3V 1-2 received a trisaccharide CRM conjugate, rabbit RRha4V 3-4 received a tetrasaccharide CRM conjugate, and rabbit RRha5V 5-6 received a pentasaccharide CRM conjugate.
[0110] Fig.38B . Recognition of LPS relative to Pa wt, Pa wzy5457 and Pa wzy5458 was determined by ELISA using pre- and post-immune (D70) rabbit sera titrated before and after immunization with CRM-oligosaccharide conjugates. Rabbit RRha3V 1-2 received a trisaccharide CRM conjugate, rabbit RRha4V 3-4 received a tetrasaccharide CRM conjugate, and rabbit RRha5V 5-6 received a pentasaccharide CRM conjugate.
[0111] Fig.39A . ELISA analysis of binding of pooled pre- and post-immune mouse sera (IgM and IgG, all diluted 1:40) to killed whole cells of P. aeruginosa strains NRCC 6678, 6667-70, 6954-60 and the negative control strain Moraxella catarrhalis 6541 (see Table 7 for full details of strains).
[0112] Fig.39B . ELISA analysis of binding of individual pre- and post-immune rabbit sera (all diluted 1:1500) to killed whole cells of P. aeruginosa strains NRCC 6678, 6667-70, 6954-60 and the negative control strain Moraxella catarrhalis 6541 (see Table 7 for full details of strains).
[0113] Fig.39C . ELISA analysis of binding of individual pre- and post-immune rabbit sera (all diluted 1:1500) to whole cells killed by clinical P. aeruginosa strains NRCC 6678, 6944-46, 6948-53 and negative control strains N. meningitidis 6263 and M. catarrhalis 6541 (see Table 7 for full details of strains). DETAILED DESCRIPTION
[0114] The present invention is based in part on the identification of new Pseudomonas aeruginosa polysaccharide structures by NMR and chemical analysis.It is believed that the structures provided herein are the first identification or first correct identification of the Pseudomonas aeruginosa A-band terminal epitope antigen (A-PS).
[0115] Pseudomonas aeruginosa (also known as Pseudomonas aeruginosa, Pseudomonas aeruginosa, P.aeruginosa) is an opportunistic bacterial pathogen and a pathogen of several potentially life-threatening infections, including healthcare-associated and ventilator-associated pneumonia, chronic lung infections in cystic fibrosis (CF) patients, and burns and soft tissue infections. The prevalence of drug-resistant Pseudomonas aeruginosa infections is increasing. Therefore, in some instances, the term "Pseudomonas aeruginosa" refers to pathogenic strains of Pseudomonas aeruginosa, including but not limited to antibiotic-resistant strains, such as Pseudomonas aeruginosa strains resistant to β-lactam antibiotics (e.g., penicillin), piperacillin, imipenem, tobramycin or ciprofloxacin. In some embodiments, the term "Pseudomonas aeruginosa" refers to pathogenic strains that infect patients with cystic fibrosis.
[0116] The term "infection" refers to any microbial infection of a subject's body. An infection includes the invasion of a microorganism into a patient's body and the subsequent replication of the microorganism within the subject's body. In a specific example, the microorganism is Pseudomonas aeruginosa.
[0117] As used herein, the term "subject" refers to an animal, and may include, for example, domestic animals such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), laboratory animals (e.g., mice, rabbits, rats, guinea pigs, etc.), mammals, non-human mammals, primates, non-human primates, rodents, birds, reptiles, amphibians, fish, and any other animals. In a specific example, the subject is a human.
[0118] Glycan
[0119] As used herein, the terms "carbohydrate", "glycan", "sugar", "oligosaccharide" and "polysaccharide" are used interchangeably and refer to oligomers or polymers composed of sugar monomers typically connected by glycosidic bonds (also referred to as linking groups in this article). Within a polysaccharide, the monosaccharide monomers can be all the same or they can be different. Common monomers include, but are not limited to, trioses, tetroses, pentoses, glucose, fructose, galactose, rhamnose and 3-O-methyl rhamnose, xylose, arabinose, lyxose, allose, altrose, mannose and 3-O-methyl mannose, gulose, idose (iodose), ribose, mannoheptulose, sedoheptulose and talose. Amino sugars can also be monomers within a polysaccharide. Polysaccharides containing such sugars are referred to herein as amino polysaccharides. As used herein, amino sugars are sugar molecules containing amine groups to replace hydroxyl groups, or in some embodiments, sugars derived from such sugars. Examples of amino sugars include, but are not limited to, glucosamine, galactosamine, N-acetylglucosamine, N-acetylgalactosamine, sialic acid (including but not limited to N-acetylneuraminic acid and N-glycolylneuraminic acid), and L-daunosamine.
[0120] In some cases, polysaccharides can be modified with one or more non-polysaccharide components, including but not limited to tags, connection handles, linkers, spacers, carriers, etc. In some embodiments, polysaccharides can include glycoconjugates. Glycoconjugates can include but are not limited to glycoproteins, glycolipids or proteoglycans. Glycoproteins include any protein containing covalently linked oligosaccharide chains (glycans). Unless otherwise indicated, the polysaccharide nomenclature used herein follows the IUB-IUPAC Joint Committee on Biochemical Nomenclature (JCBM) recommendations 1980. See JCBN, 1982, J.Biol.Chem.257:3352-3354.
[0121] As used herein, for example in the accompanying drawings, the label "D-monosaccharide" specifically refers to 3-O-methyl-rhamnose, and as used herein, for example in the accompanying drawings, the label "L-monosaccharide" specifically refers to 3-O-methyl-L-rhamnose, and as used herein, for example in the accompanying drawings, the label "disaccharide" specifically refers to: 3-O-methyl-α-D-rhamnose-(1→4)-3-O-methyl-D-rhamnose, and it will be obvious from the context.
[0122] As used herein, the term "antigen" refers to a substance that can induce and mediate an immune response. The immune response stimulated by an antigen can be either humoral or cellular, or both, and is usually antigen-specific. Antigens that stimulate or enhance an immune response are referred to as immunogenic and may be referred to as immunogens. Compositions comprising antigens may be referred to as "antigenic compositions" or "immunogenic compositions".
[0123] Therefore, antigen is a substance that can be bound by an antibody molecule or by a T cell receptor. Many types of biomolecules and other molecules can serve as antigens. For example, an antigen can be derived from such molecules, including but not limited to proteins, peptides, carbohydrates, polysaccharides, oligosaccharides, sugars, lipids, phospholipids, glycophospholipids and other molecules, and fragments and / or combinations thereof.
[0124] Antigens may be derived from an inherent source or from a source of a particular mammal or other animal (e.g., from an infectious source).Antigens may have multiple antigenic determinants, such that exposure of a mammal to an antigen may produce multiple corresponding antibodies or cellular immune responses with different specificities.
[0125] As described above, in specific examples, isolated or chemically synthesized glycan antigens from Pseudomonas aeruginosa are described.
[0126] Antigens can be used to sensitize hosts by presenting antigens in combination with MHC molecules at the cell surface. In addition, antigen-specific T cells or antibodies can be produced to allow future protection of immune hosts. Therefore, immunogenic compositions can protect hosts from bacterial infections, reduce severity, or can protect hosts from death due to bacterial infections. Antigens can also be used to produce polyclonal or monoclonal antibodies, which can be used to give subjects passive immunity. Antigens can also be used to produce functional antibodies such as those measured by killing bacteria in animal efficacy models or via opsonophagocytic killing assays.
[0127] As used herein, the term "isolated" in relation to polysaccharides refers to the separation of A-band terminal epitope antigens (A-PS) from purified polysaccharides using purification techniques known in the art, including the use of centrifugation, depth filtration, precipitation, ultrafiltration, treatment with activated carbon, diafiltration and / or column chromatography. Typically, isolated polysaccharides refer to partial removal of proteins, nucleic acids and non-specific endogenous polysaccharides. Isolated polysaccharides contain less than 10%, 8%, 6%, 4% or 2% protein impurities and / or nucleic acids.
[0128] As used herein, the term "purified" in relation to bacterial polysaccharides refers to purification of polysaccharides from cell lysates by means such as centrifugation, precipitation and ultrafiltration. Typically, purified polysaccharides are those that are free of cell debris and DNA.
[0129] Bacterial polysaccharides can be derived from naturally occurring bacteria, genetically engineered bacteria or can be produced synthetically. Polysaccharides typically undergo one or more processing steps before use, such as purification, functionalization, depolymerization using gentle acidic or oxidative conditions, deacetylation, etc. If desired, post-processing steps can also be adopted. Any suitable method known in the art for synthesizing, preparing and / or purifying suitable polysaccharides and oligosaccharides can be adopted.
[0130] Pseudomonas aeruginosa produces a wide variety of cell surface glycans. Previous studies have identified a common polysaccharide (PS) antigen, commonly referred to as A-band PS, which is composed of neutral D-rhamnose trisaccharide repeating units as a relatively conserved cell surface carbohydrate. One study showed that neutral D-rhamnose trisaccharides had no immunogenic effects
[25] . As described above, the present inventors have identified a novel Pseudomonas aeruginosa polysaccharide structure and showed that the carbohydrate antigen is composed of immunogenic methylated rhamnose oligosaccharides at the non-reducing termini of A-band PS:
[0131] α-D-Rha3OMe-4-(α-D-Rha3OMe-4-)4-
[0132] In particular, the present inventors isolated and characterized A-PS1 and A-PS2 (see Figure 1 ). It is believed that the structure provided herein is the first identification or the first correct identification of an epitope antigen at the terminal end of the A-band of Pseudomonas aeruginosa. Figure 1 The A-PS1 and A-PS2 in the 3OMe were further separated into their antigenic components to produce OS1 and OS2. It was determined that the methylated rhamnose moiety provided antigenicity. Di-, tri-, tetra- and penta-3OMe rhamnose oligosaccharides with and without a linker handle at the reducing end were synthesized.
[0133] In one aspect, the invention therefore provides an antigenic compound comprising an oligosaccharide portion of formula A:
[0134] α-Rha3OMe(-4α-Rha3OMe) n -Formula A
[0135] wherein n is 1-5, preferably 2-4, and wherein the 2-position in each Rha3OMe sugar moiety is independently substituted with -OAc or -OH.
[0136] In one aspect, the present invention provides an antigenic compound comprising an oligosaccharide portion of formula A1:
[0137] α-Rha3OMe(-4α-Rha3OMe) n -X-type A1
[0138] Wherein, n is 1-5 (preferably 2-4), and X is -H or -(4α-Man3OMe) m - a linking handle; and m is 0, 1 or 2, preferably 0 or 1; and wherein the 2-position in each Rha3OMe sugar moiety is independently substituted with -OAc or -OH.
[0139] The sugar monomer moieties may independently be in the D or L configuration.
[0140] In some examples, the sugar moieties can be independently acetylated at 2-O. In other examples, an alternating pattern of acetylated and non-acetylated 3-O-methyl rhamnose can be used. In other examples, 2-O can be substituted with groups other than acetate to improve immunogenicity, such as glycolyl and lactyl.
[0141] Specific examples of methylated rhamnose oligosaccharides include:
[0142] α-D-Rha3OMe-4-(α-D-Rha3OMe-4)4-4-α-D-Man3OMe-2-glyceraldehyde-1d(OS2);
[0143] 3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside (pentasaccharide);
[0144] 3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside (tetrasaccharide) (III);
[0145] 3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside (trisaccharide)
[0146] 3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-Methyl-α-D-rhamnopyranoside-(1→4)-4-3-O-Methyl-α-D-rhamnopyranoside
[0147]
[0148] The methylated rhamnose oligosaccharides of the present invention can be isolated or chemically synthesized. Alternatively, the isolated oligosaccharides can be further chemically modified.
[0149] Isolation of A-band terminal epitope antigen: The inventors have developed a method for isolating the A-band terminal epitope antigen (A-PS). In one aspect, a method for producing the A-band terminal epitope antigen (OS1) is provided, comprising subjecting isolated LPS (lipopolysaccharide) from Pseudomonas aeruginosa to acid or base hydrolysis to produce a polymer fraction. In one example, the polymer fraction is subjected to acid hydrolysis, such as with acetic acid. In one example, the polymer fraction is subjected to alkaline hydrolysis, such as by reaction with KOH, followed by treatment with HCl.
[0150] The polymer fraction is then subjected to an oxidation step followed by acid hydrolysis to produce OS1. In one example, the first oxidation step comprises: reacting the polymer fraction with NaIO4, reacting with ethylene glycol and NaBD4, reacting with AcOH, and desalting to produce a product, and subjecting the product to acid hydrolysis to produce an isolated A-band terminal epitope antigen (OS1). In a specific example, an isolated A-band terminal epitope antigen (OS1) from Pseudomonas aeruginosa is described, which has the following formula: α-D-Rha3OMe-4-(α-D-Rha3OMe-4)4-4-α-D-Man3OMe-2-tetratol-1d (OS1)
[0151] If OS1 is subjected to an additional oxidation step, an additional isolated A-band terminal epitope is obtained, identified herein as OS2. In one example, the second oxidation step comprises: reacting OS1 with NaIO4, reacting with ethylene glycol and NaBD4, reacting with AcOH, and desalting to produce a product, and subjecting the product to acid hydrolysis to produce an isolated A-band terminal epitope antigen (OS2). In a specific example, an isolated oxidized A-band terminal epitope antigen (OS2) of Pseudomonas aeruginosa is described, which is a polysaccharide as a compound of the formula:
[0152] α-D-Rha3OMe-4-(α-D-Rha3OMe-4)4-4-α-D-Man3OMe-2-glyceraldehyde-1d(OS2)
[0153] In some examples, the compound is an antigen.
[0154] Chemical Synthesis: The chemical synthesis of the compounds of the present invention is described in detail in the Examples and in Figure 22-24 and 30 are shown.
[0155] In one aspect, a synthetic method for preparing a compound of the present invention is provided, the method comprising:
[0156] ● deprotecting the anomeric portion of the 3-O-methylated rhamnopyranoside to form 3-O-methylated rhamnopyranose;
[0157] ● acetylation of 3-O-methylated rhamnopyranose to form acetylated 3-O-methylated rhamnopyranoside;
[0158] ● partially deprotecting the O-4 of the acetylated 3-O-methylated rhamnopyranoside to form a deprotected acetylated 3-O-methylated rhamnopyranoside;
[0159] ● coupling of O-4 deprotected acetylated 3-O-methylated rhamnopyranoside to form acetylated 3-O-methylated oligosaccharides;
[0160] ● deprotecting the O-4 of the acetylated 3-O-methylated oligosaccharide to form an O-4 deprotected acetylated 3-O-methylated oligosaccharide; and
[0161] • Deacetylation of the partially deprotected acetylated 3-O-methylated oligosaccharide to form the compound.
[0162] In one aspect, a synthetic method for preparing a compound of the present invention is provided, the method comprising:
[0163]
[0164] Linker handle: Compounds of the present invention also include compounds comprising a "linker handle". A "linker handle" in the context of the present invention is a chemical modification at a site distal to the terminal α-Rha3OMe repeat to form a reactive group. Examples include 2-glyceraldehyde, -CH2-NH2, -(CH2)2NH2, -(CH2)3NH2, -(CH2)4NH2, (CH2)5NH2, -C(O)OH, -C(O)H, -C(O)NH2, and -CH2N3. When the compound comprises -4α-Man3OMe (i.e., m is 1 or 2), the linker handle is preferably 2-glyceraldehyde. When the compound does not include 4α-Man3OMe (i.e., m is 0), the connecting handle is preferably -CH2-NH2, -(CH2)2NH2, -(CH2)3NH2, -(CH2)4NH2, (CH2)5NH2, -C(O)OH, -C(O)H, -C(O)NH2 and -CH2N3, more preferably -CH2-NH2, -(CH2)2NH2, -(CH2)3NH2, -(CH2)4NH2 or -(CH2)5NH2.
[0165] In one example, the synthesis method further comprises adding a linker handle by performing the following steps:
[0166] glycosylation of an activated O-3 methylated rhamnopyranoside intermediate at 1-O with a linker handle comprising a protected amine, wherein the activated monorhamnopyranoside intermediate comprises a protecting group at glycosylation site 4-O, and forming a protected 1-O glycoside intermediate;
[0167] ● Removal of the protecting group from 4-O and formation of a deprotected 1-O glycoside intermediate;
[0168] ● coupling the deprotected 1-0 glycoside intermediate to an activated O-3 methylated rhamnopyranoside intermediate, wherein the activated rhamnopyranoside intermediate comprises a protecting group at 4-0, and forming a protected methylated disaccharide, trisaccharide, tetrasaccharide or pentasaccharide; and
[0169] • Removal of all protecting groups from a protected disaccharide, trisaccharide, tetrasaccharide or pentasaccharide.
[0170] In one example, the method of synthesis further comprises adding a linker handle to the compound of the invention by performing the following steps:
[0171]
[0172] Linkers: The purified or synthesized oligosaccharides may optionally contain linkers, which may be conjugated to the oligosaccharides of the invention either directly or via a linker handle on the oligosaccharide. As will be appreciated by those skilled in the art, the linker may be any suitable linker for the desired purpose, for example for conjugating 4α-linked glycans to a carrier protein. Suitable linkers containing functional groups at both ends, such as acids or NHS esters or PFP esters, will be known to those skilled in the art and include, but are not limited to, for example, polyethylene glycol (PEG), linear polyamidoamine (PAA), poly(2-oxazoline) (POx), poly(adipylglycerol) (PGA), polyhydroxyalkanoates (PHA) and other linkers suitable for preparing glycoconjugates, such as those described in Munneke et al.
[42] . Examples of suitable linkers are, for example, from Available as BCN PEG and BCN reagent.
[0173] In certain embodiments, oligosaccharide can be coupled to a joint to form a polysaccharide-joint, wherein the free end of the joint is an ester group. Therefore, a joint is a joint in which at least one end is an ester group. Select another end so that it can react with the oligosaccharide to form an oligosaccharide-joint intermediate.
[0174] In certain embodiments, the linker is a bifunctional linker that provides a first ester group for reacting with a primary amine group on the connecting handle of the oligosaccharide and a second ester group for reacting with a primary amine group in a carrier molecule. A typical linker is N-hydroxysuccinimide diester of adipic acid (SIDEA). In one aspect, the linker can be a divalent linker containing an activated N-hydroxysuccinimide and a hemiacetal-protected aldehyde, wherein one end reacts with a primary amine on the connecting handle of the oligosaccharide.
[0175] Other suitable techniques use carbodiimides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, TSTU. Many are described in International Patent Application Publication No. WO 98 / 42721. Conjugation may involve a carbonyl linker, which may be formed by reaction of a free hydroxyl group of a sugar with CDI (see Bethell et al.,
[43] ), which is then reacted with the protein to form a carbamate linkage. This may involve reduction of the anomeric terminus to a primary hydroxyl group, optionally protecting / deprotecting the primary hydroxyl group, reacting the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling the CDI carbamate intermediate to an amino group on the protein.
[0176] In some instances, a joint can be used to connect at the anomeric position. In some instances, a joint can be placed at an early stage during the building-up process. It can be placed on a disaccharide, trisaccharide, tetrasaccharide or pentasaccharide, or in addition placed on the acetylated form and non-acetylated pattern / acetylated pattern of these sugars. In other instances, an oligosaccharide can be connected to any connectivity function for potential conjugation to a protein.
[0177] In one aspect, linkers such as amino-peg and functional groups such as azide and aldehyde protecting groups can be used.
[0178] In one example, a connector can be added according to the following method:
[0179]
[0180] Conjugate: conjugation to a carrier protein can improve immunogenicity. Suitable protein classes include pili, outer membrane proteins and excretion toxins of pathogenic bacteria; non-toxic or "toxoid" forms of such toxins, non-toxic proteins (i.e., cross-reactive substances or CRMs) and other proteins that are antigenically similar to bacterial toxins. In one aspect, CRMs such as CRM197 can be used as carrier proteins. CRM197 is a non-toxic variant of diphtheria toxin (DT). Other suitable carrier proteins include additional inactivated bacterial toxins, such as DT, diphtheria toxoid fragment B (DTFB), DTB C8, TT (tetanus toxin) or fragment C of TT, pertussis toxoid, cholera toxoid, Escherichia coli LT (heat-labile enterotoxin), Escherichia coli ST (heat-stable enterotoxin) and Pseudomonas aeruginosa proteins, such as exotoxin A from Pseudomonas aeruginosa. Human serum albumin (HSA) and bovine serum albumin (BSA) are also included. Other DT mutants can also be used as carrier proteins, such as CRM176, CRM228, CRM45; CRM9, CRM45, CRM102, CRM103, CRM3201 and CRM107. Clostridium perfringens exotoxin / toxoid is also included. Other suitable bacterial proteins include, but are not limited to, pneumococcal surface protein A (PspA), pneumococcal adhesin protein (PsaA), and pneumococcal surface proteins BVH-3 and BVH-11. Immunogenic carrier proteins from non-mammalian sources are also contemplated, including keyhole limpet hemocyanin (KLH), horseshoe crab hemocyanin, and edestin, as well as viral proteins such as hepatitis B surface / core antigen; rotavirus VP7 protein, and respiratory syncytial virus F and G proteins. Other carrier proteins will be known to those skilled in the art.
[0181] Glycan conjugates can be prepared by known coupling techniques.Using the chemistry discussed above with respect to linkers, the oligosaccharides of the invention can be conjugated to a carrier protein directly or via a linker handle and / or linker to form a glycoconjugate.
[0182] Conjugation between the polysaccharide and the carrier can be achieved using a variety of reagents. Conjugation can be directly between the polysaccharide and the carrier protein, such as direct covalent linkage by reductive amination. Alternatively, conjugation can be performed using a cross-linking agent.
[0183] In one example, a protein can be conjugated to a glycan-handle-linker as follows:
[0184]
[0185] Additional examples of protein and linker conjugation are shown below.
[0186] In some examples, the antigen is a natural sugar extracted and modified from Pseudomonas aeruginosa (OS2), which can be conjugated to a carrier protein such as CRM, HSA, BSA, etc. In this case, glyceraldehyde serves as the linker handle, and the protein is attached via a reductive amination reaction.
[0187]
[0188] In some examples, the antigen comprises or consists of:
[0189]
[0190] In some instances, direct reductive amination of a hemiacetal with a protein can be used as an example. In some instances, this is accomplished through the reducing end of a synthetic antigen. In some instances, a linker can first be added to the sugar via a linker handle and conjugated to an attached linker using known linking techniques.
[0191] In one aspect, the carrier protein or linker can be conjugated to an amine from the carrier protein or linker, respectively (R is the protein or linker) by direct reductive amination. The following is an example.
[0192]
[0193] In some examples, the oligosaccharide can be acetylated at the 2-O position.
[0194]
[0195] In other examples, a combination of non-acetylated and acetylated monosaccharides may be used. In other examples, an alternating pattern of acetylated and non-acetylated 3-O-methyl rhamnose may be used.
[0196]
[0197] Although specific compounds are described above, the chemistry is also applicable to other oligosaccharides of the invention, including corresponding pentasaccharides, tetrasaccharides, trisaccharides, and disaccharides.
[0198] Drug / vaccine combination
[0199] The present invention also provides compositions, including pharmaceutical compositions, immunogenic compositions, and vaccine compositions, which contain any glycan described herein, including glycans conjugated or not conjugated to a carrier protein, together with a pharmaceutically acceptable carrier, excipient and / or adjuvant, consist essentially of any glycan described herein, including glycans conjugated or not conjugated to a carrier protein, together with a pharmaceutically acceptable carrier, excipient and / or adjuvant, or consist of any glycan described herein, including glycans conjugated or not conjugated to a carrier protein, together with a pharmaceutically acceptable carrier, excipient and / or adjuvant.
[0200] Formulation can be accomplished using methods recognized in the art. For example, polysaccharides can be formulated with a physiologically acceptable vehicle to prepare a composition. Examples of such vehicles include, but are not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol), and glucose solutions.
[0201] In some aspects, compositions comprising a conjugate and a pharmaceutically acceptable excipient are described. In some aspects, compositions comprising a conjugate, a pharmaceutically acceptable excipient, and an adjuvant are described.
[0202] In some examples, vaccines are described and glycans are the antigenic component of the vaccine.
[0203] As used herein, the term "vaccine" refers to a substance used to stimulate antibody production and / or provide immunity against one or several diseases, which is prepared from the pathogen of the disease, its products or synthetic substitutes, and is treated to act as an antigen without inducing disease.
[0204] Vaccines typically contain antigens similar to pathogenic substances or antigens made of pathogenic substances in a weakened or killed form. For example, a vaccine can have one or more antigens from bacteria, one or more surface proteins, or one or more membrane components. Vaccines can be preventive (to reduce the risk of future infection caused by natural or "wild" pathogens or to improve their impact), or therapeutic (for example, vaccines for a disease or illness being studied). In some embodiments, the vaccine described herein is a preventive vaccine. In some embodiments, the vaccine described herein is a therapeutic vaccine. In some embodiments, vaccines can be preventive and therapeutic.
[0205] Initial studies with the isolated antigen allowed the generation of conjugates that were used to immunize mice and rabbits and to generate monoclonal and polyclonal antibodies. The polyclonal antibody was able to recognize most of the P. aeruginosa strains in our collection, and three monoclonal antibodies were generated, one of which was able to recognize and promote opsonophagocytic killing of most P. aeruginosa strains. This monoclonal antibody was able to recognize most of the P. aeruginosa strains in our collection, including clinical and serotype strains.
[0206] Adjuvants may be used to elicit a higher immune response in a subject. Thus, adjuvants for use according to the present invention may be selected based on their ability to affect antibody titers.
[0207] As used herein, the term "adjuvant" refers to any substance that, when used in combination with a specific vaccine antigen, acts to accelerate, prolong or enhance an antigen-specific immune response. An adjuvant can be a naturally occurring component contained in a weakened or killed immunogen. For example, an adjuvant can be a component of a whole cell, a protein or protein fragment, or a lipid membrane of a bacterial cell. An adjuvant can also be a synthetic compound. For example, an adjuvant can be an aluminum salt, a phospholipid, or a derivative thereof.
[0208] Generally, adjuvanted vaccines can help elicit stronger local and systemic immune responses compared to non-adjuvanted vaccines.
[0209] In some examples, the method of eliciting an immune response further comprises administering an adjuvant.
[0210] In some instances, water-in-oil emulsions can be used as adjuvants. Water-in-oil emulsions can act by forming a mobile antigen reservoir, promoting slow release of antigens, and enhancing presentation of antigens to immune components. Freund's adjuvant can be used as complete Freund's adjuvant (CFA), which contains dried and inactivated mycobacterial particles, or as incomplete Freund's adjuvant (IFA), which lacks such particles. Other water-in-oil based adjuvants may include Contains micron-sized oil droplets that are free of animal-based components and can be used alone or in combination with other adjuvants, including but not limited to aluminum hydroxide and CARBIGEN TM .
[0211] In other examples, immunostimulatory oligonucleotides can also be used as adjuvants. Such adjuvants can include CpG oligodeoxynucleotides (ODN). CpG ODN is recognized by Toll-like receptor 9 (TLR9), resulting in strong immunostimulatory effects. C-type CpG ODN induces plasmacytoid dendritic cells (pDC) and B cells to stimulate the production of strong IFN-α, and helper T cells (Tx) to produce IFN-γ. It has been shown that CpG ODN adjuvants significantly enhance pneumococcal polysaccharide (19F and 6B types) specific IgG2a and IgG3 in mice. CpG ODN also enhances the antibody response to protein carrier CRM197, particularly CRM197 specific IgG2a and IgG3. In addition, immunization of old mice with pneumococcal capsular polysaccharide serotype 14 (PPS14) combined with CpG-ODN has been shown to restore IgG anti-PPS14 responses to young adult levels. The CpG ODN used according to the present invention can include Class A, Class B or Class C ODNs. In some embodiments, ODN can include any one of those commercially available, such as ODN-1585, ODN-1668, ODN-1826, ODN-2006, ODN-2007, ODN-2216, ODN-2336, ODN-2395 and / or ODN-M362. In some cases, ODN-2395 can be used. ODN-2395 is the C class CpG ODN of specific stimulation people and mouse TLR9. These ODNs comprise thiophosphate backbone and CpG palindromic motif.
[0212] In some examples, in preparing vaccines according to the present disclosure, the glycan is covalently linked or otherwise conjugated to an immunogenic carrier molecule. Typically, the immunogenic carrier molecule is a protein or polypeptide.
[0213] As used herein, the term "excipient" or "pharmaceutically acceptable excipient" refers to any substance that is combined with the compounds and / or compositions of the invention prior to use. In some embodiments, the excipient is inactive and serves primarily as a carrier, diluent, or vehicle for the compounds and / or compositions of the invention. An excipient is pharmaceutically acceptable if it is physiologically compatible, i.e., does not produce an adverse or abnormal reaction when administered to an animal, including a suitable human or non-human animal.
[0214] The formulations of the pharmaceutical compositions described herein may be prepared by any method known or later developed in the art of pharmacology. Generally, such preparation methods include the step of combining the active ingredient with an excipient and / or one or more other auxiliary ingredients.
[0215] A pharmaceutical composition according to the present disclosure may be prepared, packaged, and / or sold in bulk as a single unit dose and / or as a plurality of single unit doses.
[0216] Pharmaceutically acceptable excipients for making pharmaceutical compositions include, but are not limited to, inert diluents, dispersants and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants and / or oils. Such excipients may optionally be included in the pharmaceutical compositions.
[0217] Examples of diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, the like, and / or combinations thereof.
[0218] The vaccines described herein may preferably prevent, ameliorate and / or treat an infection caused by Pseudomonas aeruginosa in a subject.
[0219] As used herein, the term "prevent" or "preventing" includes preventing the recurrence, spread or onset of Pseudomonas aeruginosa infection. It is not intended to limit the present disclosure to complete prevention. In some embodiments, prevention includes delaying the onset or reducing the severity of the infection.
[0220] As used herein, the term "treatment / treat / treating" refers to obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results may include, but are not limited to, alleviating or improving one or more symptoms or conditions, alleviating the extent of the disease, stabilizing (i.e., not worsening) the disease state, preventing the spread of the disease, delaying or slowing the progression of the disease, improving or alleviating the disease state, reducing disease recurrence, and alleviating (partially or completely), whether detectable or undetectable. "Treatment / treatment" can also mean extending survival compared to the expected survival without treatment. Therefore, the term "treatment / treat / treating" is not limited to situations where the subject (e.g., patient) is cured and the disease is eradicated. On the contrary, the examples of the present disclosure also contemplate treatments that alleviate symptoms and / or delay disease progression.
[0221] The term "symptom" of a disease or condition (eg, P. aeruginosa infection) is any morbid phenomenon or deviation from normal in structure, function, or sensation experienced by a subject and indicative of disease.
[0222] As used herein, the terms "amelioration" or "ameliorates" refer to a decrease, reduction, or elimination of a condition, disease, disorder, or phenotype, including an abnormality or symptom.
[0223] Pseudomonas aeruginosa is an important opportunistic pathogen that causes a variety of life-threatening infections in immunosuppressed or immunocompromised patients. Individuals at risk for developing P. aeruginosa infections include patients with cystic fibrosis, patients with burns, patients with severe neutropenia (e.g., cancer patients receiving chemotherapy), and patients in intensive care units receiving respiratory support.
[0224] The vaccines described herein can be administered concurrently with other existing vaccines.
[0225] The vaccines herein may be administered to a subject by any route, including intramuscular, subcutaneous, intradermal, oral, inhaled, intranasal, rectal, and intravenous. Oral administration may be suitably via tablets, capsules, or liquid suspensions or emulsions. Alternatively, the vaccine may be administered by or Administration may be in the form of a fine powder or an aerosol. Intranasal administration may be suitably in the form of a fine powder or an aerosol nasal spray or a modified or Rectal administration may suitably be via suppositories.
[0226] An immunoprotective amount of a vaccine can be administered in a single dose or in a series of doses. In the case of administering more than one dose, the doses can be administered several days, weeks, or months apart. In some instances, the vaccine can be administered as a single dose or in a series including one or more booster doses.
[0227] The vaccine dosage and administration regimen to be administered to a subject can be determined according to standard techniques well known to those of ordinary skill in the pharmaceutical and veterinary arts, taking into account factors such as the intended use, the specific antigen, adjuvant (if any), age, sex, weight, species, general condition, previous illness and / or treatment, and route of administration.
[0228] In some examples, a therapeutically effective amount of a vaccine or immunogenic composition is used.
[0229] A therapeutically effective amount refers to an amount of a specific agent sufficient to achieve a desired effect in a subject treated with the agent. For example, this can be an amount of a vaccine that can be used to elicit an immune response in a subject and / or to prevent infection. The effective amount of a vaccine (or immunogenic composition) that can be used to increase resistance, prevention, improvement and / or treatment of infection in a subject will depend on, for example, the subject being treated, the mode of administration of the therapeutic composition, and other factors.
[0230] Antibody
[0231] In some examples, methods of producing antibodies specific for a glycan antigen as described herein are provided.
[0232] In some instances, antibodies can be developed by immunizing a host with a specific antigen. As described above, such an immune response typically results in the organism producing one or more antibodies against a foreign entity, such as an antigen or a portion of an antigen. In some cases, the immunization method can be changed based on one or more desired immune results. As used herein, the term "immunization result" refers to one or more desired effects of immunization. Examples include high antibody titers and / or increased antibody specificity against a target of interest. Methods for collecting antibodies are known in the art.
[0233] As used herein, the term "antibody" is used in the broadest sense and specifically encompasses various embodiments, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies formed from, for example, at least two intact antibodies), and antibody fragments, such as diabodies, as long as they exhibit the desired biological activity. Antibodies are primarily amino acid-based molecules, but may also contain one or more modifications, such as having sugar moieties, linkers, detectable labels, etc.
[0234] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous cell (or clone) population, i.e., each antibody comprising the population is identical and / or binds to the same epitope, except for possible variants that may occur during the production of the monoclonal antibody (such variants are usually present in small amounts). In contrast to polyclonal antibody formulations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
[0235] In some examples, the antibodies described herein can be humanized.
[0236] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulins. In most cases, humanized antibodies are human immunoglobulins (recipient antibodies) in which residues from a hypervariable region of the recipient antibody are replaced by residues from a hypervariable region of an antibody from a non-human species (donor antibody) having the desired specificity, affinity, and capacity.
[0237] The method of the present invention can be conveniently implemented by providing the compounds and / or compositions used in such methods in the form of a kit. Such a kit preferably comprises a composition as described herein. Such a kit preferably comprises instructions for use thereof.
[0238] In order to better understand the invention described herein, the following examples are set forth. It should be understood that these examples are for illustrative purposes only. Therefore, they should not limit the scope of the present invention in any way.
[0239] Methods and uses
[0240] Generally, described herein are methods of increasing an immune response in a subject, the methods comprising administering to the subject an isolated or synthetic glycan, preferably an isolated or synthetic glycan antigen from Pseudomonas aeruginosa, more preferably an isolated or synthetic glycan antigen from Pseudomonas aeruginosa linked to a carrier protein in the form of a glycoconjugate.
[0241] In some aspects, methods are provided for treating a subject having, suspected of having, or at risk of developing a Pseudomonas aeruginosa infection, the method comprising administering to the subject an isolated or synthetic glycan, preferably an isolated or synthetic glycan antigen from Pseudomonas aeruginosa, more preferably an isolated or synthetic glycan antigen from Pseudomonas aeruginosa linked to a carrier protein in the form of a glycoconjugate.
[0242] In some aspects, methods are provided for treating a subject having, suspected of having, or at risk of developing a Pseudomonas aeruginosa infection, comprising administering an antibody or derivative thereof specific for a glycan antigen from Pseudomonas aeruginosa as identified in this document.
[0243] Generally, described herein are methods of diagnosing or treating Pseudomonas aeruginosa infection using antibodies, such as the monoclonal antibodies described herein. In one aspect, the antibody is the 1B1 MAb described herein.
[0244] In one aspect, the antibodies or antigen-binding fragments thereof can be used to treat Pseudomonas aeruginosa infection.
[0245] In one aspect, the antibodies or antigen-binding fragments thereof can be used to diagnose Pseudomonas aeruginosa infection.
[0246] In one aspect, a method for treating a Pseudomonas aeruginosa infection is provided, the method comprising administering an antibody or antigen-binding fragment to a subject.
[0247] In one aspect, a method for diagnosing a Pseudomonas aeruginosa bacterial infection in an animal is provided, the method comprising contacting a test sample with an antibody or antigen-binding fragment thereof, and detecting specific binding thereto.
[0248] Example
[0249] Pseudomonas aeruginosa produces a variety of cell surface glycans. Previous studies have identified a common polysaccharide (PS) antigen, commonly referred to as A-band PS, which consists of neutral D-rhamnose trisaccharide repeating units as a relatively conservative cell surface carbohydrate. However, the inventors have discovered a new epitope that has not been identified previously. Nuclear magnetic resonance (NMR) spectroscopy and chemical analysis of A-PS formulations show the presence of several additional components. In fact, the carbohydrate antigen consists of immunogenic methylated rhamnose oligosaccharides at the non-reducing end of A-band PS. Initial studies with isolated antigens allowed the production of conjugates for immunizing mice and rabbits and producing monoclonal and polyclonal antibodies. Polyclonal antibodies were able to recognize most of the tested Pseudomonas aeruginosa strains, and three monoclonal antibodies were produced, one of which was able to recognize and promote opsonophagocytic killing of most Pseudomonas aeruginosa strains. The monoclonal antibody was able to recognize all Pseudomonas aeruginosa strains we collected, including clinical and serotype strains. Synthetic oligosaccharides (monosaccharides to pentasaccharides) representing terminal 3-O-methyl D-rhamnosaccharides were prepared, and the trisaccharide was identified as the minimal epitope required to effectively mimic the natural antigen recognized by a broadly cross-reactive monoclonal antibody. Conjugates of the synthetic pentasaccharide with a carrier protein produced polyclonal antibodies in mice. These antibodies were also able to recognize whole cells of the tested Pseudomonas aeruginosa strains, further emphasizing the ability of the synthetic antigens to effectively mimic the natural antigens. These experiments demonstrate the usefulness of these new antigens and corresponding antibodies as vaccines, therapeutic targets, and in methods for treating Pa.
[0250] Table 1. Details of strains used in this study
[0251]
[0252] Example 1A: Isolation and oxidation of A-PS
[0253] The A-band terminal epitope was isolated using the following method. In addition to isolating it via LPS, it was also isolated directly from cells. A-PS was extracted from EDTA in higher yields than from LPS, but purification was more challenging when EDTA was used.
[0254] The A-banded PS was isolated from PAO1 Wzy::Gm (a mutant lacking the B-banded OPS) LPS by acetic acid hydrolysis and subsequent size exclusion chromatography. The PS fraction was then purified by anion exchange or reverse phase HPLC. The yield was generally low, yielding approximately 5 mg of A-PS from 100 mg of LPS, and was not scaled up proportionally with higher amounts of starting LPS.
[0255] Alternatively, A-PS was extracted from the same mutant cells using EDTA. This method has been previously reported as an LPS extraction method, but no significant amount of LPS was extracted in this manner. Three major components were found in the formulation: A-PS, psl-polysaccharide with a previously described structure
[15] , and cyclic phosphorylated glucan
[16] . The cyclic glucan signal was not very obvious in the spectrum of the entire mixture, but it was obtained in pure form after anion exchange separation in the fraction eluted at high salt concentration, after the A-band and psl polysaccharide. The NMR spectrum of the isolated compound showed no signals attributable to other components of lipids or LPS. Therefore, at least some portion of the A-band rhamnan is not attached to LPS as previously suggested
[17] . The yield of A-PS extracted from EDTA is much higher than that from LPS, but purification is more challenging.
[0256] A-PS was purified on a reverse phase HPLC column or a Sep-Pak C18 column, where it was completely retained in water and could be eluted with 30% methanol. All components of A-PS, including those that produced minor anomeric and methyl signals in the NMR spectrum, eluted together. In C18 column chromatography, eluted with a water-methanol gradient, A-PS eluted over a wide range of methanol gradients, starting at about 20% MeOH, with no visible peaks.
[0257] A-PS contains an acidic component and is partially retained on the anion exchange column, eluting in several fractions in the NaCl gradient. This behavior may indicate the attachment of A-PS to the LPS core, which is acidic due to phosphorylation.
[0258] Growth of Pa strains: Pseudomonas aeruginosa strain PAO1(wzy::Gm) (NRCC6667), known to lack B-band LPS, was cultured to isolate the A-band polysaccharide (PS). A Difco brain heart infusion (BHI) agar plate was streaked with 100 μg mL -1 Gentamycin sulfate was cultured at 37°C in a Forma incubator. After 7 h incubation, all plate growth material was suspended in 1.5 mL BHI broth and vortexed thoroughly to suspend the material. Ten cells with 100 mg L were inoculated with the suspended material in equal amounts. -1 BHI agar plates containing gentamicin sulfate were plated and spread using the hockey stick method and incubated at 37°C. After 16 h of incubation, two plates with 100 mg L -1 1L / 4L baffled flask of BHI broth containing gentamicin sulfate. Incubate the flask in a Forma shaking incubator at 37°C and 200 RPM for 2 hours. Once A 600nmWhen the optical density reached 2, these flask cultures were used to inoculate a 30 L new MBR (Multiple Bioreactors) fermenter with 100 mg L -1 22 L BHI broth with gentamicin sulfate. Dissolved oxygen was controlled at 15% saturation using variable air flow, agitation rate, and oxygen mixing as needed. 3 After 4 hours of growth, the temperature was lowered to 10°C until harvest. After 22 hours, A 600nm Reach 13.4, pH is 8.35.Use Millipore tangential flow Pellicon harvesting device (3x0.22μ membrane) culture is concentrated to 4L. Kill 4L of concentrated cells by adding 90ml of 95% (w / v) phenol solution, and place it in Forma shaking incubator at 10 ℃ and shake for 4h at 175RPM.After washing 3 times with PBS, the viability check of material is carried out.4L concentrate is rotated 30 minutes with 11K RPM in SorvalRC6+ centrifuge to pelletize (pellet) cells. Obtain 2767g gelatinous paste particles of wet weight, and disperse it in three 1L containers. One container is rotated for another 30 minutes at 11K RPM to obtain the final wet weight of 1110g. Cells are freeze dried and stored for future use.
[0259] Several other strains were also grown and used in this study as detailed in Table 1. After inoculum accumulation and growth as described above, all biomass was harvested from the 24 L fermentor.
[0260] Isolation of A-PS by EDTA extraction of whole cells: 20 g of dried cells of Pseudomonas aeruginosa strain PAO1 (wzy::Gm) (NRCC 6667) were stirred in 10% (w / v) disodium EDTA for 1 h at 25°C. The solution was dialyzed and acetic acid was added to a final concentration of 10% to precipitate the nucleic acids. The precipitate was removed by centrifugation, the solution was dialyzed and freeze-dried. The material was dissolved in water, ultracentrifuged, and the resulting clear solution was separated on a Biogel P6 column. The polymer fractions were collected and separated by anion exchange chromatography.
[0261] Isolation of A-PS from LPS: LPS was isolated from Pseudomonas aeruginosa cells of strain PAO1 (wzy::Gm) (NRCC 6667) as previously described
[14] . LPS (100 mg) was hydrolyzed with 2% acetic acid (100 °C, 2 h). The resulting solution was centrifuged to remove the precipitate and separated on a Biogel P6 column. The polymer fractions were collected and separated by anion exchange chromatography.
[0262] Periodate oxidation: The polymer fractions (10 mg at a time) from both the above isolates were dissolved in water (2 mL) and NaIO4 (20 mg) was added. The solution was kept at RT in the dark for 24 h after which ethylene glycol (0.2 mL) and excess NaBD4 were added and the solution was kept for another 1 h, neutralized with 0.2 mL of AcOH and desalted on a Sephadex G-15 column. The product was hydrolyzed with 2% AcOH at 100 °C for 2 h and separated on a Sephadex G-15 column to give OS1. A similar methodology was followed to prepare OS2 from OS1, wherein OS1 was oxidized with periodate, the reaction was quenched with ethylene glycol without borohydride reduction and purified on a Sephadex G-15 column. The structures of OS1 and OS2 are shown in Figure 1 as shown in .
[0263] Gel chromatography: Gel chromatography was performed on a Sephadex G-15 column (1.5 x 60 cm) or a Biogel P6 column (2.5 x 60 cm) in 1% acetic acid and monitored by a refractive index detector (Gilson).
[0264] Anion exchange chromatography: Up to 50 mg of sample was dissolved in water at 3 mL min -1 Inject into HiTrap Q column (Amersham, two columns x 5 mL, each connected together), wash with water for 5 min, then elute with a linear gradient from water to 1 M NaCl over 1 h, UV detection at 220 nm, and spot test on silica TLC plates, which were developed by immersion in 5% H2SO4 in ethanol and heating with a heat gun until brown spots became visible. Carbohydrate positive samples were combined and desalted on a Sephadex G-15 column in 1% AcOH with a refractive index detector.
[0265] Example 1B: Structural Characterization of the Immunodominant Epitope at the Tip of the A-band Rhamnosan of Pseudomonas aeruginosa (Pa)
[0266] Determination of neutral sugars and amino sugars as alditol acetates: The sample (0.2-1 mg) was hydrolyzed with 3M TFA (120°C, 3h), dried, reduced with NaBD4, and the excess reagent was destroyed with 0.5 mL of AcOH. The solution was dried under a stream of air, dried twice after adding MeOH (1 mL), and acetylated with 0.2 mL Ac2O and 0.2 mL pyridine at 100°C for 30 min. The reaction mixture was dried and analyzed by GC-MS on a Thermo Trace 1310 instrument with an ITQ1100 ion trap detector, capillary column HP-5, 160-260°C, 4°C min -1 .
[0267] Absolute configuration: Acetyl chloride (20 μL) was added to samples and prepared standards (-0.5 mg) (R)- or (RS)-2-octanol (0.2 mL) at RT and heated in a closed vial (100° C., 2 h). The reaction mixture was dried by air flow, acetylated (0.2 mL Ac2O with 0.2 mL pyridine, 100° C., 30 min), and dried before analysis by GC-MS as described above.
[0268] NMR spectroscopy: using acetone internal reference ( 1 H is 2.225 ppm and 13 C was 31.45 ppm) using the standard pulse sequences cosygpprqf (gCOSY), mlevphpr (TOCSY, 120 ms mixing time), roesyphpr (ROESY, 500 ms mixing time), hsqcedetgp (HSQC), hsqcetgpml (HSQC-TOCSY, 80 ms TOCSY delay) and hmbcgplpndqf (HMBC, 100 ms long transfer delay) on a Bruker AVANCE III 600 MHz ( 1 The NMR experiments were performed on a Bruker Topspin 2.1 spectrometer. The resolution was kept <3 Hz / pt in the proton-proton related F2 and <5 Hz / pt in the HC related F2. The spectra were processed and analyzed using the Bruker Topspin 2.1 program.
[0269] Through COSY, TOCSY and NOESY cross peak diagram and 13 Monosaccharides were identified by C NMR chemical shifts. The position of the amino group was inferred from the position of the upfield signal of the aminated carbon (CH at 45-60 ppm). The linkage between monosaccharides was determined by transglycosidic NOE and HMBC correlation.
[0270] Mass Spectra: ESIMS were obtained using a Waters SQ Detector 2 instrument. Samples were injected in 50% MeCN with 0.1% TFA.
[0271] Structure: Pseudomonas aeruginosa A-PS contains a major component consisting of repeating D-rhamnose trisaccharide units:
[0272] -2-α-Rha-3-α-Rha-3-α-Rha-A-PS repeating unit
[0273] ABC
[0274] The NMR spectrum of the A-PS formulation contains signals for the repeating unit and additional signals ( Figure 2 Some minor anomeric signals were previously identified as belonging to 3-O-methyl-rhamnose
[18] , which has a signal for the O-methyl group at approximately 3.3 ppm, but the complete structure has never been determined.
[0275] Polysaccharides obtained from LPS and by EDTA extraction have similar NMR spectra. Minor differences exist, but due to the complex nature of the spectra it is not possible to identify these minor components and distinguish impurities from the true composition of A-PS. Because A-PS is presumed to be attached to the LPS core, it is expected that A-PS obtained from LPS should contain core components, but these components have not been reliably identified.
[0276] Monosaccharide analysis of A-PS (GC-MS of alditol acetates) showed the presence of Rha as the major component, as well as small amounts of Man, Glc, 2-O-methyl-Rha, 3-O-methyl-Rha (about 5-8 times more than other minor components), 2-O-methyl-Man and 3-O-methyl-Man. No heptose derivatives were detected.
[0277] Periodate oxidation of A-PS with subsequent NaBD4 reduction, mild hydrolysis, and separation of the products on a Sephadex G-15 column resulted in the separation of the expected D-rhamnan oxidation products α-D-Rha-3-α-D-Rha-2-Gro1d and the oligosaccharide OS1 ( Figure 1 ). OS1 was analyzed by NMR and ESI-MS. Interpretation of the 2D NMR spectrum of OS1 (Table 2, Figure 3 ) led to the identification of several overlapping spin systems of a homo-oligomer of a terminal 3-O-methyl-α-Rha residue (E) and 4-substituted 3-O-methyl-α-Rha residues (F). The number of residues in this oligomer was not apparent from the NMR data, but MS determined the presence of five 3-O-methyl-Rha residues ( Figure 4 ). The next residue in the sugar chain of OS1 after the 3-OMe rhamnosyl oligosaccharide is represented by 3-O-methyl-α-Man (L), which in turn is linked to O-2 of 1-deuterated erythritol X. 3-O-methyl-Man was identified by GC-MS (albitol acetate) using K. pneumoniae O5OPS as a standard source
[19] . Erythritol can only be produced by the redox reaction of 4-substituted pyranose hexases. The position of the methyl group was determined by NOE and HMBC data as well as 13 This is inferred from the large downfield shift of the C signal at the methylated position.
[0278] Table 2. NMR data of OS1 and free 3-O-methyl-rhamnose, isolated from A-PS (δ, ppm, 500 MHz 25° C.) Me in free Rha3Me: 3.44 / 57.3 ppm.
[0279]
[0280] In order to be able to unambiguously determine the absolute configuration of 3-OMe rhamnose, since two isomers of rhamnose have been identified in P. aeruginosa LPS
[20] , synthetic standards of D- and L-rhamnose monosaccharides were prepared. NMR analysis confirmed the authenticity of these standards ( Figure 5A and 5B The absolute D-configuration of 3-O-methyl-Rha was determined by GC-MS of the acetylated 2-octanol derivative of OS1 compared with the same derivative obtained from a synthetic standard ( Figure 6 ).
[0281] Positive mode ESIMS of compound OS1 showed two peaks at m / z 1117.8 and 1122.6 in a 1:1 ratio, corresponding to the ammonium and sodium adducts of Rha5Man1tetranitol-1d1Me6 with a calculated accurate mass of 1099.5 ( Figure 4 ). Thus, OS1 contains five 3-O-methyl-D-Rha residues connected by 1-4-bonds.
[0282] Similar oligosaccharides were proposed previously
[18] , but in this study xylose was detected instead of 3-O-methyl-α-Man and the linkage position was not identified.
[0283] Interpretation of the NMR spectra of the intact A-PS confirmed the signals of the repeating rhamnosyl trisaccharide -ABC- (data not shown) and also showed the presence of less intense spin systems corresponding to the intact OS1 and two residues G and H identified as 2-O-methyl-Man (G) and 2-O-Me-Rha (H) (Table 3). The spectra always contained two weak spin systems of the terminal α-Glc (N,N'), assumed to be Glc from the Pseudomonas LPS core, but these residues did not give rise to interpretable NOEs.
[0284] Table 3. NMR data of A-PS ((δ, ppm, 600 MHz, 40° C.). Methyl groups: G, H: 3.47 / 59.7 ppm; E, F, L: 3.46 / 57.5 ppm.
[0285]
[0286]
[0287] 3-O-methyl-Man L in A-PS is linked to O-4 of α-Man M, so the erythritol X in OS1 originates from oxidized Man M. There are several spin systems of α-Man, which form the trisaccharide-4-α-Man-4-α-Man-4-α-Man-(MKD), linked to 2-O-methyl-Rha H or 2-O-methyl-Man G. The chain could not be followed further because no other components could be identified. The linkage between the D-rhamnan trisaccharide repeating unit and the methylated oligosaccharide was not identified.
[0288] Since all signals of OS1 remain in the same position in A-PS and OS1, we can conclude that oligomers of 3-O-methyl-Rha occupy the non-reducing ends of A-PS chains and are likely to be immunogenic due to their terminal position.
[0289] As described herein, the detailed structure of the non-reducing end of A-PS has been determined, and it has been shown that the polymer does not contain only neutral rhamnose trisaccharide repeating units, but is instead terminated with a pentasaccharide of a 3-O-methylrhamnose residue linked to the neutral mannose trisaccharide via a methylmannose molecule. The point of attachment to the neutral rhamnose has not been determined, however the fact that identical signals for 3-O-methyl Rha residues remain at the same position in A-PS and OS1 strongly suggests that oligomers of 3-O-methyl-Rha occupy the non-reducing end of the A-PS chain. Others have observed signals consistent with 3-O-methylrhamnose residues in their A-PS preparations, but none have been able to elucidate the structural unit described here [18,21].
[0290] Example 2: Preparation and immunological evaluation of glycoconjugates (BSA-OS2 and CRM-OS2) made with isolated A-band epitope (OS2)
[0291] Three mAbs specific for the terminus of A-PS have been identified, and preliminary epitope mapping studies indicate that they recognize distinct regions within this terminal unit. These mAbs, and to a lesser extent polyclonal sera raised to the terminus of A-PS, were able to promote killing of P. aeruginosa strains in both SBA and OPA experiments. Previous studies by Makarenko et al. using synthetic glycoconjugate vaccines based on neutral rhamnose failed to generate antibodies capable of recognizing, let alone promoting killing of, P. aeruginosa strains
[25] . Furthermore, studies from the Lam laboratory have observed that the mAb N1F10, which is specific for neutral rhamnose, was able to recognize approximately 70% of P. aeruginosa strains
[26] , but recent studies of N1F10 or its scFv derivatives have failed to show any function
[27] . It appears that a critical region of this conserved antigen may have been overlooked in previous studies, and the examples described herein demonstrate that the methylated tip region of A-PS is indeed immunogenic and that the immune response is able to promote opsonophagocytic activity. 1B1, one of the three mAbs described herein, appears to recognize a highly conserved epitope, as most of the tested P. aeruginosa strains were recognized by it, including commonly encountered virulent serotypes and recent clinical isolates. The other two mAbs described herein, 3B8 and 3C4, are more specific than the 1B1 mAb, with their recognition limited to wt serotype 5 strains PAO1BAA-47 and 5937. Studies using synthetic oligosaccharides based on terminally methylated pentasaccharides confirmed that mAb 1B1 has a broader specificity when compared to the other mAbs described herein. Inhibition ELISA data using synthetic oligosaccharides revealed that mAb 1B1 can be effectively inhibited with 3-O-methylrhamnose trisaccharides. Given the broad cross-reactivity of mAb 1B1, recognizing that most clinical isolates in our collection and ATCC serotype strains that cause most of the disease caused by P. aeruginosa, it appears that the synthetic oligosaccharides described herein have prospects as vaccine antigens or as a means of generating broadly cross-reactive therapeutics.
[0292] The importance of the A-PS antigen remains the subject of some discussion in the field, but the observation that in the CF lung, serotype-specific O-antigens are no longer established, but A-PS is still present, suggests that the A-PS immunogenic tip structure may be a key epitope to target in the clinical niche.
[0293] Conjugates: BSA and CRM conjugates were prepared by standard direct reductive amination chemistry as previously described
[22] . Briefly, oxidized A-band terminal epitope material (OS2) (4.5 mg and 2 mg) was reacted with CRM (2.3 mg) or BSA (1 mg), respectively, by mixing solutions of both reactants in water and leaving at RT before lyophilization. The lyophilized material was dissolved in 10 ml of 100 mM NaPO4 and NaCNBH3 (5 mg mL) was then added. -1 ) and the resulting solution was placed at room temperature (RT) for 16 h. The conjugate was purified on a 30 KDa molecular weight cutoff spin column in PBS with 10 mM sodium citrate, and the supernatant was assayed for protein, filter sterilized and frozen at -20°C. Aliquots were examined by MALDI-MS as previously described
[23] .
[0294] Generation of antibodies against the terminal epitope of the A-band of P. aeruginosa: To generate antibodies targeting the terminal epitope of the A-band of P. aeruginosa, six Balb / C mice (6-8 weeks) and two New Zealand white rabbits (1.5-2 kg) were immunized with purified and oxidized glycoconjugates of the terminal A-band molecule using CRM as a carrier protein. Immunizations were scheduled and adjuvants were added as previously described
[22] .
[0295] mAb production: Mice immunized against polyclonal sera were screened for recognition of A-banded PS, and mice giving the highest titers were selected for fusion after final intravenous injection. All procedures for fusion of harvested splenocytes from immunized mice, hybridoma selection, and growth and purification of high-density mAb supernatants were performed as previously described
[24] .
[0296] Characterization of mAbs against the terminal epitope of the A-band of Pseudomonas aeruginosa
[0297] Antibody variable region sequencing: The rearranged variable heavy chains (VHs) encoding the three mAbs generated (1B1, 3C4, and 3B8) were determined by Illumina MiSeq amplicon sequencing as previously described
[24] . H ) and variable light chain (V L ) domain DNA sequences
[24] . Table 4 provides the amino acid sequences of the VH and VL domains of the three mAbs.
[0298] Table 4. Antibody sequences
[0299]
[0300]
[0301]
[0302]
[0303] *Bold highlights indicate the location of the CDR sequence
[0304] ELISA: Binding of anti-P. aeruginosa A-band terminal epitope mAbs and polyclonal sera to BSA conjugates, purified LPS and to whole cells was evaluated by ELISA as described previously
[24] .
[0305] mAb competition ELISA: The wells of Nunc Maxisorp EIA plates were coated with 1 μg of Pseudomonas aeruginosa LPS in PBS at 4°C overnight and then placed at RT before use. The plates were blocked with 1% BSA-PBS for 1 h at RT and the wells were washed with PBS-T. One mAb (1B1 or 3B8) was titrated and added to the plate for 1 h at RT. After washing with PBS-T, a second mAb (3C4) of a predetermined concentration was added and incubated at RT for 1 h. After washing with PBS-T, an AP-labeled goat anti-mouse IgG2b (Southern Biotech) specific for mAb 3C4 was added at 1:250 dilution in 1% BSA-PBS for 1 h at room temperature. The plates were then washed with PBS-T and developed with a phosphatase substrate system (Kirkegaard and Perry Laboratories). After 60 min, the absorbance was measured at 405 nm using a microtiter plate reader.
[0306] mAb inhibition ELISA: The wells of Nunc Maxisorp EIA plates were coated overnight in a drying oven with 1 μg of P. aeruginosa LPS in PBS at 4°C or with P. aeruginosa killed whole cells in dH2O, and then placed at RT before use. The plates were blocked with 1% BSA-PBS for 1 h at RT, and the wells were then washed with PBS-T. During the blocking step, inhibition was established. LPS or synthetic oligosaccharides were added to the test tubes at 1 mg / ml or 3 mg / ml, and then serially diluted with 1% BSA-PBS, and then an equal volume of mAb (1B1, 3B8, or 3C4) was added at a constant concentration of 10 μg / ml in 1% BSA-PBS, and the mixture was incubated at RT for 1 h. After washing the EIA plate with PBS-T, 100 μl from the mixing tube was added to the plate and incubated at RT for 1 h for LPS-coated plates, or 3 h for killed whole cell-coated plates. After washing with PBS-T, appropriate AP-labeled goat anti-mouse Ig (Southern Biotech) specific for the mAb used was added at 1:250 dilution in 1% BSA-PBS at RT for 1 h. The plate was then washed with PBS-T and developed with a phosphatase substrate system (Kirkegaard and Perry Laboratories). After 60 min, the absorbance was measured at 405 nm using a microtiter plate reader.
[0307] Serum bactericidal assay: The ability of polyclonal sera and mAbs to promote bactericidal killing of selected P. aeruginosa strains was determined as previously described
[22] .
[0308] Opsonophagocytosis assay: The ability of polyclonal sera and mAbs to promote opsonophagocytic killing of selected P. aeruginosa strains was assayed as previously described
[23] .
[0309] Surface plasmon resonance (SPR): SPR binding assays were performed at 25°C on a Biacore T200 instrument in HBS-EP running buffer (Cytiva Life Sciences, Mississauga, Canada) essentially as described previously
[24] . Briefly, approximately 13,000 RU of IgM (PA1B1 and control Fn 4F1) were amine coupled to a CM7S sensor chip in 10 mM acetate buffer, pH 4.0 (Cytiva). Synthetic oligosaccharides were reconstituted to 25 mM in HBS-EP and a series of dilutions were prepared for injection onto the IgM surface. The contact time was 60 s and the dissociation time was 120 s (mono-, di-) or 180 s (tri-, tetra-, penta-). The injection concentration range was as follows: mono-(1 mM-62.5 μM), di-(200 μM-12.5 μM), and tri-, tetra- and penta-(10 μM-625 nM). Mcat lgt2 / 4, an oligosaccharide from Moraxella catarrhalis, was used as a control and injected at 10 μM. The surface was regenerated by extensive washing with HBS-EP. The reference flow cell-subtracted sensorgrams were fitted to a 1:1 binding model to determine binding kinetics and affinity, or affinity was determined by steady-state analysis.
[0310] Example 2: Results
[0311] Conjugation: The reducing terminal erythritol in OS1 was efficiently targeted by periodate oxidation, generating a reactive aldehyde group for conjugation. Oxidized oligosaccharide OS2 ( Figure 7 ) was conjugated to the carrier proteins BSA and CRM via direct reductive amination 197 , MALDI-MS analysis indicated that the resulting glycoconjugates contained ~13 and ~10 kDa of attached conjugated carbohydrates (10-13 sugar chains / protein), respectively ( Figures 8A to 8D ).
[0312] Immunization: Six mice and two rabbits received a prime and two boost immunization strategies with CRM glycoconjugates as described in "Experiments". ELISA using final bleed sera highlighted that both animals had seroconverted to the conjugated oligosaccharide, as demonstrated by titration against BSA conjugate and LPS ( Fig. 9A and 9B ). Mice titered more strongly to the BSA conjugate than to LPS, whereas rabbit titer curves were roughly similar to both antigens.
[0313] mAb development: Mice with the best titers to PAO1 LPS (NRCC 6667) after glycoconjugate immunization were selected for mAb development and their spleens were fused with a bone marrow cell line as described in the experimental section. Three mAbs were obtained, 3C4 (IgG2b), 3B8 (IgM), and 1B1 (IgM). The heavy and light chain variable regions of these mAbs were sequenced and their amino acid sequences are shown in Table 4. Each mAb could recognize the homologous PAO1(wzy::Gm) LPS and in the case of mAb 1B1, P. aeruginosa purified LPS from the A-band locus mutants PAO1(wzy::Gm)(Δpa5457) and PAO1(wzy::Gm)(Δpa5458) ( Fig.10 Similarly, each mAb recognized killed whole cells of wt serotype 5 strains PAO1 BAA-47 and 5937, and again confirming the LPS ELISA data, mAb 1B1 was the only mAb that cross-reacted with killed whole cells of the A-band locus mutants PAO1(wzy::Gm)(Δpa5457), PAO1(wzy::Gm)(Δpa5458), and PAO1(wzy::Gm)(Δpa5459), as well as a subset of ATCC-type strains corresponding to the most commonly encountered clinical serotypes ( Figures 11A to 11C This behavior was replicated when a panel of clinical isolates was examined ( Fig.12 ), among which mAb 1B1 showed broad cross-reactivity.
[0314] SBA and OPA: Initial efforts focused on demonstrating the ability of polyclonal rabbit serum to promote serum bactericidal killing of PAO1 wt P. aeruginosa strains. However, limited evidence of killing was observed with polyclonal rabbit serum. Subsequent efforts focused on opsonophagocytosis assays (OPA) as reports in the literature [8-10] utilized OPA to demonstrate the potential functionality of antisera against P. aeruginosa. Similar to the SBA, we obtained preliminary evidence that rabbit serum could promote opsonophagocytic activity against PAO1 O-antigen-deficient strains. However, when mAbs were examined, high opsonophagocytic titers were observed against PAO1 serotype 5 strains, PAO1 BAA-47 and 5937 ( Fig.13A and 13B ).
[0315] mAb epitope mapping: Preliminary experiments were performed to examine whether the mAbs recognized the same, different, or overlapping epitopes on 3-O-Me rhamnose. Competition ELISA studies showed that mAb1B1 recognized a unique epitope compared to 3C4, whereas 3C4 and 3B8 recognized similar overlapping epitopes ( Fig.14A and 14B), which is consistent with the ability of 1B1 mAb to recognize a broader subset of strains compared to mAbs 3B8 and 3C4.
[0316] Inhibition ELISA with synthetic oligosaccharides: To further characterize the immunogenic epitopes recognized by the mAbs, synthetic oligosaccharides representing mono- (D- and L-isomers), di- (with and without linkers), tri-, tetra-, and pentasaccharides of the terminal unit of 3-O-methyl D-rhamnose were prepared as described herein and tested in inhibition ELISA experiments. Initially, the experiments were validated using LPS molecules known to be recognized or not recognized by the three mAbs. Subsequently, the synthetic oligosaccharides were used as inhibitors, revealing that trisaccharides, tetrasaccharides, and pentasaccharides were effectively equivalent in inhibiting mAb 1B1 binding to its target LPS and killing whole cells ( Figures 15A to 15F ). There was some evidence that disaccharides and monosaccharides (D-isomer only) had inhibitory effects, but not to the extent observed with trisaccharides and larger oligosaccharides. The L-monosaccharides were completely ineffective in inhibition, confirming that the D-isomer is the correct configuration for rhamnose in 3-O-methylrhamnose. None of the synthetic oligosaccharides were effective in inhibiting binding of mAbs 3C4 or 3B8 to their LPS targets or killing whole-cell targets. These results are consistent with earlier data suggesting that mAb 1B1 can recognize terminal 3-O-methylrhamnose and that trisaccharides may be sufficient to effectively mimic the native structure.
[0317] SPR analysis: SPR was used to further delineate the minimal epitope recognized by 1B1 and to determine affinity for synthetic oligosaccharides ( Fig.16 and Table 5). Synthetic carbohydrates from monosaccharides to pentasaccharides were flowed over the high density surface of 1B1 IgM and an irrelevant IgM, FN 4F1. No observable binding was detected for monosaccharides up to 1 mM. The disaccharides showed specific binding to the 1B1 surface with rapid association and dissociation rates, and K was determined. D =84 μM steady-state affinity. Trisaccharides, tetrasaccharides, and pentasaccharides all specifically bind to 1B1 with significantly higher affinity than disaccharides (K D s = 1.42, 0.66 and 0.55 μM, respectively). All three synthetic oligosaccharides had measurable kinetics, highlighted by slow off-rates not typically observed in carbohydrate-antibody interactions. max The value is approximately the theoretical R max The binding affinity of the 1B1 IgM surface was approximately 25% of that of the 1B1 surface, indicating acceptable 1B1 IgM surface activity. When an irrelevant oligosaccharide, Mcat lgt2 / 4 (886 Da) from Moraxella catarrhalis was injected at 10 μM, no observable binding was detected on either IgM surface. Taken together, these data suggest that the trisaccharide may be the minimal antigen recognition domain that mimics the native structure, although higher 1B1 binding affinity was observed for the tetrasaccharide and pentasaccharide.
[0318] Table 5. SPR-derived binding affinity of 1B1 to synthetic oligosaccharides.
[0319]
[0320]
[0321] a Steady-state affinity.
[0322] Theo R max : Theoretical maximum binding response; Obs R max : maximum observed binding response; nb: no binding observed.
[0323] Example 3A-Synthesis of 3-O-methyl rhamnose oligosaccharides
[0324] This example describes the synthesis of the target pentasaccharide (see Figure 22-24 Schemes 1-3 in). The synthesis of 3-OD-rhamnose and 3-OL-rhamnose and derivatization to their respective acetylated has-2-octyl glycosides demonstrated the purity of each enantiomer produced by GC-MS. Large-scale synthesis of the intermediate thioglycoside donor 16 and acceptor 17 led to the disaccharide 18 bisaccharide. After benzyl deprotection, the new acceptor 19 bisaccharide was obtained, and further iterative glycosylation and hydrogenation reactions ultimately led to 18 bisaccharide. After overall deprotection, the synthesis of the target pentasaccharide resulted in a 1.0% overall yield starting from D-mannose. In addition, an aminoethyl linker was added to the disaccharide to develop a method for additional conjugated vaccine development. The method described in this example illustrates that a sufficient amount of pure pentasaccharide can be obtained by synthesis to facilitate the development of a Pseudomonas aeruginosa glycoconjugate vaccine using this polysaccharide.
[0325] All chemicals were purchased from Aldrich, Fisher Scientific, Alpha Aeser or Combi Blocks. They were used without further purification. 1 H 500MHz, 13 C 125MHz, 31 The NMR spectrum was measured on a P 200 MHz) spectrometer, reporting the residual solvent signal (CDCl3, 1 H is 7.26 ppm and 13 C is 77.1ppm; CD3OD, 1 H is 3.31 ppm and 13 C is 49.0ppm; D2O, 1 H is 4.79 ppm, and for 13C, external use of dioxane (67.2 ppm), and for 31 P, 85% H3PO4 was used in a separate experiment before measuring the spectrum). Standard two-dimensional NMR experiments such as HMBC, COSY, HSQC and 13 CNMR confirmed the identity of the compound. RF Systems and Compounds were purified on RF silica columns. MS data were recorded on a SQ2 from Waters and HRMS data were recorded on an Ultima from Waters with LC / MS calibrant mixtures from Agilent as internal standards.
[0326] 1,4-O-Dibenzyl-2,3-O-isopropylidene-α-D-rhamnopyranoside (4)
[0327] 1-O-Benzyl-2,3-O-isopropylidene-α-D-rhamnopyranoside (9.70 g, 32.9 mmol) was dissolved in anhydrous DMF (200 mL) and the solution was cooled to 0 ° C. 60% sodium hydride (1.97 g, 49.3 mmol) in mineral oil was added in batches and the solution was stirred at 0 ° C for 30 minutes under nitrogen. Next, benzyl bromide (4.70 mL, 39.5 mmol) was added dropwise and the reaction was stirred for 1 h before completion by TLC. Once completed, the reaction was quenched with Et3N (8 mL) and poured into a cold solution of saturated NH4Cl (500 mL). When the product precipitated from the solution, it was filtered out, washed with water, and dried under high vacuum overnight to produce the product 4 (12.6 g, 32.9 mmol, 100%) as a beige solid. Rf = 0.75, (EtOAc / hexane, 2 / 8) [α] D 25 23.45(c 0.22,CHCl3) 1 H NMR (500MHz, CDCl3): δ7.38-7.26(m,10H,2 x Bn),5.05(s,1H,H1α),4.89(d,1H,J A,B =11.6Hz,CHA,OBn),4.69(d,1H,J A,B =11.8Hz,CHA,OBn),4.64(d,1H,J B,A =11.6Hz, CHB,OBn),4.51(d,1H,J B,A =11.8Hz, CHB,OBn),4.29(dd,1H,J 3,4 =6.2Hz, J 3,2 =6.2Hz, H3),4.19(d,1H,J 2,3=5.8Hz,H2),3.80-3.73(m,1H,H5),3.24(dd,1H,J 4,3 =7.2Hz, J 4,5 =9.9Hz,H4),1.51,1.36(2 xs,3H,CH3),1.29(d,3H,J 6,5 =6.3Hz, H6) 13 C NMR (125MHz, CDCl3): δ138.4,137.2,128.6(x2),128.4(x2),128.3(x2),128.1(x2),128. 0,127.7(Bn),109.3(C(CH3)2),96.3(C1),81.3(C4),78.7(C3),76.2(C2),73.1,69.1(2x CH2(Bn),64.8(C5),28.1,26.4(2x CH3),17.9(C6)J C1,H1 =174Hz, HRMS:C 23 H 28 NaO5[M+Na] + Calculated m / z: 407.1834; found: 407.1828.
[0328] 1,4-O-Dibenzyl-α-D-rhamnopyranoside (5)
[0329] Compound 4 (0.46 g, 1.21 mmol) was dissolved in 80% (v / v) AcOH (8 mL) solution, and the solution was heated to 60° C. for 4 h. The solution was then evaporated under reduced pressure, and the crude product was crystallized from CH2Cl2 / hexane to yield 5 (395 mg, 1.15 mmol, 95%) as white crystals. Rf=0.6 (EtOAc / hexane, 7 / 3) [α] D 25 1.49(c 0.09,CHCl3) 1 HNMR (500MHz, CDCl3): δ7.36-7.26(m,10H,2x Bn),4.86(s,1H,H1),4.78-4.73(m,2H,CHA,CHB,OBn),4.69(d,1H,J A,B =11.9Hz,CHA,OBn),4.51(d,1H,J B,A =11.9Hz, CHB,OBn),3.99-3.94(m,2H,H2,H3),3.83-3.76(m,1H,H5),3.37(dd,1H,J 4,3 =J 4,5=9.1Hz, H4),2.26(d,1H,J OH,2 =3.6Hz, OH), 2.24(d, 1H, J OH,3 =4.8Hz, OH), 1.36(d, 3H, J 6,5 =6.3Hz, H6). 13 C NMR (125MHz, CDCl3): δ138.3,137.3,128.7(x2),128.6(x2),128.1,128.1(x2),128.0(x2),128.0,( Bn),98.6(C1),81.8(C4),75.2(CH2,Bn),71.6(C3),71.3(C2),69.2(CH2,Bn),67.5(C5),18.1(C6)J C1,H1 =167Hz LRMS:C 20 H 24 NaO5[M+Na] + m / z calculated: 367.4; found: 367.3
[0330] 1,4-Di-O-benzyl-3-O-methyl-α-D-rhamnopyranoside (6)
[0331] Compound 5 (25.1g, 72.9mmol) is co-evaporated with toluene three times and dried overnight under high vacuum. Then 5 is dissolved in anhydrous toluene (500mL), purged with nitrogen and dibutyltin oxide (IV) (21.8g, 87.5mmol) is added. The reaction mixture is stirred at reflux for 16h, then cooled to RT and evaporated under vacuum. The crude mixture is dried for 5h under high vacuum, then dissolved in the anhydrous DMF of 500mL. The mixture is purged with nitrogen, then cesium fluoride (16.5g, 109mmol) and iodomethane (51.7mL, 830.4mmol) are added. The reaction is stirred at 40 ° C for 16h under nitrogen, then completed by TLC. The reaction mixture is cooled to RT and diluted with EtOAc (300mL), washed with water (5x 60mL), saturated NaHCO (1x60mL) and brine (1x 60mL). The combined organic layers were then dried over Na2SO4, evaporated and purified by flash chromatography (eluent: EtOAc / hexane) to yield 6 as a light oil (23.7 g, 66.3 mmol, 91%-2 steps). Rf = 0.35 (EtOAc / hexane, 7 / 3) [α] D 25 58.3(c 0.43,CHCl3) 1H NMR (500MHz, CDCl3): δ7.37-7.26(m,10H,2x Bn),4.91(d,1H,J 1,2 =1.2Hz, H1),4.86(d,1H,J A,B =11.0Hz,CHA,OBn),4.71(d,1H,J A,B =11.8Hz,CHA,OBn),4.64(d,1H,J B,A =11.6Hz, CHB,OBn),4.47(d,1H,J B,A =11.0Hz, CHB,OBn),4.08(dd,1H,J 2,1 =1.7Hz, J 2,3 =3.3Hz,H2),3.83-3.73(m,1H,H5),3.61(dd,1H,J 3,2 =3.4Hz, J 3,4 =9.1Hz,H3),3.49(s,3H,OMe),3.39(dd,1H,J 4,3 =9.4Hz, J 4,5 =9.4Hz,H4),2.43(d,1H,J OH,3 =2.0Hz, OH), 1.31(d, 3H, J 6,5 =6.3Hz, H6). 13 C NMR (125MHz, CDCl3): δ138.6,137.3,128.5(x2),128.5(x2),128.1(x2),12 8.1(x2),128.0,127.8(Bn),98.3(C1),81.8(C3),80.0(C4),75.4,69.2(2x CH2(Bn)),68.0(C2),67.4(C5),57.5(OCH3),18.0(C6)J C1,H1 =174Hz HRMS:C 21 H 26 NaO5[M+Na] + Calculated m / z: 381.1672; Found: 381.1668.
[0332] 3-O-Methyl-D-rhamnose (D-monosaccharide)
[0333] 1-O-Benzyl-3-O-methyl-α-D-rhamnopyranoside (43.7 mg, 162.9 μmol) was dissolved in a 16:10 (V:V) solution of 4M HCl and MeCN (10 mL), and the solution was heated at 80°C for 16 h. The solution was then evaporated and purified by flash chromatography (eluent: MeOH / CH2Cl2, 1 / 5) to provide the monosaccharide as a white solid (18.9 mg, 106.1 μmol, 65%). Rf=0.30, (EtOAc), 1 H NMR (600MHz, CD3OD): δ5.18(d,0.7H,J 1α,2α =1.6Hz,H1α),4.74(d,0.3H,J 1β,2β =1.0Hz,H1β),4.07(dd,0.7H,J 2β,1β =0.7Hz, J 2β,3β =2.9Hz,H2β),4.03(dd,0.7H,J 2α,1α =0.9Hz, J 2α,3α =1.9Hz, H2α),3.89-3.83(m,0.7H,H5α),3.50-3.48(2x s,3H,OCH3α / β),3.46(dd,0.7H,J 4α,3α =3.0Hz, J 4α,5α =9.4Hz, H4α), 3.43-3.39 (m, 1H, H3α and H4β), 3.42-3.35 (m, 0.3H, H5β), 3.15 (dd, 1H, J 3β,2β =3.0Hz, J 3β,4β =9.2Hz, H3β),1.34-1.25(m,3H,H6α / H6β). 13 C NMR (151MHz, CD3OD): δ95.7(C1α),95.4(C1β),84.5(C3β),81.8(C3α),73.0(C4α),72.4(C4β),71. 1(C5β),69.2(C5α),69.0(C2β),68.8(C2α),57.3(OCH3α),57.2(OCH3β),18.1(C6α),18.1(C6β).J C1,H1α =172Hz, J C1,H1β =161Hz, HRMS: C7H 14 NaO5[M+Na] + The calculated value of m / z is 201.0739; the measured value is 201.0734. The NMR spectrum is shown in Figure 5B middle.
[0334] 3-O-Methyl-L-rhamnose(L-monosaccharide)
[0335] 1,2-Di-O-acetyl-3-O-methyl-L-rhamnopyranoside S9 (100 mg, 381 μmol) was dissolved in 10 mL of MeOH / H2O / Et3N (7 / 2 / 1) solution and the reaction was stirred at RT for 16 h. The solution was then evaporated under reduced pressure and filtered through Na + Filter, then pass The fractions containing the product were collected and evaporated to give a clear oil 13 as an α / β mixture (8 / 5) (37.5 mg, 210 μmol, 55%), 1 H NMR (600MHz, CD3OD): δ5.06(d,0.8H,J 1α,2 α=1.7Hz,H1α),4.87(d,0.2H,J 1β,2β =1.7Hz,H1β),4.05(d,0.2H,J 2β,1β =0.9Hz, J 2β,3β =3.1Hz, H2β),4.01(dd,0.8H,J 2α,1α =1.8Hz, J 2α,3α =2.9Hz, H2α),3.83(m,0.8H,H5α),3.48(s,0.6H,OCH3β),3.48(s,2.4H,OCH3α),3.44(dd,0.8H,,J 4α,3α =J 4α,5α =9.6Hz, H4α),3.41-3.36(m,1H,H3α,H4β),3.29(m,0.2H,H3β),1.30(d,0.6H,J 6β,5β =6.1Hz),1.25(d,2.4H,J 6α,5α =6.1Hz, H6α). 13 C NMR (151MHz, CD3OD): δ95.7(C1α),95.3(C1β),84.5(C3β),81.8(C3α),73.0(C4α),72.4(C4β),73. 3(C5β),69.2(C5α),69.0(C2β),68.8(C2α),57.3(OCH3α),57.2(OCH3β),18.1(C6α),18.1(C6β).J C1,H1α =172Hz, J C1,H1β =162Hz.HRMS:C7H 14 NaO5[M+Na] +The calculated value of m / z is 201.0733; the found value is 201.0735. The NMR spectrum is shown in Figure 5A middle.
[0336] 4-O-Benzyl-3-O-methyl-D-rhamnose (14)
[0337] Compound 6 (1.54 g, 4.30 mmol) was dissolved in a 16:10 solution of 4M HCl and MeCN (219 mL), and the solution was heated at 80 ° C for 3 h. TLC analysis showed that the reaction reached completion after 3 h. The solution was then evaporated and purified by flash chromatography (eluent: MeOH / CH2Cl2, 1 / 5) to provide a clear oily compound 14 as an α / β mixture (6 / 5) (0.75 g, 2.80 mmol, 65%). Rf = 0.25 (EtOAc / hexane, 1 / 1) 1 H NMR (500MHz, CDCl3): δ7.36-7.27(m,5H,Bn),5.25(s,1H,H1α),4.85(d,1H,J A,B =11.1Hz,CHA,OBn),4.72(s,1H,H1β),4.63(d,1H,J B,A =10.9Hz, CHB, OBn), 4.10-4.08 (m, 2H, H2α, H2β), 3.99-3.92 (m, 1H, H5α), 3.62 (dd, 1H, J3α, 4α =9.1Hz, 3.3Hz, H3α), 3.52, 3.50 (2x s, 3H, OCH3α / β), 3.38 (dd, 1H, J 4α,3α =9.4Hz, J 4α,5α =9.4Hz, H4α),3.37-3.31(m,3H,H3β,H4β,H5β),2.56(br.s,1H,OH),2.46(br.s,1H,OH),1.33(d,3H,J 6β,5β =5.7Hz, H6β),1.29(d,3H,J 6α,5α =5.7Hz, H6α). 13C NMR (125MHz, CDCl3): δ128.5,128.4,128.3,128.0,127.9,127.8,127.7(Bn),93.9(C1α),93.8(C1β),83.8(C3β),81.3(C3α),79.8(C4α),79. 3(C4β),75.2(CH2,Bn),71.1(C5β),68.3(C2α),68.0(C2β),67.3(C5α),57.5(OCH3α),57.4(OCH3β),18.0(CH3,C6α),17.9(CH3,C6β).HRMS: C 14 H 20 NaO5[M+Na] + Calculated m / z: 291.1203; found: 292.1205.
[0338] p-Tolyl 2-acetyl-4-O-benzyl-3-O-methyl-1-thio-D-rhamnopyranoside (16)
[0339] Compound 15 (925 mg, 2.63 mmol) was dissolved in anhydrous CH2Cl2 (20 mL), and the solution was cooled to 0 ° C under nitrogen. Thiocresol (456 mg, 3.67 mmol) was added next, followed by boron trifluoride etherate (452.9 μL, 3.67 mmol). The reaction was stirred at 0 ° C for 3 h and then reached completion. The solution was then diluted with CH2Cl2 (20 mL) and washed with water (2 x 20 mL) and saturated NaHCO3 solution (1 x 20 mL). The combined organic layers were then dried with Na2SO4, evaporated, and purified by flash chromatography (eluent: EtOAc / hexane) to generate brown oily compound 16, which was an α / β mixture (5 / 2) (880 mg, 2.11 mmol, 80%). Rf=0.6 (EtOAc / hexane, 3 / 7) [α] D 25 23.1(c 2.1,CHCl3) 1 H NMR (500MHz, CDCl3): δ7.43-7.28(m,7H,Bn / Stol),7.20-7.10(m,2H,Stol),5.71(d,0.5H,J 2β,3β =2.5Hz, H2β),5.56(dd,0.5H,J 2α,3α =1.6Hz, 3.2Hz, H2α),5.35(d,0.5H,J 1α,2α =1.3Hz,H1α),4.92(d,0.5H,J Aα,Bα= 11.0 Hz, CHAα,OBn), 4.87 (d, 0.5H, J Aβ,Bβ = 11.0 Hz, CHAβ,OBn), 4.75 (s, 0.5H, H1β), 4.64 (d x 2, 1H, J Bα,Aα和Bβ,Aβ = 10.7 Hz, CHBα and CHBβ,OBn), 4.27 - 4.20 (m, 0.5H, H5α), 3.65 (dd, 1H, J 3α,4α = 9.3 Hz, J 3α,2α = 3.3 Hz, H3α), 3.47 (s, 1.5H, OCH3α), 3.45 (s, 1.5H, OCH3β), 3.45 - 3.42 (m, 0.5H, H4α), 3.40 - 3.34 (m, 1.5H, H3β, H4β, H5β), 2.34 (s, 1.5H, CH3, STolβ), 2.33 (s, 1.5H, CH3, STolα), 2.23 (s, 1.5H, Acβ), 2.15 (s, 1.5H, Acα), 1.40 (d, 1.5H, J 6β,5β = 5.5 Hz, H6β), 1.35 (d, 1.5H, J 6α,5α = 6.2 Hz, H6α). 13 C NMR (125 MHz, CDCl3): δ 170.5 (COβ), 170.3 (COα), 138.6, 138.5, 138.1, 138.0, 132.3 (x2), 132.3 (x2), 130.2, 130.2, 129.9 (x2), 129.9, 129.1, 128.5 (x2), 128.5, 128.3, 128.1, 128.0 (x2), 127.8, 127.8, 125.4 (Ar), 86.5 (C1α), 85.8 (C1β), 84.0 (C3β), 80.5 (C3α), 80.4 (C4α), 79.3 (C4β), 76.1 (C5β), 75.4 (CH2, Bnα, Bnβ), 70.4 (C2α), 70.0 (C2β), 68.9 (C5α), 57.8 (OCH3β), 57.7 (OCH3α), 21.2 (CH3, Stolβ), 21.2 (CH3, Stolα), 21.1 (Acα), 20.9 (Acβ), 18.3 (C6β), 17.9 (C6α). J C1,H1α = 169 Hz, J C1,H1β = 154 Hz, ESI-MS: C 23 H 28 NaO5S [M + Na] + The calculated m / z value of: 439.1550; the measured value: 439.1545.
[0340] 1,2-Diacetyl-3-O-methyl-α-D-rhamnopyranoside (17)
[0341] Compound 15 (450 mg, 1.28 mmol) was dissolved in 10.0 mL of MeOH, and palladium hydroxide on carbon (40 mg, 0.28 mmol) was added to the solution. The solution was bubbled with a hydrogen balloon for 5 minutes and stirred under a hydrogen atmosphere for 3 h before reaching completion. The solution was then filtered through celite and evaporated to yield pure 17 (323 mg, 1.23 mmol, 96%) as a clear oil. Rf = 0.25 (EtOAc / hexane, 1 / 1) [α] D 25 -21.2(c 3.4,CHCl3) 1 H NMR (500MHz, CDCl3): δ = 5.96 (s, 1H, H1), 5.24 (d, 1H, J 2,1 =2.0Hz, H2),3.76-3.67(m,1H,H5),3.48(dd,1H,J 4,5 =9.4Hz, J 4,3 =9.4Hz,H4),3.43(dd,1H,J 3,2 =3.2Hz, J 3,4 =9.5Hz,H3),3.37(s,3H,OCH3),2.96(br.s,1H,OH),2.08,2.07(2x s,6H,CH3),1.28(d,3H,J 6,5 =6.3,H6) 13 C NMR (125MHz, CDCl3): δ169.9,168.5(2x C=O),91.2(C1),79.3(C3),71.1(C4),70.4(C5),66.4(C2),57.4(OCH3),20.9,20.7(2x Ac),17.7(C6).J C1,H1 =170Hz, LRMS: C 11 H 18 NaO7[M+Na] + m / z calculated: 285.1; found: 285.1.
[0342] 2-O-Acetyl-4-O-benzyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-1,2-O-diacetyl-3-O-methyl-α-D-rhamnopyranoside (18-)
[0343] Compounds 16 (615 mg, 1.48 mmol) and 17 (323 mg, 1.23 mmol) were co-evaporated with toluene (5 x 10 mL) and dried under high vacuum overnight. Anhydrous CH2Cl2 (20 mL) was added followed by 0.6 g of activated powdered Molecular sieves. The reaction was then cooled to -78 ° C under a nitrogen atmosphere, N-iodosuccinimide (406 mg, 1.80 mmol) was added, followed by trifluoromethanesulfonic acid (20 μL, 226 μmol). The reaction was stirred for 3 h and then reached completion. The reaction was then filtered through a Buchner funnel and diluted with 20 mL of CH2Cl2, washed with 10% Na2S2O3 (2x 20 mL) and saturated NaHCO3 solution (1x 20 mL). The organic layer was then dried over Na2SO4, filtered, and purified by flash chromatography (eluent: EtOAc / hexane) to generate a clear oily compound 18 bis (363 mg, 655 μmol, 53%). Rf=0.55 (EtOAc / hexane, 1 / 1) [α] D 25 183(c18.7,CHCl3) 1 H NMR(500MHz, CDCl3)δ7.40-7.16(m,5H,Bn),6.02(d,1H,J 1,2 =1.7Hz,H1),5.39(dd,1H,J 2′,3′ =1.9Hz, 3.0Hz, H2′),5.31(dd,1H,J 2,1 =1.7,1.7Hz,H2),5.17(d,1H,J 1′,2′ =1.7Hz, H1′),4.92(d,1H,J A,B =10.9Hz,CHA,OBn),4.65(d,1H,J B,A =10.9Hz, CHB, OBn), 3.88-3.81 (m, 1H, H5), 3.79-3.72 (m, 1H, H5′), 3.64-3.59 (m, 3H, H3, H3′, H4), 3.48, 3.45 (2x s, 6H, OCH3), 3.40 (dd, 1H, J 4′,5′ =J 4′,3′ =9.5Hz, H4′),2.17,2.16,2.15(3x s,9H,Ac),1.35(d,3H,J 6′,5′ =6.2Hz, H6′),1.34(d,3H,J 6,5 =6.1Hz, H6). 13C NMR (125MHz, CDCl3): δ170.2,170.0,168.6 (3x C=O),138.5,128.5(x2),128.1(x2),127.8(Bn),99.5(C1′),91.1(C1),80.0(C4,C3′),79.9 (C4′),77.9(C3),75.5(CH2,Bn),69.3(C5′),68.7(C5),68.6(C2′),66.9(C2),57.6,57.6(2x OCH3),21.2,21.0,20.9(3x Ac),18.3(C6),18.0(C6′).J C1,H1 =173Hz, J C1′,H1′ =179Hz LRMS:C 27 H 38 NaO 12 [M+Na] + Calculated m / z: 577.2; found: 577.9.
[0344] 2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-1,2-O-diacetyl-3-O-methyl-α-D-rhamnopyranoside (19-)
[0345] Same procedure as 17. Compound 18 bis (363 mg, 655 μmol), palladium hydroxide on carbon (40 mg, 285 μmol), MeOH (10 mL). Isolate clear oily compound 19 bis (273 mg, 588 μmol, 92%). Rf = 0.2 (EtOAc / hexane, 1 / 1) [α] D 25 44(c 4.3,CHCl3) 1 H NMR(500MHz, CDCl3)δ5.93(d,1H,J 1,2 =1.6Hz,H1),5.31(dd,1H,J 2,1 =1.9Hz, J 2,3 =2.8Hz, H2′),5.22(m,1H,H2),5.09(d,1H,J 1′,2′ =1.7Hz, H1′),3.76-3.66(m,2H,H5,H5′),3.54-3.51(m,2H,H3,H4),3.44(dd,1H,J 4′,5′ =9.4Hz, J 4′,3′=9.4Hz, H4′),3.35,3.34(2x s,6H,OCH3),3.34-3.29(m,1H,H3′),2.88(br.s,1H,OH),2.08,2.06,2.05(3x s,9H,Ac),1.29-1.25(m,6H,H6′,H6). 13 C NMR (125MHz, CDCl3): δ170.1,170.0,168.5 (3x C=O),99.7(C1′),91.0(C1),79.9(C4),79.4(C3′),77.5(C3),71.4(C4′),69.2(C5′),69.0(C 5),67.4(C2),66.8(C2′),57.5,57.2(OCH3),21.0,20.9,20.8(3xAc),18.2(C6),17.5(C6′).J C1,H1 =173Hz, J C1′,H1′ =168Hz LRMS:C 20 H 32 NaO 12 [M+Na] + Calculated m / z: 487.2; found: 486.9.
[0346] 2-O-Acetyl-4-O-benzyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-1,2-O-diacetyl-3-O-methyl-α-D-rhamnopyranoside (18-tri)
[0347] Compound 16 (243 mg, 584 μmol) and 19 bis (226 mg, 487 μmol) were co-evaporated with toluene (5×10 mL) and dried under high vacuum overnight. Anhydrous CH 2 Cl 2 (10 mL) was added, followed by 0.3 g of activated powdered Molecular sieves. The reaction was then cooled to -78 ° C under a nitrogen atmosphere, N-iodosuccinimide (161 mg, 715 μmol) was added, followed by trifluoromethanesulfonic acid (10 μL, 115 μmol). The reaction was stirred for 3 h and then reached completion. The reaction was then filtered through a Buchner funnel and diluted with 20 mL of CH2Cl2, washed with 10% Na2S2O3 (2x 10 mL) and saturated sodium bicarbonate solution (1×10 mL). The organic layer was then dried over Na2SO4, filtered, and purified by flash chromatography (eluent: EtOAc / hexane) to produce a clear oily compound 18 tris (254 mg, 336 μmol, 69%). Rf=0.55 (EtOAc / hexane, 1 / 1), [α]<h2 style=";text-align:left;direction:ltr"> D <h2 style=";text-align:left;direction:ltr"> 25 <h2 style=";text-align:left;direction:ltr"> 157(c 15,CHCl3)<h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500MHz,CDCl3):δ7.36-7.25(m,5H,Bn),5.98(d,1H,J<h2 style=";text-align:left;direction:ltr"> 1,2 <h2 style=";text-align:left;direction:ltr"> =1.7Hz,H1),5.36-5.32(m,2H,H2′,H2″),5.28(m,1H,H2),5.11(m,2H,H1′,H1″),4.87(d,1H,J<h2 style=";text-align:left;direction:ltr"> A,B <h2 style=";text-align:left;direction:ltr"> (10.9Hz, CHA, OBn), 4.62(d, 1H, J<h2 style=";text-align:left;direction:ltr"> B,A <h2 style=";text-align:left;direction:ltr"> (10.9Hz, CHB, OBn), 3.85-3.78(m, 1H, H5″), 3.78-3.70(m, 2H, H5′, H5), 3.60-3.54(m, 3H, H3′, H3″, H4), 3.54-3.47(m, 2H, H3, H4′), 3.43(s, 3H, OCH3), 3.39(s, 6H, OCH3 x2), 3.36(dd, 1H, J<h2 style=";text-align:left;direction:ltr"> 4″,3″ <h2 style=";text-align:left;direction:ltr"> =9.6Hz,H4″),2.12(s,6H,Ac x 2),2.11(s,3H,Ac),2.08(s,3H,Ac),1.31(d,3H,J<h2 style=";text-align:left;direction:ltr"> 6″,5″ <h2 style=";text-align:left;direction:ltr"> (6.2Hz, H6″), 1.30(d, 3H, J<h2 style=";text-align:left;direction:ltr"> 6,5 <h2 style=";text-align:left;direction:ltr"> (6.3Hz, H6), 1.29(d, 3H, J<h2 style=";text-align:left;direction:ltr"> 6′,5′ <h2 style=";text-align:left;direction:ltr"> (6.3Hz, H6′).<h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR(125MHz,CDCl3):δ170.1,170.0,169.9,168.4(C=O),138.5,128.4(x2),128.0(x2),127.7 (Bn),99.4(C1′),99.3(C1″),91.0(C1),79.9(C4″),79.9(C3),79.8(C3′),79.8(C3″),78.2(C 4′),78.0(C4),75.3(CH2,Bn),69.1(C5),68.6(C2′),68.4(C2″),67.8(C5′),67.8(C5″),66.7 (C2),57.5(OCH3),57.2(OCH3),21.1,21.0,20.9,20.8(Ac),18.2(C6″),18.0(C6′),17.8(C6)J<h2 style=";text-align:left;direction:ltr"> C1,H1 <h2 style=";text-align:left;direction:ltr"> =179Hz,J<h2 style=";text-align:left;direction:ltr"> C1′,H1′ <h2 style=";text-align:left;direction:ltr"> <179Hz,J<h2 style=";text-align:left;direction:ltr"> C1″,H1″ <h2 style=";text-align:left;direction:ltr"> =179Hz HRMS:C<h2 style=";text-align:left;direction:ltr"> 36 <h2 style=";text-align:left;direction:ltr"> H52 NaO 17 [M+Na] + Calculated m / z: 779.3102; found: 779.3079.
[0348] 2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-1,2-O-diacetyl-3-O-methyl-α-D-rhamnopyranoside (19-tri)
[0349] Same procedure as 17. Compound 18 tri (228 mg, 301 μmol), palladium hydroxide on carbon (40 mg, 285 μmol), MeOH (10 mL). Isolate clear oily compound 19 tri (195.5 mg, 293 μmol, 97%). Rf = 0.25 (EtOAc / hexane, 1 / 1) [α] D 25 118(c 13.3,CHCl3) 1 H NMR (500MHz, CDCl3): δ5.98(d,1H,J 1,2 =1.4Hz, H1),5.36-5.32(m,2H,H2′,H2″),5.2(m,1H,H2),5.14(d,1H,J 1′,2′ =0.9Hz, H1′),5.10(d,1H,J 1″,2″ =1.2Hz, H1″),3.82-3.72(m,3H,H5,H5′,H5″),3.58-3.52(m,3H,H3,H3′,H4′),3.52-3.47(m,2H,H3″,H4″),3.40,3.39,3.38(3x s,3H,OCH3),3.41-3.36(m,1H,H4),2.48(br.s,1H,OH),2.13(s,3H,Ac),2.11 (s,3H,Ac),2.09(s,3H,Ac),2.08(s,3H,Ac),1.35-1.29(m,9H,H6,H6′,H6″). 13C NMR (125MHz, CDCl3): δ170.1,170.1,170.0,168.5 (4x C=O),99.6(C1′),99.5(C1″),91.1(C1),80.0(C3″),79.9(C3),79.4(C3′),78.1(C4),78.0(C4′),7 1.6(C4″),69.2(C5),68.9(C5′),67.9(C5″),67.8(C2″),67.4(C2′),66.8(C2),57.6,57.3,57.2(3x OCH3),21.1(x2),21.0,20.9(4x Ac),18.3(C6″),18.1(C6′),17.6(C6).J C1,H1 =172Hz, J C1′,H1′ =171Hz, J C1″,H1″ =171Hz LRMS:C 29 H 46 NaO 17 [M+Na] + Calculated m / z: 689.3; found: 688.8.
[0350] 2-O-Acetyl-4-O-benzyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-1,2-O-diacetyl-3-O-methyl-α-D-rhamnopyranoside (18-tetra)
[0351] Compounds 16 (146 mg, 351 μmol) and 19 (195 mg, 293 μmol) were co-evaporated with toluene (5×10 mL) and dried under high vacuum overnight. Anhydrous CH 2 Cl 2 (10 mL) was added, followed by 0.2 g of activated powdered Molecular sieves. The reaction was then cooled to -78 ° C under a nitrogen atmosphere, N-iodosuccinimide (96.5 mg, 429 μmol) was added, followed by trifluoromethanesulfonic acid (5 μL, 57.5 μmol). The reaction was stirred for 3 h and then reached completion. The reaction was then filtered through a Buchner funnel and diluted with 10 mL of CH2Cl2, washed with 10% Na2S2O3 (2x 5 mL) and saturated NaHCO3 solution (1×5 mL). The organic layer was then dried over Na2SO4, filtered, and purified by flash chromatography (eluent: EtOAc / hexane) to produce a clear oily compound 18 four (149.7 mg, 156 μmol, 53%). Rf=0.55 (EtOAc / hexane, 1 / 1) [α] D25 54.7(c 5.0,CHCl3) 1 H NMR(500MHz,CDCl3):δ7.37-7.26(m,5H,Bn),5.99(d,1H,J 1,2 =1.7Hz,H1),5.37-5.32(m,3H,H2′,H2″,H2″′),5.28(m,1H,H2),5.11(s,3H,H1′,H1″,H1″′),4.86(d,1H,J A,B =10.9Hz,CHA,OBn),4.62(d,1H,J B,A =10.9Hz,CHB,OBn),3.85-3.71(m,4H,H5,H5′,H5″,H5″′),3.61-3.53(m,4H,H3,H4,H4′,H4″),3.53-3.49(m,3H,H3′,H3″,H3″′),3.44,3.40,3.39,3.38(4x s,12H,OCH3),3.37-3.31(m,1H,H4″′),2.13,2.12(2x s,6H,Ac),2.11,2.08,2.07(3x s,9H,Ac),1.34(d,3H,J 6,5 =6.2Hz,H6),1.31(d,3H,J 6′,5′ =6.3Hz,H6′),1.30(d,3H,J 6″,5″ =6.3Hz,H6″),1.28(d,3H,J 6″′,5″′ =6.3Hz,H6″′). 13C NMR (125MHz, CDCl3): δ170.1,170.0,170.0,169.9,168.5(C=O),138.5,128.4(x2),128.0(x2),127.8 ,(Bn),99.5(C1″′),99.4(C1″),99.3(C1′),91.0(C1),80.0(C3),80.0(C3′),79.8(C3″,C3″′ and C4″′), 78.3(C4),78.1(C4′ and C4″),75.4(CH2,Bn),69.1(C5),68.6(C2″′),68.4(C5″′),67.9(C2″),67.8(C2′ ),67.7(C5′),67.7(C5″),66.8(C2),57.5,57.5,57.3,57.2(4xOCH3),21.1,21.0,21.0,21.0,20.9(5x Ac),18.3(C6),18.1(C6′),18.1(C6″),18.0(C6″′).J C1,H1 =185Hz, J C1′,H1′ =179Hz, J C1″,H1″ =179Hz, J C1″′,H1″′ =179Hz, HRMS:C 45 H 66 NaO 22 [M+Na] + Calculated m / z: 981.3943; found: 981.3910.
[0352] 2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-1,2-O-diacetyl-3-O-methyl-α-D-rhamnopyranoside (19-tetra)
[0353] Same procedure as 17. Compound 18 quaternary (110 mg, 114.7 μmol), palladium hydroxide on carbon (20.0 mg, 143 μmol), MeOH (10 mL). Compound 19 quaternary (95.6 mg, 110.0 μmol, 96%) was isolated as a white solid. Rf = 0.40 (EtOAc / hexane, 1 / 1) [α] D 25 52.40 (c 4.78, CHCl3) 1 H NMR (600MHz, CD3OD): δ5.96(d,1H,J 1,2=1.6Hz,H1),5.41(dd,1H,J 2′,1′ =3.0Hz,J 2′,3′ =5.6Hz,H2′),5.40(dd,1H,J 2″,1″ =3.0Hz,J 2″,3″ =5.1Hz,H2″),5.37(s,1H,H2″′),5.33(dd,J 2,1 =3Hz,J 2,3 =5.8Hz,H2),5.08(m,2H,H1′,H1″′),5.07(m,1H,H1″),3.88-3.80(m,3H,H5,H5′,H5″),3.80-3.73(m,1H,H5″′),3.69(dd,1H,J 3,2 =3.9Hz,J 3,4 =11.2Hz,H3),3.61-3.55(m,2H,H3′,H3″),3.55-3.45(m,3H,H4,H4′,H4″),3.42-3.32(m,2H,H3″′,H4″′),3.41(2x s,3H,OCH3),3.40(2x s,3H,OCH3),2.15,2.13,2.11,2.11,2.09(5x s,15H,Ac),1.34-1.26(m,12H,H6,H6′,H6″,H6″′). 13 C NMR(125MHz,CD3OD / CDCl 3, 1 / 1):δ171.0,170.9,170.9,170.7,169.3(C=O),99.9(C1″′),99.8(C1″),99.8(C1′),91.4(C1),80.4(C3″),80.3(C3′),80.2(C3),79.4(C3″′),78.9(C4),78.8(C4′),78.5(C4″),71.8(C4″′),69.8(C5″′),69.5(C5),68.6(C2″′),68.5(C2′),68.4(C2″),68.2(C5′,C5″),67.3(C2),57.7(x2),57.5(x2)(4x OCH3),21.0,21.0,21.0,20.9,20.9(5x Ac),18.5(C6′),18.3(C6″),18.2(C6″′),17.6(C6)J C1,H1 =179Hz,J C1′,H1′ =177Hz,J C1″,H1″ =177Hz,J C1″′,H1″′ =176Hz HRMS:C38 H 60 NaO 22 [M+Na] + Calculated m / z: 891.3474; Found: 891.3429.
[0354] 2-O-Acetyl-4-O-benzyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-1,2-O-diacetyl-3-O-methyl-α-D-rhamnopyranoside (185)
[0355] Compound 16 (37.4 mg, 89.9 μmol) and 19 (48.8 mg, 56.2 μmol) were co-evaporated with toluene (5×10 mL) and dried under high vacuum overnight. Anhydrous CH 2 Cl 2 (5 mL) was added, followed by 50 mg of activated powdered Molecular sieves. The reaction was then cooled to -78 °C under a nitrogen atmosphere, N-iodosuccinimide (24.7 mg, 109.8 μmol) was added, followed by trifluoromethanesulfonic acid (10 μL, 113 μmol). The reaction was stirred for 3 h and then reached completion. The reaction was then filtered through a Buchner funnel and diluted with 10 mL of CH2Cl2, washed with 10% Na2S2O3 (2 x 5 mL) and saturated NaHCO3 solution (1 x 5 mL). The organic layer was then dried over Na2SO4, filtered, and purified by flash chromatography (eluent: EtOAc / hexane) to produce a clear oily compound 18 5 (35.6 mg, 30.7 μmol, 55%). Rf = 0.70 (EtOAc / hexane, 7 / 3) [α] D 25 22.26 (c1.75, CHCl3) 1 H NMR (500MHz, CDCl3): δ7.36-7.26(m,5H,Bn),5.98(d,1H,J 1,2 =1.5Hz, H1),5.35-5.31(m,4H,H2′,H2″,H2″′,H2″″),5.27(s,1H,H2),5.10(s,4H,H1′,H1″,H1″′,H1″″),4.86(d,1H,J A,B =10.9Hz,CHA,OBn),4.61(d,1H,J B,A=10.9Hz, CHB,OBn),3.84-3.70(m,5H,H5,H5′,H5″,H5″′,H5″″),3.60-3.51(m,5 H,H3,H4,H4′,H4″,H3″″),3.51-3.46(m,4H,H3′,H3″,H3″′,H4″′),3.43,3.39(2x s,3H,OCH3),3.38(s,6H,OCH3x2),3.37(s,3H,OCH3),3.37-3.31(m,1H,H4″″),2.12,2.12,2.11,2.08(4x s,12H,Ac),2.07(s,6H,Ac x2),1.36-1.26(m,15H,H6,H6′,H6″,H6″′,H6″″). 13 C NMR (125MHz, CDCl3): δ170.2,170.1,170.1,170.0,169.9,168.5(C=O),138.5,128.4(x2),128.0(x2),127.8(B n),99.5(C1″′),99.4(C1″),99.4(C1′),99.3(C1″″),91.0(C1),80.0(C3″″),80.0(C3),79.9(C3′),79.9(C3″, C3″′,C4″″),78.3(C4),78.3(C4′),78.2(C4″),78.1(C4″′),75.4(CH2,Bn),69.1(C5),68.7(C2″″),68.4(C5″″ ),67.9(C2″),67.9(C2″′),67.8(C2′),67.8(C5′),67.7(C5″,C5″′),66.8(C2),57.5,57.5,57.3,57.3,57.2(5x OCH3),21.1,21.1,21.0,21.0,21.0,20.9(6xAc),18.3(C6),18.1(C6′),18.1(C6″),18.1(C6″′),17.9(C6″″)J C1,H1 =174Hz, J C1′,H1′ =177Hz, J C1″,H1″ =177Hz, J C1″′,H1″′ =177Hz, J C1″″,H1″″ =177Hz HRMS:C 54 H 80 NaO 27 [M+Na] + Calculated m / z: 1183.4785; found: 1180.4753.
[0356] 2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-1,2-O-diacetyl-3-O-methyl-α-D-rhamnopyranoside (195)
[0357] Same procedure as 17. Compound 18 5 (35.0 mg, 30.1 μmol), palladium hydroxide on carbon (15.0 mg, 105.0 μmol), MeOH (5 mL). White solid compound 19 5 (32.2 mg, 30.1 μmol, 100%) was isolated. Rf = 0.45 (EtOAc / hexane, 7 / 3) [α] D 25 19.6 (c 1.66, CD3OD) 1 H NMR (500MHz, CD3OD): δ5.97(d,1H,J 1,2 =1.4Hz,H1),5.34-5.29(m,4H,H2′,H2″,H2″′,H2″″),5.26(s,1H,H2),5.12(s,1H,H1″″),5.09(s,3H,H1′,H1″,H1″′),3.81-3. 72(m,5H,H5,H5′,H5″,H5″′,H5″″),3.57-3.35(m,4H,H3,H4′,H4″,H4″′),3.51-3.44(m,5H,H4,H4″″,H3′,H3″,H3″′),3.38(2x s,3H,OCH3),3.37(s,6H,OCH3),3.36(s,3H,OCH3x2),3.37-3.31(m,1H,H3″″),2.12,2.12,2.10,2.08,2.07(4xs,12H,Ac),2.06(s,6H,Ac x2),1.35-1.25(m,15H,H6,H6′,H6″,H6″′,H6″″). 13C NMR (125MHz, CD3OD): δ170.1(x2),170.1,170.1,170.0,168.5(C=O),99.6(C1″″),99.6(C1″),99.5(C 1′),99.4(C1″′),91.1(C1),80.1(C3″),80.0(C3′),80.0(C3),79.9(C3″′),79.4(C3″″),78.3(C4′), 78.3(C4″),78.2(C4″′),78.1(C4),71.6(C4″″),69.2(C5),68.9(C5″″),68.0(C2″′),68.0(C2″),67. 9(C2″″),67.8(C2′),67.8(C5′),67.7(C5″),67.5(C5″′),66.8(C2),57.6,57.3,57.3,57.3,57.2(5x OCH3),21.1(x2),21.1,21.0(x2),20.9(6x Ac),18.3(C6),18.2(C6′,C6″,C6″′),18.1(C6″″)LRMS: C 47 H 74 NaO 27 [M+Na] + Calculated m / z: 1093.4; found: 1093.8.
[0358] 3-O-Methyl-α-D-rhamnopyranoside - (1→4)-3-O-methyl-D-rhamnopyranose (disaccharide)
[0359] Compound 18 bis (18 mg, 38.7 μmol) was dissolved in MeOH (5 mL), and sodium metal (1 mg) was added to the reaction mixture. After 16 h, rexin-H + Add to the mixture until a pH of 5 is obtained. The mixture is then filtered and evaporated to give the compound disaccharide without further purification (13.1 mg, 38.7 μmol, 100% yield). Rf = 0.5 (MeOH / CH2Cl2, 1 / 5) 1 H NMR (600MHz, CD3OD): δ5.08(d,1H,J 1′,2 =1.8Hz,H1′),4.99(d,0.8H,J 1α,2 =1.7Hz,H1α),4.65(d,0.2H,J 1β,2 =0.9Hz, H1β),4.04(dd,1H,J 2′,1′ =1.9Hz, J 2′,3′ =3.1Hz, H2′),3.99(dd,0.2H,J2β,1β =1.1Hz, J 2β,3β 3.9Hz, H2β), 3.96(dd, 0.8H, J 2α,1α =1.9Hz, J 2α,3α =2.9Hz, H2α),3.82(m,0.8H,H5α),3.68(m,1H,H5′),3.51(dd,0.8H,J 4α,5α =3.0Hz, J 4α,3α =9.3Hz, H4α),3.48(m,0.2H,H4β)3.46(dd,0.8H,J 3α,2α =3.0Hz, J 3α,4α =9.3Hz, H3α), 3.42-3.40 (m, 4H, H4′ and OCH3′), 3.38 (s, 3H, OCH3), 3.31 (m, 0.2H, H5β), 3.24 (dd, 1H, J 3′,2′ =3.2Hz, J 3′,4′ =9.4Hz, H3′),3.23(m,0.2H,H3β),1.34(d,0.6H,J 6β,5β =6.0Hz, H6β)1.24(d,2.4H,J 6α,5α =6.3Hz,H6α),1.20(d,3H,J 6′,5′ =6.4Hz, H6′). 13 C NMR (150MHz, CD3OD): δ103.2(C1′),95.5(C1α),95.4(C1β),85.5(C3β),83.0(C3α),82.0(C3′),79.8(C4α),79.2(C4β),72.6(C4′),72 .0(C5β),70.5(C5′),68.5(C2α),68.4(C2β and C2′),67.8(C5α),57.3(OCH3′),56.7(OCH3α),56.5(OCH3β),18.8(C6α and C6β),17.9(C6′).J C1′,H1′α =173Hz, J C1,H1α =172Hz, J C1,H1β =165Hz. NMR spectrum is shown in Fig.17 middle.
[0360] 3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside (trisaccharide)
[0361] Compound 19 tris (25 mg, 37.5 μmol) was dissolved in 10 mL of anhydrous MeOH and the solution was stirred under a nitrogen atmosphere. Sodium metal (10.0 mg, 0.44 mmol) was then added and the reaction was stirred until it reached completion by TLC. The solution was then neutralized with Rexin, filtered through celite, and evaporated to yield a transparent solid compound trisaccharide (18.1 mg, 36.3 μmol, 97%). Rf = 0.45 (MeOH / CH2Cl2, 1 / 4) [α] D 25 16.754 (c 1.4, MeOH) 1 H NMR (600 MHz, CD3OD): δ 5.16 (m, 2H, H1′ and H1″), 5.07 (d, 0.8H, J 1α,2 =1.6Hz,H1α),4.65(d,0.2H,J 1β,2 =0.6Hz, H1β),4.12(dd,1H,J 2′,1′ =2.2Hz, J 2′,3′ =2.6Hz, H2′),4.11(dd,1H,J 2″,1″ =1.9Hz, J 2″,3″ =3.0Hz, H2″),4.07(dd,0.2H,J 2β,1β =0.9Hz, J 2β,3β 2.9Hz, H2β),4.04(dd,1H,J 2α,1α =2.0Hz, J 2α,3α =2.8Hz, H2α),3.90(m,0.8H,H5α),3.80(m,1H,H5′)3.74(m,1H,H5″),3.62(dd,1H,J 4α,5α =J 4α,3α =9.2Hz, H4′),3.58(dd,0.8H,J 4α,5α =J 4α,3α =9.3Hz, H4α), 3.56-3.49 (m, 1H, H3α and H4β), 3.45 (m, 1H, H3′), 3.49-3.48 (m, 4H, OCH3″, H 4″),3.46(s,3H,OCH3′),3.45(s,3H,OCH3),3.39(m,0.2H,H5β),3.33-3.29(dd,1.2H,J 3″,2″ =3.0Hz, J 3″,4″ =9.5Hz, H3″ and H3β), 1.35(d, 0.6H, J 6β,5β =6.0Hz,H6β),1.32(d,3H,J 6′,5′=6.4Hz, H6′),1.29(d,2.4H,J 6α,5α =6.3Hz,H6α),1.28(d,3H,J 6″,5″ =6.2Hz, H6″). 13 C NMR (150MHz, CD3OD): δ103.2(C1″),103.2(C1′),95.5(C1α),95.4(C1β),85.4(C3β),83.1( C3′),82.9(C3α),82.0(C3″),80.0(C4α),79.4(C4β),79.3(C4′),72.6(C4″),71.9(C5β),7 0.5(C5″),69.0(C5′),68.6(C2β),68.5(C2α),68.3(C2″),68.0(C2′),67.7(C5α),57.3(OC H3″),56.7(OCH3α),57.6(OCH3′),56.5(OCH3β),18.8(C6′ and C6β),18.6(C6α),17.9(C6″).J C1′,H1′α =J C1″,H1″ =173Hz, J C1α,H1α =172Hz, J C1β,H1β =163Hz J C1′,H1′α =170Hz LRMS: C 21 H 38 NaO 13 [M+Na] + The calculated value of m / z is 521.2; the found value is 521.2. The NMR spectrum is shown in Fig.18 middle.
[0362] 3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-Methyl-α-D-rhamnopyranoside (tetrasaccharide)
[0363] Compound 19 (22.6 mg, 26.0 μmol) was dissolved in 10 mL of anhydrous MeOH and the solution was stirred under a nitrogen atmosphere. Sodium metal (10 mg, 0.44 mmol) was then added and the reaction was stirred until it reached completion by TLC. The solution was then treated with Rexin-H + The resin was neutralized, filtered through celite, and evaporated to yield the tetrasaccharide compound as a transparent solid (15.9 mg, 24.1 μmol, 93%). Rf = 0.45 (MeOH / CH2Cl2, 1 / 4) [α] D 25 7.7 (c 0.63, MeOH)1 H NMR (600MHz, CD3OD): δ5.08(m,3H,H1′,H1″,H1″′),5.00(d,0.8H,J 1α,2 =1.8Hz,H1α),4.66(d,0.2H,J 1β,2 =0.8Hz, H1β),4.05(m,2H,J 2′,1′ =2.2Hz, J 2′,3′ =2.6Hz, H2′ and H2″), 4.04(dd, 1H, J 2″,1″ =1.9Hz, J 2″,3″ =3.0Hz, H2″′),4.01(dd,0.2H,J 2β,1β =0.8Hz, J 2β,3β 3.0Hz, H2β), 3.96(dd, 1H, J 2α,1α =1.9Hz, J 2α,3α =2.8 Hz, H2α), 3.83 (m, 0.8H, H5α), 3.76-3.69 (m, 2H, H5′ and H5″), 3.67 (m, 1H, H5″′), 3.56-3.53 (m, 2H, H4′ and H4″), 3.51 (dd, 0.8H, J 4α,5α =J 4α,3α =9.3Hz, H4α), 3.52-3.49 (m, 1H, H3α and H4β), 3.46 (dd, J 3′,2′ =3.0Hz, J 3′,4′ =9.3 Hz, 1H, H3′), 3.42-3.40 (m, 4H, OCH3″′, H4″′), 3.40-3.35 (s, 11H, OCH3′, OCH3″, OCH3, H3″ and H3′), 3.33 (m, 0.2H, H5β), 3.25-3.22 (m, 1.2H, H3″′ and H3β), 1.28-1.21 (m, 9H, H6β, H6′, H6α and H6″), 1.20 (d, 3H, J 6″′,5″′ =6.2Hz, H6″′). 13C NMR (150MHz, CD3OD): δ103.2(C1″′),103.0(C1″),103.0(C1′)95.5(C1α),95.4(C1β),85.4(C3β),83.0(C3′),83 .0(C3″)82.9(C3α),82.0(C3″′),80.0(C4α),79.7(C4β),79.4(C4′),79.2(C4″),72.6(C4″′),71.9(C5β),70.5( C5″′),69.0(C5′),68.9(C5″),68.6(C2β),68.2(C2α),68.3(C2″′),68.0(C2′ and C2″),67.7(C5α),57.3(OCH3″′), 56.7(OCH3α),56.7(OCH3′),56.6(OCH3″),56.5(OCH3β),18.8(C6α),18.7(C6β),18.5(C6′ and C6″),17.9(C6″′).J C1′,H1′ =J C1″,H1″ =J C1″′,H1″′ =173Hz, J C1α,H1α =174Hz, J C1β,H1β =162Hz,LRMS:C 28 H 50 NaO 17 [M+Na] + The calculated value of m / z is 681.3; the found value is 680.9. The NMR spectrum is shown in Fig.19 middle.
[0364] 3-O-Methyl-α-D-Rhamnoside-(1→4)-3-O-Methyl-α-D-Rhamnoside-(1→4)-3-O-Methyl-α-D-Rhamnoside-(1→4)-3-O-Methyl-α-D-Rhamnoside-(1→4)-3-O-Methyl-α-D-Rhamnoside (Pentasaccharide)
[0365] Compound 19 pentose (33.1 mg, 30.9 μmol) was dissolved in 10.0 mL of anhydrous MeOH and the solution was stirred under a nitrogen atmosphere. Metallic sodium (10.0 mg, 0.44 mmol) was then added and the reaction was stirred until it reached completion by TLC. The solution was then neutralized with Rexin, filtered through celite, and evaporated to yield a transparent solid compound pentose (25.3 mg, 30.9 μmol, 100%). Rf = 0.45 (MeOH / CH2Cl2, 1 / 4) [α] D 25 12.6 (c 1.0, MeOH) 1H NMR (600MHz, CD3OD): δ5.12(m,4H,H1′,H1″,H1″′,H1″″),5.03(d,0.8H,J 1α,2 =1.8Hz, H1α), 4.71(s, 0.2H, H1β), 4.09(m, 3H, H2′ and H2″, H2″′), 4.04(dd, 1H, J 2″″,1″″ =1.9Hz, J 2″″,3″″ =2.8Hz, H2″″),4.05(dd,0.2H,J 2β,1β =0.8Hz, J 2β,3β 2.8Hz, H2β),4.00(dd,1H,J 2α,1α =2.0Hz, J 2α,3α =2.6 Hz, H2α), 3.87 (m, 0.8H, H5α), 3.80-3.73 (m, 3H, H5′, H5″ and H5″′), 3.71 (dd, 1H, J 5″″,4″″ =9.1Hz, J 5″″,6″″ =6.3Hz, H5″″),3.60-3.56(m,3H,H4′,H4″,H4″′),3.55(dd,0.8H,J 4α,5α =J 4α,3α =9.3Hz, H4α), 3.52-3.47 (m, 0.8H, H3α and H4β), 3.46-3.39 (m, 19.2H, OCH3 x 5, H4″″, H3′, H3″ and H3″′, H5β), 3.29 (m, 1.2H, H3β and H3″″), 1.23-1.22 (m, 12H, H6β, H6′, H6α, H6″, H6″′), 1.24 (d, 3H, J 6″″,5″″ =6.1Hz, H6″″). 13C NMR (151MHz, CD3OD): δ103.2(C1″″), 103.1(C1″′), 103.0(C1″ and C1′), 95.5(C1α), 95.3(C1β), 85.3(C3β), 83.0(C3′), 83.0 (C3″),83.0(C3″′),82.9(C3α),82.0(C3″″),80.0(C4α),79.5(C4β and C4′),79.4(C4″),79.2(C4″′),72.6(C4″″)71.9(C5β) ,70.5(C5″″),69.0(C5′),69.0(C5″),68.9(C5″′),68.6(C2β),68.4(C2α),68.3(C2″″),68.0(C2′,C2″ and C2″′),67.7(C5α) ,57.3(OCH3″″),56.7(OCH3α,OCH3′,OCH3″,OCH3″′),56.6(OCH3β),18.8(C6α),18.6(C6β,C6′,C6″ and C6″′),17.9(C6″″).J C1′,H1′ =J C1″,H1″ =J C1″′,H1″′ =J C1″″,H1″″ =173Hz, J C1α,H1α =170Hz, J C1β,H1β =160Hz, LRMS: C 35 H 62 NaO 21 [M+Na] + The calculated value of m / z is 841.4; the found value is 841.3. The NMR spectrum is shown in Fig. 20 middle.
[0366] 2-[N-(tert-Butyloxycarbonyl)amino]ethyl 2-O-acetyl-4-O-benzyl-3-O-methyl-α-D-rhamnopyranoside (21)
[0367] Compound 16 (46.4 mg, 111 μmol) and N-boc-ethanolamine (19 μL, 123 μmol) were co-evaporated with toluene (5×10 mL) and dried under high vacuum overnight. Anhydrous CH2Cl2 (5 mL) was added, followed by 0.1 g of activated powdered The reaction was then cooled to -78 °C under a nitrogen atmosphere, N-iodosuccinimide (33.7 mg, 150 μmol) was added, followed by trifluoromethanesulfonic acid (10 μL, 115 μmol). The reaction was stirred for 3 h and then reached completion. The reaction was then filtered through a Buchner funnel and diluted with 10.0 mL of dichloromethane, washed with 10% Na2S2O3 (2 x 10 mL) and saturated sodium bicarbonate solution (1 x 10 mL). The organic layer was then dried over Na2SO4, filtered, and purified by flash chromatography (eluent: EtOAc / hexane) to produce a clear oily compound 21 (42.0 mg, 88 μmol, 80%). Rf = 0.30 (EtOAc / hexane, 3 / 7) [α] D 25 108.8(c 22.5,CHCl3) 1 H NMR alpha, (500MHz, CDCl3): δ7.37-7.32(m,4H,Bn),7.31-7.28(m,1H,Bn),5.29(dd,1H,J 2,1 =1.3Hz, J 2,3 =3.1Hz, H2),4.88(d,1H,J A,B =10.9Hz,CHA,OBn),4.85(br.s,1H,NH),4.71(d,1H,J 1,2 =1.3Hz,H1),4.60(d,1H,J B,A =10.9Hz, CHB, OBn), 3.73-3.66 (m, 2H, H5 and CHA, CH2CH2NHBoc), 3.63 (dd, 1H, J 3,2 =3.4Hz, J 3,4 =9.4Hz,H3),3.50-3.44(m,1H,CHB,CH2CH2NHBoc),3.44(s,3H,CH3O),3.39-3.32(m,2H,H4 and CHA,CH2CH2 NHBoc),3.30-3.22(m,1H,CHB,CH2CH2NHBoc),2.15(s,3H,Ac),1.45(s,9H,C(CH3)3,Boc),1.32(d,3H,J 6,5 =6.3Hz, H6). 13C NMR (125MHz, CDCl3): δ=170.5,155.9(C=O),138.6,128.5(x2),128.0(x2),127.8(Bn),97.8(C1),80.1(C4),79.9(C3),79.5(CC(CH3)3),75 .4(CH2,Bn),68.6(C2),67.8(C5),67.3(CH2CH2NHBoc),57.6(OCH3),40.3(CH2CH2NHBoc),28.5((CH3)3,BOC),21.1(Ac),18.0(C6).HRMS: C 23 H 35 NNaO8[M+Na] + Calculated m / z: 476.2255; found: 476.2249.
[0368] 2-[N-(tert-Butyloxycarbonyl)amino]ethyl 2-O-acetyl-4-O-benzyl-3-O-methyl-α-D-rhamnopyranoside (22)
[0369] Compound 21 (46 mg, 101.5 μmol) was dissolved in MeOH (5 mL) and loaded with palladium on carbon (40 mg, 0.38 mmol). The solution was then bubbled with a hydrogen balloon for 5 minutes and stirred at room temperature under a hydrogen atmosphere. After 4 h, the reaction reached completion and was therefore filtered and evaporated through diatomaceous earth to produce pure 22 (21.0 mg, 57.8 μmol, 62%) as a clear oil. Rf = 0.35 (EtOAc / hexane, 1 / 1), 1 H NMR (500MHz, CDCl3): δ5.30(dd,1H,J 2,1 =1.8Hz, J 2,3 =3.1Hz,H2),4.78(br.s,1H,NH),4.74(d,1H,J 1,2 =1.6Hz, H1), 3.76-3.65 (m, 2H, H5 and CHA, CH2CH2NHBoc), 3.53-3.43 (m, 3H, H3, H4 and CHB, CH2CH2NHBoc), 3.41 (s, 3H, C H3O),3.39-3.26(m,2H,CH2CH2NHBoc),2.34(br.s,OH),2.12(s,3H,Ac),1.46(s,9H,C(CH3)3,Boc),1.34(d,3H,J 6,5 =6.2Hz, H6). 13C NMR (125MHz, CDCl3): δ = 170.3, 155.9 (C = O), 98.0 (C1), 79.4 (C4), 71.6 (C3), 68.3 (C2), 67.5 (C5), 67. 2(CH2CH2NHBoc),57.3(OCH3),40.2(CH2CH2NHBoc),28.4((CH3)3,BOC),20.9(Ac),17.7(C6).HRMS: C 16 H 29 NNaO8[M+Na] + Calculated m / z: 386.1791; found: 386.1784.
[0370] 2-[N-(tert-Butyloxycarbonyl)amino]ethyl 2-O-acetyl-4-O-benzyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-acetyl-3-O-methyl-α-D-rhamnopyranoside (23)
[0371] Compound 22 (21.0 mg, 57.8 μmol) and 16 (28.9 mg, 69.4 μmol) were co-evaporated with toluene (5×10 mL) and dried under high vacuum overnight. Anhydrous CH 2 Cl 2 (5 mL) was added, followed by 0.1 g of activated powdered Molecular sieves. The reaction was then cooled to -78 ° C under a nitrogen atmosphere, N-iodosuccinimide (19.1 mg, 84.9 μmol) was added, followed by trifluoromethanesulfonic acid (5.0 μL, 57.5 μmol). The reaction was stirred for 3 hours and then reached completion. The reaction was then filtered through a Buchner funnel and diluted with CH2Cl2 (10 mL), washed with 10% Na2S2O3 (2x 10 mL) and saturated NaHCO3 solution (1x10 mL). The organic layer was then dried over Na2SO4, filtered, and purified by flash chromatography (eluent: EtOAc / hexane) to produce a clear oily compound 23 (18 mg, 26.5 μmol, 47%). (Rf=0.65 EtOAc / hexane 3 / 7). 1 H NMRalpha, (500MHz, CDCl3): δ7.38-7.32(m,4H,Bn),7.31-7.27(m,1H,Bn),5.35(m,1H,H2′),5.28(m,1H,H2),5.12(s,1H,H1′),4.88(d,1H,J A,B =10.8Hz,CHA,OBn),4.83(br.s,1H,OH),4.69(s,1H,H1),4.62(d,1H,J B,A=10.9Hz, CHB, OBn), 3.85-3.77 (m, 1H, H5′), 3.75-3.68 (m, 1H, CHA, CH2CH2NHBoc), 3.66-3.61 (m, 1H, H5), 3.61-3.56 (m, 1H, H3′), 3.56-3.51 (m, 4H, H3 and H4), 3.51-3.42 (m, 4H, CHB, CH2CH2NHBoc and CH3O), 3.41-3.34 (m, 4H, H4′ and CH3O), 3.33-3.24 (m, 2H, CH2CH2NHBoc), 3.30 (bs, 1H, NH) 2.13, 2.10 (2x s,6H,Ac x 2), 1.46 (s, 9H, C(CH3)3, Boc), 1.33-1.27 (m, 6H, H6 and H6′). 13 C NMR (125MHz, CDCl3): δ=170.4,170.2 155.9 (C=O), 138.6, 128.4 (x2), 128.0 (x2), 127.8 (Bn), 99.4 (C1′), 97.8 (C1), 80.0 (C4′), 80.0 (C4), 79.9 (C3′), 79.6 (C(CH3)3), 78.3 (C3), 75.4 (CH2, Bn), 68.7 (C2′), (C5′), 67.9 (C2), 67.3 (CH2CH2NHBoc), 67.1 (C5), 57.6 and 57.4 (OCH3), 40.3 (CH2CH2NHBoc), 28.5 ((CH3)3, BOC), 21.2 and 21.1 (Ac), 18.2 and 17.9 (C6 and C6′).J C1′,H1′α =171Hz, J C1,H1α =168Hz HRMS:C 32 H 49 NNaO 13 [M+Na] + The calculated m / z value is 678.3102; the found value is 678.3092. The NMR spectrum is shown in Fig.21 middle.
[0372] 2-Aminoethyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranose (linker disaccharide)
[0373] Compound 23 (18 mg, 27 μmol) was dissolved in MeOH (2 mL) and PD / C (10 mg, 93 μmol) was added, and the mixture was stirred for 16 h under a hydrogen atmosphere by balloon pressure. The compound was then diluted with MeOH (10 mL), filtered through celite and concentrated. The concentrate was then dissolved in MeOH (2 mL) and sodium solid (10 mg, 435 μmol) was added. The reaction was stirred for 16 h under a nitrogen atmosphere, and rexin-H was added. + Resin until a pH of 5 is reached. The mixture is filtered and the filtrate is concentrated. The compound is then dissolved in DCM (2 mL) and TFA (160 μL) is added at 0°C. After 30 min at 0°C, the DCM and TFA mixture is evaporated to produce a yellow oily disaccharide. (10.3 mg, 27 μmol, 100% yield). (Rf=0.12, DCM / MeOH / water / NH4OH, 60 / 35 / 6 / 1) 1 H NMR (600MHz, D2O): δ5.16(d,1H,J 1,2 =1.6Hz, H1′),4.87(d,1H,J 1,2 =1.7 Hz, H1), 4.23 (m, 2H, H2′ and H2), 3.97 (m, 1H, CHACH2NH2), 3.80 (m, 2H, H5′ and H5), 3.70 (m, 1H, CHBCH2NH2), 3.64 (dd, 1H, J 3,2 =3.3Hz, J 3,4 =9.2Hz, H3),3.58(dd,1H,J 4,3 =J 4,5 =9.2Hz,H4),3.50(dd,1H,J 4′,3′ =J 4′,5′ =9.6Hz, H4′),3.44(s,3H,OCH3),3.44(s,3H,OCH3),3.41(dd,1H,J 3′,2′ =3.3Hz, J 3′,4′ =9.7Hz, H3′),3.27(m,2H,CH2NH2),1.33(d,3H,J 6,5 =5.9Hz, H6),1.29(d,3H,J 6′,5′ =6.4Hz, H6′). 13C NMR (150MHz, D2O): δ101.4(C1′),99.7(C1),80.5(C3),79.4(C3′),78.1(C4),70. 6(C4′),69.5(C5′),67.2(C5),66.0(C2′),65.8(C2),63.4(CH2CH2NH2),56.1(2x OCH3),39.0(CH2NH2),17.3(C6),16.5(C6′).J C1′,H1′α =174Hz, J C1,H1α =173Hz ESI-MS: C 16 H 32 NO9[M+H] + Calculated m / z: 382.2072; found: 382.2071.
[0374] Example 3A: Results and Discussion
[0375] Synthesis of 3-O-methyl D-rhamnose: D-rhamnose was first synthesized as described by Zunk et al. and others [28-31] (with slight modifications) (Scheme 1, as Fig. 22 ). Acetylation of D-mannose followed by anomeric benzylation gave the 1-O-benzyl derivative 1 in 49% yield over 2 steps. Crude purification and treatment of 1 with sodium methoxide followed by iodination at C6 gave the iodide 2 in excellent yield. Reduction of 2 with palladium hydroxide and hydrogen provided the D-rhamnose derivative 3 in 100% yield. 1 The doublet at 1.28 ppm in the H NMR spectrum confirmed the dehydroxylation at C6. 2,3-O-acetonide protection of the D-rhamnose derivative 3 followed by O-4-benzylation gave 4 in 90% yield over 2 steps. Diol 5 was obtained after acetonide deprotection. Subsequently, selective 3-O-methylation by treatment with dibutyltin oxide and reaction with cesium fluoride and iodomethane afforded 6 in excellent yield (91%) over 2 steps
[32] . Long-range HMBC coupling between the O-methyl singlet and C3 confirmed the regioselective introduction of the methyl group. Global deprotection of intermediate 6 gave 3-O-methyl D-rhamnose 7 in 59% yield over 2 steps (HRMS: C7H 14 NaO5[M+Na] + m / z calculated: 201.0739; found: 201.0734).
[0376] Synthesis of 3-O-methyl L-rhamnose: Naturally abundant and inexpensive L-rhamnose was converted to the thioglycoside donor 8 in excellent yields after acetylation and reaction with thiocresol [31–36]. Intermediate 9 was obtained after deacetylation and acetonide protection under Zemplén conditions. Benzylation and acetonide deprotection gave the diol 10 in excellent yield. Selective methylation of 3-O using dibutyltin oxide followed by treatment with cesium fluoride and methyl iodide gave the methylated derivative 11 in 55% yield over 2 steps. As previously described for intermediate 6, the strong long-range signal between the O-methyl singlet and C3 confirmed the regioselectivity of the reaction. N-Bromosuccinimide gave the hemiacetal 12 in 71% yield in acetone and water. Acetylation followed by benzylic reduction and subsequent deacetylation gave 3-O-methyl L-rhamnose 13 in 24% yield over 3 steps (HRMS: C7H 14 NaO5[M+Na] + m / z calculated: 201.0733; found: 201.0735) (Scheme 2, shown in Fig.23 middle).
[0377] Synthesis of 3-O-methyl D-rhamnosyl oligosaccharides: In the presence of pure D-enantiomer intermediate 6, anomeric deprotection of 6 with a mixture of HCl, acetonitrile gave hemiacetal 14 in 65% yield. 14 was then acetylated and treated with thiocresol and BF3OEt2 to give donor 16 in good yield. Acceptor 17 was then generated in excellent yield (96%) after hydrogenation of benzylated intermediate 15. Subsequent glycosylation reaction between 16 and 17 activated with N-iodosuccinimide and trifluoromethanesulfonic acid led to disaccharide 18 di (α only) in 53% yield. The long-range HMBC signal between H1′ and C4 additionally confirmed the coupling. The additional ortho-C1′, H1′ coupling constant (J) obtained was 0. C1′,H1′ =179 Hz) indicates an α-configuration, which is consistent with previous literature data
[34] . The disaccharide acceptor 19 is formed after benzyl deprotection, as 1 The absence of signals in the benzyl region of the H NMR spectrum indicates that the pentasaccharide 18 is finally obtained after repeated glycosylation and hydrogenation reactions. Each repeated glycosylation produces slightly lower amounts of the corresponding oligosaccharide, as shown in Scheme 3 ( Fig.24 ). Regardless of the length of the oligosaccharide, the benzyl removal rate remained consistently high with high yields (90-100%). Final deprotection of 19-5 under Zemplén conditions generated the target pentasaccharide 1 in 100% yield with an overall yield of 1.0% from D-mannose. Targets 19-, 19-tri, and 19-tetra were also deprotected under Zemplén conditions to provide compounds 20-, 20-tri, and 20-tetra in excellent yields.
[0378] 2-Aminoethyl linker glycosylation: To conjugate oligosaccharides to proteins for the production of conjugate vaccines, a common method is to glycosylate the reducing end of the oligosaccharide with a linker [37, 38]. Intermediate 16 was glycosylated with N-bocethanolamine to produce intermediate 21 in good yield (Scheme 4, as shown in Fig.25 ). The long-range HMBC signal between H1 and the adjacent linker CH2 additionally confirmed the coupling. The resulting ortho-C1,H1 coupling constants were consistent with the α-configuration.
[34] Deprotection of the benzyl group with Pd / C gave compound 22 in 62% yield; subsequent glycosylation of compound 22 with 16 gave 23 in 53% yield. Overall deprotection of 23 gave the final target 24 in 100% yield.
[0379] Example 4: Pseudomonas aeruginosa methylated rhamnose synthetic pentasaccharide conjugated to HSA (without linker or linker)
[0380] 1.25mg HSA in water has 5mg of methylated rhamnose synthetic pentasaccharide (without connecting handle or joint) prepared according to Example 3 added thereto in 300μl of 20% methanol. Then it is placed at room temperature for 1h and lyophilized. The lyophilized material is immediately dissolved in 300μl of 0.2M sodium borate containing 0.5M sodium sulfate and 15mg / ml sodium cyanoborohydride, and placed at 55°C for 72h. Millipore ultra-15 30K MWCO spin column is used to convert the sample to water (rotate 3 times with water). Aliquots are checked by MALDI and SDS-PAGE, and the remainder is lyophilized (1.1mg) and stored at -20°C until used for immunizing mice. Six Balb / C mice are immunized by the primary immunity and two boosting schemes of glycoconjugates and adjuvants. The cross-reactivity of serum after the second boosting with LPS and whole cells from Pseudomonas aeruginosa is checked in ELISA.
[0381] SDS-PAGE illustrates the conjugation by means of the change in the migration of HSA molecules relative to the conjugate ( Fig.26A and 26B ). MALDI analysis showed that since each pentasaccharide unit is 872 amu, about 6 pentasaccharides have been conjugated to HSA (Figure 27), and its mass has increased by about 5 kDa. ELISA analysis showed that the derived serum recognized LPS from Pseudomonas aeruginosa ( Figures 28A to 28F ) and kill whole cells ( Fig.29 ), highlighting the ability of synthetic pentasaccharide glycoconjugates to achieve the desired response for recognition of target P. aeruginosa epitopes as demonstrated for whole cells.
[0382] Example 5: Synthesis of 3-O-methyl tri-, tetra-, and penta-rhamnose oligosaccharides with a connecting handle and an optional linker
[0383] refer to Fig.30 . The aminoethyl handle protected with Boc was attached to the thiotoluene intermediate S8 (same as 16 above) in 84% yield. The benzyl protecting group was then removed under hydrogenation conditions to give donor S10 (same as 22 above) in excellent yield. S8 protected with thiotoluene (same as 16 above) was subjected to repeated 1,4 glycosylation followed by 4-O-benzyl deprotection to produce S11 (same as 23 above), S13, S15 and S17. Quantitative 4-O-benzyl deprotection of S13, S15 and S17 followed by deacetylation using sodium methoxide and Boc deprotection with TFA produced S19 (same as 24 above), S20 and S21. Without further purification, these compounds were conjugated with a divalent linker containing activated N-hydroxysuccinimide and a hemiacetal-protected aldehyde after semi-preparative reverse phase purification (see Scheme 5, Fig.30 ).
[0384]
[0385] p-Tolyl 1-thio-α-D-mannopyranoside (S1)
[0386] In a 2000mL round-bottom flask, acetylated mannose (142.5g, 365.1mmol) was dissolved in 800mL of anhydrous CH2Cl2 under N2 atmosphere, and the solution was cooled to 0°C. Next, thiocresol (63.5g, 511.0mmol) was added, followed by boron trifluoride etherate (63.1mL, 511.0mmol) and the solution was stirred at RT for 48h, when TLC showed completion. The reaction was then washed with water (2x 200mL) and NaHCO3 (2x 200mL). The organic layer was separated and dried with Na2SO4, filtered, and evaporated under reduced pressure. The crude product was then dissolved in 1000mL of anhydrous MeOH and cooled to 0°C. Sodium metal (0.873g, 36.4mmol) was then added and the reaction was stirred at RT for 30h, then completion was reached. The solution was washed with Dowex H + Neutralize, filter and evaporate. The crude product was then dissolved in water (500 mL) and extracted with CH2Cl2 (3 x 150 mL). The aqueous layer was then evaporated to provide S1 as a light green powder (96.86 g, 245 mmol, 67% over 2 steps). Rf = 0.65 (MeOH / CH2Cl2, 15 / 85, V / V) [α] D 25 2.5(c 0.16,MeOH) 1H NMR (400MHz, CD3OD): δ7.39(d,2H),7.11(d,2H),5.33(s,1H),4.08-3.98(m,2H),3.83-3.62(m,3H),3.29(s,1H),2.29(s,3H) 13 C NMR (100MHz, CD3OD): δ138.9,133.5(2C),132.1,130.8(2C),90.8,75.5,73.7,73.1,68.7,62.6,21.1ESI-MS: C 13 H 18 O5NaS[M+Na] + Calculated m / z: 309.0767; found: 309.0769.
[0387]
[0388] p-Tolyl 6-iodo-1-thio-α-D-mannopyranoside (S2)
[0389] Compound S1 (96.86g, 338.2mmol) is dissolved in anhydrous THF (600mL) and the solution is refluxed at 60 ℃ under N2. Next, triphenylphosphine (133.05g, 507.3mmol), imidazoles (46.04g, 676.4mmol) and I2 (128.76g, 507.3mmol) are slowly added. When the purple color of iodine persists, the reaction is completed after 10 minutes. Then the solution is cooled to RT and concentrated under reduced pressure. The crude mixed mixture is dissolved in ethyl acetate (600mL) and washed with 10% Na2S2O3 (2x150mL) and (2x 150mL). Then the organic layer is dried with Na2SO4, filtered, evaporated, and purified by flash chromatography (eluent: MeOH / CH2Cl2, 1 / 5, V / V), to generate white solid compound S2 (87.37g, 220.5mmol, 65%). Rf=0.65(MeOH / CH2Cl2, 1 / 9, V / V)[α]D 25 -2.1(c 0.041,MeOH) 1 H NMR (400MHz, CD3OD): δ7.47(d,2H),7.14(d,2H),5.34(s,1H),3.93(dd,1H),3.67-3.52(m,3H),3.31(s,1H),2.32(s,3H) 13C NMR (100MHz, CD3OD): δ138.9,133.4(2C),132.2,130.7(2C),91.0,74.9,73.8,72.7,72.6,21.1,6.0ESI-MS: C 13 H 17 O4INaS[M+Na] + Calculated m / z: 418.9784; found: 418.9786.
[0390]
[0391] p-Tolyl 1-thio-α-D-rhamnopyranoside (S3)
[0392] Compound S2 (1.76 g, 4.44 mmol) was dissolved in MeOH (30 mL) and Pd(OH)2 (0.39 g, 2.76 mmol) was added to the solution, and the solution was bubbled with H2. Next, N,N-diisopropylethylamine (1.8 mL, 10.3 mmol) was added, and the solution was stirred under an atmosphere of H2 for 6 h before reaching completion. The solution was then filtered through a pad of celite, evaporated, and purified by flash chromatography (eluent: MeOH / CH2Cl2, 1 / 5, V / V) to provide a clear oily compound S3 (0.65 g, 2.40 mmol, 54%). Rf = 0.50 (MeOH / CH2Cl2, 1 / 9, V / V) [α] D 25 0.91(c 0.043,MeOH) 1 H NMR (400MHz, CD3OD): δ7.35(d,2H),7.14(d,2H),5.29(s,1H),4.10-4.00(m,2H),3.64(dd,1H),3.45(dd,1H),3.31(s,1H),2.31(s,3H),1.26(d,3H) 13 C NMR (100MHz, CD3OD): δ138.8,133.3(2C),132.2,130.8(2C),90.6,74.2,73.8,72.9,72.6,21.1,17.8ESI-MS: C 13 H 18 O4NaS[M+Na] + m / z calculated: 293.0818; found: 293.0818.
[0393]
[0394] p-Tolyl 2,3-O-isopropylidene-1-thio-α-D-rhamnopyranoside (S4)
[0395] Compound S3 (10.16g, 37.6mmol) is dissolved in 250mL of anhydrous acetone. 2,2-dimethoxypropane (8.29mL, 67.6mmol) and p-toluenesulfonic acid monohydrate (0.71g, 0.376mmol) are added to the solution, and the reaction is stirred for 3h at RT, then completion is reached. The solution is evaporated under reduced pressure, dissolved in ethyl acetate (300mL), and washed with saturated NaHCO (2x100mL). The combined organic layers are dried with Na2SO4, filtered, and purified by flash chromatography (eluent: EtOAc / hexane, V / V) to provide compound S4 (10.68g, 34.4mmol, 92%) as a white solid. Spectral data are consistent with literature values. 1
[0396]
[0397] p-Tolyl 4-O-benzyl-2,3-O-isopropylidene-1-thio-α-D-rhamnopyranoside (S5)
[0398] Compound S4 (10.68 g, 34.4 mmol) was dissolved in anhydrous DMF (150 mL), and the solution was cooled to 0 ° C. Next, NaH (2.06 g, 51.6 mmol) was added in batches, and the solution was stirred for 30 mins. Benzyl bromide (4.91 mL, 41.3 mmol) was added dropwise and the solution was stirred for 2 h at RT, and then completion was achieved. The reaction was quenched by adding Et3N (10 mL), and then poured into a saturated cold solution of NH4Cl (400 mL). The solution was stirred for 1 h at 0 ° C, and then filtered. The solid was collected and dried under high vacuum to generate S5 (13.43 g, 33.5 mmol, 98%) as a beige solid. The spectral data were consistent with the literature values. 2
[0399]
[0400] p-Tolyl 4-O-benzyl-1-thio-α-D-rhamnopyranoside (S6)
[0401] Compound S5 (1.09 g, 2.72 mmol) was dissolved in 80% (v / v) AcOH solution (10 mL) and stirred overnight at RT. The solution was then heated to 55 ° C in an oil bath for 3 h to drive the reaction to completion. The solution was then evaporated under reduced pressure and co-evaporated with toluene (4 x 30 mL) to provide a clear oil S6 (909 mg, 2.52 mmol, 92%). Spectral data were consistent with literature values. 2
[0402]
[0403] p-Tolyl 4-O-benzyl-3-O-methyl-1-thio-α-D-rhamnopyranoside (S7)
[0404] Compound S6 (14.3 g, 39.7 mmol) was co-evaporated with toluene (3×100 mL) and dried under high vacuum overnight. S6 was then dissolved in anhydrous toluene (400 mL), purged with N2 gas and dibutyltin (IV) oxide (11.85 g, 47.6 mmol) was added. The reaction mixture was then stirred at reflux for 16 h, cooled to RT, and evaporated under reduced pressure. The crude tin acetal was placed under high vacuum for 5 h, dissolved in anhydrous DMF (793 mL) and purged with N2. Cesium fluoride (9.00 g, 59.6 mmol) and iodomethane (28.15 mL, 396.6 mmol) were added, and the reaction was stirred at 40° C. under N2 for 16 h. The mixture was cooled to RT and diluted with EtOAc (350 mL), washed with water (5×150 mL), saturated NaHCO3 (150 mL) and brine (150 mL). The combined organic layers were then dried over Na2SO4, evaporated and purified by flash chromatography (eluent: EtOAc / hexane, V / V) to provide S7 (10.87 g, 29.0 mmol, 73%) as a clear oil. Rf = 0.40 (EtOAc / hexane, 3 / 7, V / V) [α] D 25 8.2(c 0.38,CHCl3) 1 H NMR (400MHz, CD3Cl): δ7.40-7.27(m,8H),7.11(d,2H),5.47(d,1H),4.86(d,1H).4.64(d,1H),4.30(dd ,1H),4.20(dq,1H),3.58(dd,1H),3.52(s,3H),3.44(dd,1H),2.32(s,3H),2.28(br.s,1H),1.30(d,3H) 13 C NMR (100MHz, CD3Cl): δ138.6.137.8,132.2(2C),130.4,130.0(2C),128.6(2C), 128.1(2C),127.9,87.6,82.1,80.2,75.4,69.5,68.6,57.6,21.2,17.9ESI-MS:C 21 H 26 O4NaS[M+Na] + m / z calculated: 397.1444; found: 397.1444.
[0405]
[0406] p-Tolyl 2-O-acetyl-4-O-benzyl-3-O-methyl-1-thio-α-D-rhamnopyranoside (S8 (same as 16 above))
[0407] Compound S7 (10.85 g, 29.0 mmol) is dissolved in acetic anhydride (20 mL) and pyridine (20 mL) and the solution is stirred at RT for 16 h. The solution is then evaporated under reduced pressure and co-evaporated with toluene (5x30 mL). The crude oil is then purified by flash chromatography (eluent: EtOAc / hexane, V / V) to generate a clear oil compound S8 (10.77 g, 25.9 mmol, 89%). Spectral data conform to literature values. 3
[0408]
[0409] 2-(tert-Butyloxycarbonylamino)ethyl 2-O-acetyl-4-O-benzyl-3-O-methyl-α-D-rhamnopyranoside (S9 (same as 21 above))
[0410] Compound S8 (46.4 mg, 0.11 mmol) and N-boc-ethanolamine were co-evaporated with toluene (5 x 10 mL) and dried under high vacuum overnight. Anhydrous CH2Cl2 (5 mL) was added, followed by 0.1 g of activated powdered Molecular sieves, and the reaction was cooled to -78 ° C under a N2 gas atmosphere. Next, N-iodosuccinimide (33.7 mg, 0.12 mmol) was added, followed by trifluoromethanesulfonic acid (10.0 μL, 0.12 mmol), and the reaction was stirred for 3 h, then reached completion. The mixture was then filtered through a Buchner funnel, diluted with CH2Cl2 (10 mL), and washed with 10% Na2S2O3 (2x 10 mL) and saturated NaHCO3 (10 mL). The organic layer was then dried over Na2SO4, filtered, and purified by flash chromatography (eluent: EtOAc / hexane) to generate a clear oily compound S9 (42.0 mg, 0.093 mmol, 84%). Rf=0.55 (EtOAc / hexane, 1 / 1, V / V) [α] D 25 108.8 (c 2.3, CHCl3) 1H NMR (500MHz, CDCl3): δ7.45-7.36(m,5H),4.89(d,1H),4.84(br.s,1H),4.70(s,1H),4.61(d,1H),3.72-3.65(m,2H),3.63(dd, 1H),3.49-3.44(m,1H),3.42(s,3H),3.36-3.30(m,1H),3.35(dd,1H),3.30-3.21(m,1H),2.14(s,3H),1.44(s,9H),1.31(d,3H) 13 C NMR (150MHz, CDCl3): δ170.5,155.9,138.6,128.5(2C),128.0(2C),127.8,97 .8,80.1,79.9,75.4,68.6,67.8,67.3,57.6,40.3,28.5,21.1,18.0ESI-MS: C 23 H 35 NO8H[M+H] + Calculated m / z: 454.2435; found: 454.2435.
[0411]
[0412] 2-(tert-Butyloxycarbonylamino)ethyl 2-O-acetyl-3-O-methyl-α-D-rhamnopyranoside (S10 (same as 22 above))
[0413] Palladium hydroxide on carbon (1.00 g, 7.00 mmol) was added to MeOH (20 mL), and the solution was bubbled with H2 for 30 minutes. Next, compound S9 (1.37 g, 3.02 mmol) was added, and the solution was stirred at RT for 3 h under a continuous flow of H2. The reaction was then filtered through a pad of celite and evaporated to provide a clear oil S10 (1.07 g, 2.94 mmol, 98%). Rf = 0.35 (EtOAc / hexane, 1 / 1, V / V) [α] D 25 9.6(c 0.28,CHCl3) 1 H NMR (500MHz, CDCl3 / CD3OD): δ5.29(s,1H),4.78(br.s,1H),4.74(s,1H),3.76-3.65(m,2H),3.54-3.47(m, 2H),3.46(dd,1H),3.41(s,3H),3.38-3.36(m,2H),2.34(br.s,1H),2.11(s,3H),1.46(s,9H),1.33(d,3H) 1H NMR (125MHz, CDCl3 / CD3OD): δ170.4,155.9,98.0,79.5,71.6,68.3,67.5,67.2,57.3,40.3,28.4,20.9,17.7ESI-MS: C 16 H 29 NO8H[M+H] + Calculated m / z: 364.1966; found: 364.1963.
[0414]
[0415] 2-O-Acetyl-4-O-benzyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(tert-butyloxycarbonyl)amino]ethyl 2-O-acetyl-3-O-methyl-α-D-rhamnopyranoside (S11 (same as 23 above))
[0416] Compound S10 (1.07 g, 2.93 mmol) and S8 (1.47 g, 3.53 mmol) were co-evaporated with toluene (5 x 20 mL) and dried under high vacuum overnight. Anhydrous dichloromethane (50 mL) was added followed by 0.500 g of activated powdered Molecular sieves. The reaction was then cooled to -78 ° C under N2 atmosphere, and N-iodosuccinimide (1.13 g, 4.11 mmol) was added, followed by trifluoromethanesulfonic acid (0.50 mL, 5.66 mmol). The reaction was stirred for 3 h and then reached completion. The reaction was then filtered through a Buchner funnel, diluted with CH2Cl2 (100 mL), and washed with 10% Na2S2O3 (2x100 mL) and saturated NaHCO3 (100 mL). The organic layer was then dried over Na2SO4, filtered, and purified by flash chromatography (eluent: EtOAc / hexane, V / V) to generate a clear oily compound S11 (1.56 g, 2.38 mmol, 81%). Rf=0.65 (EtOAc / hexane, 1 / 1, V / V) [α] D 25 66.8(c 1.0,CHCl3) 1H NMR (400MHz, CDCl3): δ7.38-7.27(m,5H),5.35(dd,1H),5.28(s,1H),5.12(d,1H),4 .89(d,1H),4.82(br.s,1H),4.69(d,1H),4.61(d,1H),3.86-3.77(m,1H),3.75-3.66 (m,1H),3.66-3.55(m,1H),3.55-3.45(m,3H),3.44(s,3H),3.39(s,3H),3.39-3.33 (m,2H),3.33-3.23(m,1H),2.13(s,3H),2.10(s,3H),1.46(s,9H),1.34-1.28(m,6H) 13 C NMR (125MHz, CDCl3): δ170.4,170.2,155.9,138.6,128.4(2C),128.0(2C),127.8,99.4,97.8,80.1,80.0 ,79.9,78.3,75.4,68.7,68.5,67.9,67.3,67.1,57.6,57.4,40.3,28.5,21.2,21.0,18.2,17.9ESI-MS: C 32 H 49 NNaO 13 [M+Na] + Calculated m / z: 678.3096; found: 678.3092.
[0417]
[0418] 2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(tert-butyloxycarbonyl)amino]ethyl 2-O-acetyl-3-O-methyl-α-D-rhamnopyranoside (S12)
[0419] Palladium hydroxide on carbon (1.20 g, 8.55 mmol) was added to MeOH (50 mL), and the solution was bubbled with H2 for 30 minutes. Next, compound S11 (1.71 g, 2.61 mmol) was added, and the solution was stirred at RT for 3 h under a continuous flow of H2. The reaction was then filtered through a pad of celite and evaporated to provide a clear oil S12 (1.47 g, 2.59 mmol, 99%). Rf = 0.20 (EtOAc / hexane, 1 / 1, V / V) [α] D 25 1.07(c 0.33,CHCl3) 1H NMR (400MHz, CDCl3): δ5.36(dd,1H),5.31-5.26(m,1H),5.14(s,1H),4.82(br.s,1H),4.70(s,1H),3.84-3.75(m,1H),3.75-3.62( m,1H),3.58-3.44(m,4H),3.43-3.34(m,8H),3.34-3.21(m,1H),2.38(br.s,1H),2.12-2.08(m,6H),1.46(s,9H),1.35-1.29(m,6H) 13 C NMR (100MHz, CDCl3): δ170.5,170.2,155.9,99.8,97.9,80.1,79.7,79.5,78.4,77.4,71 .7,69.0,67.9,67.5,67.4,67.2,57.5,57.3,40.4,28.6,21.2,21.1,18.3,17.7ESI-MS: C 32 H 43 O 13 NH[M+H] + Calculated m / z: 566.2807; found: 566.2788.
[0420]
[0421] 2-O-Acetyl-4-O-benzyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(tert-butyloxycarbonyl)amino]ethyl 2-O-acetyl-3-O-methyl-α-D-rhamnopyranoside (S13)
[0422] Compound S12 (1.46 g, 2.57 mmol) and S8 (1.29 g, 3.10 mmol) were co-evaporated with toluene (5 x 20 mL) and dried under high vacuum overnight. Anhydrous dichloromethane (50 mL) was added followed by 0.400 g of activated powdered Molecular sieves. The reaction was then cooled to -78 ° C under N2 atmosphere, and N-iodosuccinimide (990.0 mg, 3.60 mmol) was added, followed by trifluoromethanesulfonic acid (0.40 mL, 4.52 mmol). The reaction was stirred for 3 h and then reached completion. The reaction was then filtered through a Buchner funnel, diluted with CH2Cl2 (100 mL), washed with 10% Na2S2O3 (2x100 mL) and saturated NaHCO3 (100 mL). The organic layer was then dried over Na2SO4, filtered, and purified by flash chromatography (eluent: EtOAc / hexane, V / V) to generate a clear oily compound S13 (1.65 g, 1.92 mmol, 75%). Rf=0.45 (EtOAc / hexane, 1 / 1, V / V) [α] D 25 2.0(c 0.46,CHCl3) 1 H NMR (600MHz, CDCl3): δ7.37-7.26(m,5H),5.35(s,1H),5.33(s,1H),5.27(s,1H),5.10(s,1H),5 .09(s,1H),4.88(d,1H),4.83(br.s,1H),4.61(d,1H),3.85-3.71(m,1H),3.77-3.65(m,3H),3. 59(dd,1H),3.56-3.45(m,5H),3.44(s,3H),3.40(s,3H),3.38(s,3H),3.38-3.33(m,2H),3.32- 3.26(m,1H),2.13(s,3H),2.10(s,3H),2.08(s,3H),1.46(s,9H),1.33-1.30(m,6H),1.28(d,3H) 13 C NMR (150MHz, CDCl3): δ170.4,170.2,170.1,155.9,138.6,128.5(2C),128.1(2C),127.8,99.5,97.9,80.1,80.0,80.0,78. 7,78.4,75.5,68.7,68.5,68.0,67.9,67.8,67.3,67.1,57.6,57.5,57.3,40.4,28.5,21.2,21.1,18.3,18.1,17.9ESI-MS: C 41 H 63 O 18 NNa[M+Na] + Calculated m / z: 880.3937; found: 880.3943.
[0423]
[0424] 2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(tert-butyloxycarbonyl)amino]ethyl 2-O-acetyl-3-O-methyl-α-D-rhamnopyranoside (S14)
[0425] Palladium hydroxide on carbon (807.0 mg, 5.67 mmol) was added to MeOH (50 mL), and the solution was bubbled with H2 for 30 minutes. Next, compound S13 (1.65 g, 1.92 mmol) was added, and the solution was stirred at RT for 3 h under a continuous flow of H2. The reaction was then filtered through a pad of celite and evaporated to provide a clear oil S13 (1.57 g, 1.89 mmol, 98%). Rf = 0.20 (EtOAc / hexane, 1 / 1, V / V) [α] D 25 2.3(c 0.51,CHCl3) 1 H NMR (600MHz, CD3OD): δ5.40(dd,1H),5.36(s,1H),5.32(s,1H),5.10(d,1H),5.06(d,1H), 4.75(s,1H),3.88-3.82(m,1H),3.81-3.75(m,2H),3.75-3.71(m,1H),3.69(dd,1H),3.57( dd,1H),3.53-3.45(m,3H),3.43(s,3H),3.40(s,3H),3.39(s,3H),3.35-3.32(m,4H),3.32 -3.24(m,2H),2.13-2.11(m,6H),2.10(s,3H),1.50(s,9H),1.33-1.30(m,6H),1.29(d,3H) 13 C NMR (150MHz, CD3OD): δ171.7(2C),171.6,158.5,101.0,100.8,98.7,81.5,81.3,80.8,80.4,79.6,72.9 ,72.9,70.8,69.6,69.3,69.2,69.0,68.0,67.5,58.0,57.7,41.1,28.9,20.7,18.6,18.5,17.9ESI-MS: C 34 H 57 O 18 NNa[M+Na] + Calculated m / z: 790.3468; Found: 790.3462.
[0426]
[0427] 2-O-Acetyl-4-O-benzyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(tert-Butyloxycarbonyl)amino]ethyl 2-O-acetyl-3-O-methyl-α-D-rhamnopyranoside (S15)
[0428] Compound S14 (1.45 g, 1.89 mmol) and S8 (943.9 mg, 2.27 mmol) were co-evaporated with toluene (5 x 20 mL) and dried under high vacuum overnight. Anhydrous dichloromethane (50 mL) was added followed by 0.400 g of activated powdered Molecular sieves. The reaction was then cooled to -78 ° C under N2 atmosphere, and N-iodosuccinimide (727.0 mg, 2.64 mmol) was added, followed by trifluoromethanesulfonic acid (0.35 mL, 3.96 mmol). The reaction was stirred for 3 h and then reached completion. The reaction was then filtered through a Buchner funnel, diluted with CH2Cl2 (100 mL), washed with 10% Na2S2O3 (2x100 mL) and saturated NaHCO3 (100 mL). The organic layer was then dried over Na2SO4, filtered, and purified by flash chromatography (eluent: EtOAc / hexane, V / V) to generate a clear oily compound S15 (1.49 g, 1.41 mmol, 74%). Rf=0.40 (EtOAc / hexane, 1 / 1, V / V) [α] D 25 1.7(c 0.31,CHCl3) 1 H NMR (600MHz, CDCl3): δ7.37-7.26(m,5H),5.35(s,3H),5.28(s,1H),5.13-5.06(m,3H),4.89(d,1H),4.83(br.s,1H),4.70(s,1H),4.61(d,1H), 3.87-3.63(m,5H),3.63-3.57(m,1H),3.57-3.46(m,7H),3.44(s,3H),3 .41-3.24(m,13H),2.15-2.04(m,12H),1.46(s,9H),1.35-1.26(m,12H) 13C NMR (150MHz, CDCl3): δ170.1,170.3,170.2,170.1,155.9,138.6,128.5(2C),128.1(2C),127.9,99.6,99.5,97.9,80.1,80.0,79.9,79. 7,78.9,78.4,77.4,75.5,68.7,68.5,68.1,68.0,67.9,67.8,67.7,67.3,67.1,40.4,28.6,21.3,21.2,18.4,18.2,18.1,18.0ESI-MS: C 50 H 77 NO 23 H[M+H] + Calculated m / z: 1060.4959; found: 1060.4977.
[0429]
[0430] 2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(tert-Butyloxycarbonyl)amino]ethyl 2-O-acetyl-3-O-methyl-α-D-rhamnopyranoside (S16)
[0431] Palladium hydroxide on carbon (720.0 mg, 5.13 mmol) was added to MeOH (50 mL), and the solution was bubbled with H2 for 30 minutes. Next, compound S15 (1.42 g, 1.34 mmol) was added, and the solution was stirred at RT for 3 h under a continuous flow of H2. The reaction was then filtered through a pad of celite and evaporated to provide a clear oil S16 (1.30 g, 1.34 mmol, 100%). Rf = 0.15 (EtOAc / hexane, 3 / 2, V / V) [α] D 25 3.4(c 0.67,CHCl3) 1H NMR (600MHz, CD3OD): δ5.42(dd,1H),5.40(dd,1H),5.38(dd,1H),5.33(dd,1H),5.10(d,1H),5. 08(d,1H),5.06(d,1H),4.75(d,1H),3.90-3.82(m,2H),3.82-3.76(m,2H),3.76-3.72(m,1H),3 .72-3.66(dd,1H),3.62-3.55(m,2H),3.55-3.46(m,4H),3.46-3.43(s,3H),3.43-3.36(m,11H) ,3.33-3.22(m,2H),2.14-2.11(m,9H),2.11(s,3H),1.51(s,9H),1.36-1.31(m,9H),1.30(d,3H) 13 C NMR (150MHz, CD3OD): δ171.7(2C),171.6(2C),158.5,101.0,100.9,100.8,98.7,81.4,81.3,81.2,80.9,80.3,80.2,80.0,79 .6,72.9,70.7,69.6,69.3,69.2,69.1,69.0,68.9,68.0,67.6,58.0,57.6,41.1,29.0,20.7,18.6,18.5,18.4,17.9ESI-MS: C 43 H 71 O 23 NNa[M+Na] + Calculated m / z: 992.4309; found: 992.4313.
[0432]
[0433] 2-O-Acetyl-4-O-benzyl-3-O-methyl-α-D-rhamnoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnoside-(1→4)-2-(tert-Butyloxycarbonyl)amino]ethyl 2-O-acetyl-3-O-methyl-α-D-rhamnoside (S17)
[0434] Compound S16 (878.9 mg, 0.91 mmol) and S8 (452.9 mg, 1.09 mmol) were co-evaporated with toluene (5 x 20 mL) and dried under high vacuum overnight. Anhydrous dichloromethane (50 mL) was added followed by 0.200 g of activated powdered Molecular sieves. The reaction was then cooled to -78 ° C under N2 atmosphere, and N-iodosuccinimide (348.8 mg, 1.27 mmol) was added, followed by trifluoromethanesulfonic acid (0.15 mL, 1.70 mmol). The reaction was stirred for 3 h and then reached completion. The reaction was then filtered through a Buchner funnel, diluted with CH2Cl2 (50 mL), washed with 10% Na2S2O3 (2x 50 mL) and saturated NaHCO3 (50 mL). The organic layer was then dried over Na2SO4, filtered, and purified by flash chromatography (eluent: EtOAc / hexane, V / V) to generate a clear oily compound S17 (693.0 mg, 0.55 mmol, 64%). Rf=0.50 (EtOAc / hexane, 3 / 2, V / V) [α] D 25 1.5(c 0.27,CHCl3) 1 H NMR (600MHz, CDCl3): δ7.39-7.27(m,5H),5.33(s,4H),5.28(s,1H),5.10(s ,4H),4.88(d,1H),4.83(br.s,1H),4.70(s,1H),4.61(d,1H),3.86-3.54(m ,6H),3.62-3.46(m,10H),3.44(s,3H),3.41-3.34(m,13H),3.34-3.23(m,2 H),2.13(s,3H),2.10(s,3H),2.08(s,9H),1.46(s,9H),1.36-1.22(m,15H) 13 C NMR (150MHz, CDCl3): δ170.4,170.3,170.2,170.1,170.0,155.9,138.6,128.5(2C ),128.1(2C),127.9,99.7,99.6,99.5,99.4,97.9,80.1,80.0,79.9,79.7,78.8,78 .5,78.3,78.3,77.4,75.5,68.7,68.5,68.0,67.9,67.8,67.7,67.3,67.0,57.6,5 7.5,57.4(2C),57.3,40.4,28.5,21.2,21.1,18.4,18.3,18.2,18.1,17.9ESI-MS:C 59 H91 O 28 NH[M+H] + Calculated m / z: 1262.5800; found: 1262.5806.
[0435]
[0436] 2-O-Acetyl-3-O-methyl-α-D-rhamnoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnoside-(1→4)-2-O-Acetyl-3-O-methyl-α-D-rhamnoside-(1→4)-2-(tert-Butyloxycarbonyl)amino]ethyl 2-O-acetyl-3-O-methyl-α-D-rhamnoside (S18)
[0437] Palladium hydroxide on carbon (300.0 mg, 2.14 mmol) was added to MeOH (30 mL), and the solution was bubbled with H2 for 30 minutes. Next, compound S17 (623.3 mg, 0.49 mmol) was added, and the solution was stirred at RT for 3 h under a continuous flow of H2. The reaction was then filtered through a pad of celite and evaporated to provide a clear oil S18 (537.0 mg, 0.46 mmol, 93%). Rf = 0.25 (EtOAc / hexane, 3 / 2, V / V) [α] D 25 0.12(c 0.033,CHCl3) 1 H NMR (600MHz, CD3OD): δ5.44-5.41(m,3H),5.39(s,1H),5.34(dd,1H),5.11(s,1H),5.09(s ,2H),5.07(s,1H),4.76(s,1H),3.92-3.83(m,3H),3.83-3.77(m,2H),3.77-3.73(m,1H),3 .70(dd,1H),3.62-3.56(m,3H),3.56-3.46(m,6H),3.45(3H),3.45-3.38(m,15H),3.34-3 .24(m,2H),2.14-2.12(m,12H),2.11(s,3H),1.52(s,9H),1.36-1.32(m,12H),1.31(d,3H) 13C NMR (150MHz, CDCl3): δ171.7(2C),171.6(3C),158.4,101.0,100.8,98.6,81.4,81.3,81.2,80.9,80.3,80.2,81.1,80.0,79 .6,72.9,70.7,69.6,69.3,69.2,69.1,69.0,68.9,68.0,67.5,58.0,57.6,41.1,29.0,20.7,18.6,18.5(3C),17.9ESI-MS:C 52 H 85 O 28 NNa[M+Na] + Calculated m / z: 1194.5150; found: 1194.5153.
[0438]
[0439] 3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(tert-butyloxycarbonyl)amino]ethyl 3-O-methyl-α-D-rhamnopyranoside (S19)
[0440] Compound S14 (755.0 mg, 0.98 mmol) was dissolved in MeOH (30.0 mL) and sodium metal (15.0 mg, 0.65 mmol) was added. The reaction was stirred at RT for 16 h and concentrated with Dowex H + Neutralize, filter and evaporate. The crude product was then dissolved in CH2Cl2 (100 mL) and trifluoroacetic acid (5.8 mL) and stirred at RT for 10 mins, then evaporated under reduced pressure to yield beige powder S19 (532.4 mg, 0.98 mmol, 100%). [α]D 25 1.5(c 0.52,CH3OH) 1 H NMR (600MHz, CD3OD): δ5.13(s,2H),4.80(s,1H),4.12(s,1H),4.09(s,1H) ,4.07(s,1H),3.96-3.90(m,1H),3.80-3.74(m,2H),3.67-3.51(m,4H),3.5 2-3.45(m,1H),3.46(s,3H),3.44(s,3H),3.42(s,3H),3.41-3.35(m,1H),3 .29-3.24(m,1H),3.25-3.15(m,2H),1.32(d,3H),1.30(d,3H),1.26(d,3H) 13C NMR (150MHz, CD3OD): δ103.2,103.1,101.7,83.1,82.8,82.0,79.5,79.3,72.6,70.5, 69.1,68.7,68.3,68.0,67.5,64.6,57.3,56.7,56.6,40.5,18.7,18.6,17.9ESI-MS:C 23 H 43 O 13 NH[M+H] + Calculated m / z: 542.2807; found: 542.2804.
[0441]
[0442] 3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(tert-butyloxycarbonyl)amino]ethyl 3-O-methyl-α-D-rhamnopyranoside (S20)
[0443] Compound S16 (390 mg, 0.40 mmol) was dissolved in MeOH (30.0 mL) and sodium metal (10 mg, 0.44 mmol) was added. The reaction was stirred at RT for 16 h and concentrated with Dowex H + Neutralize, filter and evaporate. The crude product was then dissolved in CH2Cl2 (50 mL) and trifluoroacetic acid (2.4 mL) and stirred at RT for 10 mins, then evaporated under reduced pressure to yield a beige powder S20 (282.1 mg, 0.40 mmol, 100%). [α]D 25 1.1(c 0.13,CH3OH) 1 H NMR (600MHz, CD3OD): δ5.14(m,3H),4.81(s,1H),4.13(s,1H),4.09(s,3H ),3.96-3.91(m,1H),3.82-3.75(m,2H),3.75-3.67(m,2H),3.67-3.57(m ,4H),3.57-3.52(m,1H),3.51-3.42(m,12H),3.42-3.36(m,3H),3.31-3. 26(m,1H),3.25-3.15(m,2H),1.34(d,3H),1.32-1.28(m,6H),1.27(d,3H) 13C NMR (150MHz, CD3OD): δ103.2,103.1,103.0,101.7,83.1,83.0,82.8,79.4,79.3,79.2,72.6,70.5 ,69.1,68.7,68.4,68.4,68.0,67.5,64.6,57.3,56.7,56.6,40.4,18.7,18.5(2C),17.9ESI-MS:C 30 H 55 O 17 NH[M+H] + Calculated m / z: 702.3543; found: 702.3532.
[0444]
[0445] 3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(tert-butyloxycarbonyl)amino]ethyl 3-O-methyl-α-D-rhamnopyranoside (S21)
[0446] Compound S18 (500 mg, 0.47 mmol) was dissolved in MeOH (30.0 mL) and sodium metal (10 mg, 0.44 mmol) was added. The reaction was stirred at RT for 16 h and concentrated with Dowex H + Neutralize, filter and evaporate. The crude product was then dissolved in CH2Cl2 (50 mL) and trifluoroacetic acid (2.7 mL) and stirred at RT for 10 mins, then evaporated under reduced pressure to yield a beige powder S21 (402 mg, 0.47 mmol, 100%). [α]D 25 1.0(c 0.26,CH3OH) 1 H NMR (600MHz, CD3OD): δ5.15(s,4H),4.80(s,1H),4.14-4.12(m,1H),4.12-4.08(m,4H),3.96-3.91(m,1H),3.81-3.74(m,3H),3.75-3.67(m,2H ),3.67-3.58(5H),3.57-3.52(dd,1H),3.50-3.38(m,19H),3.31-3.28( dd,1H),3.26-3.15(m,2H),1.34(d,3H),1.32-1.28(m,9H),1.27(d,3H) 13C NMR (150MHz, CD3OD): δ103.2,103.1,103.0(2C),101.7,83.1(3C),82.8,82.0,79.4,79.3,79.2(2C),72.6,7 0.5,69.1(2C),68.7,68.4,67.4(2C),67.5,64.6,57.3,56.7,56.6(2C),40.4,18.7,18.6(3C),17.9ESI-MS:C 37 H 67 O 21 NH[M+H] + Calculated m / z: 862.4278; found: 862.4265.
[0447]
[0448] 3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(2,2-dimethoxybutylcarbonyl)amino]ethyl 3-O-methyl-α-D-rhamnopyranoside (S22)
[0449] 5,5-dimethoxypentanoic acid 2,5-dioxopyrrolidin-1-yl ester (239 mg, 0.92 mmol) is dissolved in anhydrous DMF (9.2 mL) and compound S19 (50 mg, 92 μmol) is added to the solution. The reaction is stirred at RT for 16 h and completed by adding 1 drop of EtN. The sample is evaporated under reduced pressure and co-evaporated with toluene (5 x 10 mL). The crude sample is then suspended in H2O (2 mL) and extracted with CHCl3 (5 x 1 mL). The water layer is collected, evaporated and purified by HPLC (C-18, H2O / MeOH) to produce a white powder S22 (7.4 mg, 10.8 μmol, 12%). 1 H NMR (600MHz, CD3OD): δ5.16-5.13(m,2H),4.75(d,1H),4.41(t,0.73H),4.13-4.08(m,2H),4.08-4.06(m,1H),3.84-3.71(m,3.5H),3.71-3 .65(m,1H),3.64-3.55(m,3H),3.55-3.37(m,17H),3.36-3.32(m,4H) ,3.29(dd,1H),2.26(t,1.6H),1.73-1.60(m,3.3H),1.33-1.25(m,9H) 13C NMR (150MHz, CD3OD): δ176.2,105.8,103.2,103.1,101.3,83.2,83.1,83.0,82.0,79.7,79.2,72.6, 70.5,69.0,68.3,68.0,67.6,67.0,57.3,56.7,53.5,53.4,40.2,36.6,33.1,22.0,18.7,18.6,17.8.
[0450]
[0451] 3-O-Methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-2-(2,2-dimethoxybutylcarbonyl)amino]ethyl 3-O-methyl-α-D-rhamnopyranoside (S23)
[0452] 5,5-dimethoxypentanoic acid 2,5-dioxopyrrolidin-1-yl ester (185mg, 0.71mmol) is dissolved in anhydrous DMF (7.1mL) and compound S20 (50.0mg, 71.2μmol) is added to the solution. The reaction is stirred at RT for 16h and completed by adding 1 drop of EtN. The sample is evaporated under reduced pressure and co-evaporated with toluene (5x 10mL). The crude sample is then suspended in H2O (2mL) and extracted with CHCl3 (5x 1mL). The collected water layer is evaporated and purified by HPLC (C-18, eluent: H2O / MeOH, V / V) to produce a white powder S23 (11.0mg, 13.0μmol, 18%). 1 H NMR (600MHz, CD3OD): δ5.16-5.13(m,3H),4.75(d,1H),4.41(t,1H),4.13-4.09(m,3H),4.07(dd,1H),3.82-3.71(m,4H),3.71-3.65(m,1H),3 .64-3.56(m,3H),3.54-3.47(m,6H),3.47-3.36(m,14H),3.35-3.32(m ,6H),3.31(dd,1H),2.26(t,2H),1.72-1.61(m,4H),1.34-1.25(m,12H) 13C NMR (150MHz, CD3OD): δ176.0,105.8,103.2,103.1,103.0,101.3,83.1,83.0,82.9,82.0,79.8,79.4,79.2,72.6,70 .5,69.1,69.0,68.4,68.3,68.0,67.7,67.0,57.3,56.7,53.5,53.4,40.2,36.6,33.1,22.0,18.7,18.6(2C),17.9.
[0453]
[0454] 3-O-Methyl-α-D-rhamnoside-(1→4)-3-O-methyl-α-D-rhamnoside-(1→4)-3-O-methyl-α-D-rhamnoside-(1→4)-3-O-methyl-α-D-rhamnoside-(1→4)-2-(2,2-dimethoxybutylcarbonyl)amino]ethyl 3-O-methyl-α-D-rhamnoside (S24)
[0455] 5,5-dimethoxypentanoic acid 2,5-dioxopyrrolidin-1-yl ester (150mg, 0.58mmol) is dissolved in anhydrous DMF (5.8mL) and compound S21 (50mg, 58.0μmol) is added to the solution. The reaction is stirred at RT for 16h and completed by adding 1 drop of EtN. The sample is evaporated under reduced pressure and co-evaporated with toluene (5x 10mL). The crude sample is then suspended in H2O (2mL) and extracted with CHCl3 (5x 1mL). The water layer is collected, evaporated and purified by HPLC (C-18, eluent: H2O / MeOH) to produce a white powder S24 (20.3mg, 20.2μmol, 35%). 1 H NMR (600MHz, CD3OD): δ5.17-5.13(m,4H),4.75(d,1H),4.41(t,1H),4.13-4.10(m,4H),4.07(dd,1H),3.82-3.71(m,5H),3.71-3.65 (m,1H),3.65-3.56(m,4H),3.52-3.38(m,22H),3.36-3.33(m,7H),3.31(dd,1H),2.26(t,1H),1.73-1.61(m,4H),1.34-1.25(m,15H) 13C NMR (150MHz, CD3OD): δ176.0,105.8,103.2,103.1,101.3,83.1,83.0,82.0,79.8,79.4,79.2,72.7,70.5,6 9.0(2C),68.3,68.0(2C),67.6,67.1,57.3,56.7,53.5,53.4,40.2,36.6,33.1,22.0,18.7,18.6(3C),17.9.
[0456] Example 6: Screening of novel oligosaccharide linkers in inhibition ELISA against mAb 1B1
[0457] Oligosaccharides (from Example 5) connected with a linker are shown to effectively mimic the methyl rhamnose tip epitope. The 1B1 mAb previously identified as having specificity for the methyl rhamnose tip at a constant concentration of 10ug / ml in PBS-Tween was incubated with dilutions of Pseudomonas aeruginosa (Pa) PAO1 BAA-47 (wt) lipopolysaccharide (LPS) (positive control for inhibition) and Neisseria meningitidis (Nm) galE / lpt3 LPS (negative control for inhibition) and synthetic oligosaccharides (S19-21) with a linker at a ratio of 1:1. The final concentration of mAb 1B1 was 5ug / ml. Starting with a concentration of 3mg / ml (final 1.5mg / ml), Pa and Nm LPS and synthetic oligosaccharides were titrated and diluted 2-fold, 12 times in PBS-Tween. The mixture was incubated together at room temperature for 1h, then added to the ELISA plate coated with Pa wt LPS and incubated at room temperature for 1h.
[0458] If there is enough LPS / oligosaccharides present during the inhibition step to bind all available 1B1, there will be no free 1B1 to bind to the LPS on the ELISA plate, and therefore there will be no color reaction in the ELISA. However, if the LPS / oligosaccharides do not bind to the antibody, or there is not enough LPS / oligosaccharides to block 1B1 binding, the intensity of color produced in the ELISA will be similar to incubation with PBS alone.
[0459] like Fig.33 As shown in , Pa wt LPS binds and blocks 1B1, as no color is produced in the ELISA until LPS is diluted to approximately 100 μg / ml. The irrelevant Nm LPS does not block 1B1 binding, nor does PBS.
[0460] Oligosaccharides blocked 1B1 binding to tetrasaccharides and pentasaccharides behaved similarly, titrating only at approximately 5 μg / ml, whereas trisaccharides also blocked binding but titrated earlier at approximately 100 μg / ml.
[0461] Thus, these results confirm the data from the oligosaccharides prepared earlier (without linkers). Addition of linkers to these oligosaccharides did not change the conformation of the oligosaccharide nor affect the ability of the oligosaccharide to bind and block mAb 1B1. Thus, the synthetic oligosaccharides with linkers effectively mimic the epitope on Pa recognized by mAb 1B1.
[0462] Example 7: Conjugation of oligosaccharide linkers to activated CRM (for immunization) and activated BSA (for screening) to prepare glycoconjugates
[0463] Aminooxy activation of CRM and BSA: Initially, the lysine of the protein (CRM or BSA) was activated by dissolving it in 200mM sodium phosphate buffer pH 7.4 at 10mg / ml and cooling it to 4°C. Then add about 85X molar excess of bromoacetic acid N-hydroxysuccinimide ester dissolved in DMSO at 3mg / ml and place it at 4°C for 18h. Then the bromine-activated protein was desalted (three times) to a volume of about 500μl using an amicon ultra-10 30K MWCO spin column. 500μl of 200mM sodium phosphate buffer pH 7.4 was added and cooled to 4°C. About 75X molar excess of 3-(aminooxy)-1-propanethiol hydrochloride dissolved in 100μl of 200mM sodium phosphate buffer pH 7.4 was added and placed at room temperature for 2 hours. Then the resulting aminooxy-activated protein was desalted (three times) using an amicon ultra-10 30K MWCO spin column. Activation levels were determined by MALDI MS (Table 6)
[0464] Activation of linkers to generate aldehyde functionalities: To convert linkers on S22, S23 and S24 into active aldehyde functionalities, oligosaccharides (S22-24) were dissolved in 50% acetic acid at 3 mg / ml and placed at 37° C. for 7 hours. Once cooled, the reaction mixture was then lyophilized.
[0465] Conjugation and characterization of conjugate: at 0 hour, 3 hours and 6 hours, 1 mg of activated oligosaccharide (three, four or five) dissolved in 50 μ l of 200 mM sodium phosphate buffer pH 6 was added to the activated protein. The amount of the activated protein used was adjusted in each case to keep the oligosaccharide of about 8X molar excess per aminooxy group of the protein. The reactant was placed at room temperature for 18 hours. Then amicon ultra-10 30K MWCO spin columns were used to separate the product (three times) for PBS and stored at 4 ° C.
[0466] 3 mg of each activated oligosaccharide (tri-, tetra- and penta-) was conjugated, representing approximately an 8X molar ratio per aminooxy group on the activated CRM (2.1 mg / 1.7 mg / 1.5 mg CRM-oxy groups for tri- / tetra- / penta-, respectively). The degree of conjugation was determined by MALDI MS (Table 6)
[0467] Table 6. Summary of activation and oligosaccharide loading of CRM and BSA conjugates
[0468]
[0469] Example 8: Immunization of mice and rabbits with the conjugate
[0470] Female BALB / c mice aged 6 to 8 weeks were immunized intraperitoneally three times. Each mouse received the same amount of oligosaccharide conjugates and SIGMA adjuvant and PBS buffer at each time point. Mice were primed on day 0 and received boosters on days 21 and 42, and blood samples were collected on days 0, 35 and 56.
[0471] Each mouse in the MRha3V group received 3ug of trisaccharide conjugate, resulting in 28ug of CRM, together with 50% v / v SIGMA adjuvant and a total of 100ul of PBS buffer, administered intraperitoneally. Each mouse in the MRha4V group received 3ug of tetrasaccharide conjugate, resulting in 25.5ug of CRM, together with 50% v / v SIGMA adjuvant and a total of 100ul of PBS buffer, administered intraperitoneally. Finally, each mouse in the MRha5V group received 3ug of pentasaccharide, resulting in 23ug of CRM, together with 50% v / v SIGMA adjuvant and a total of 100ul of PBS buffer, administered intraperitoneally. Blood samples were obtained by submandibular vein collection, and approximately 100ul of serum was produced after blood separation.
[0472] Example 9: Screening of derived mouse sera with BSA-conjugates and LPS
[0473] Individual sera from mice that had received a prime and two boost immunization regimen were screened for their ability to recognize BSA-oligosaccharide conjugates and Pa wt LPS in ELISA.
[0474] All mice produced good IgM responses to the conjugates as measured by their relative abundance in ELISA relative to pre-immune sera ( Fig.34A ) recognizes BSA-oligosaccharide conjugates ( Fig.35A -C) and relative to pre-immune serum ( Fig.34B ) for LPS( Fig.35D All mice produced moderate IgG responses to the conjugate, as measured by their relative IgG levels in ELISA relative to pre-immune sera ( Fig.36A ) recognizes BSA-oligosaccharide conjugates ( Fig.37A Similarly, all mice receiving the tetrasaccharide and pentasaccharide conjugates produced moderate IgG responses to the conjugates, as evidenced by their relative IgG levels in ELISA relative to pre-immune sera ( Fig.36B )Identify LPS( Fig.37B Because mice immunized with CRM-tetrasaccharide and pentasaccharide conjugates showed improved IgG responses to Pa wt LPS in ELISA relative to mice receiving trisaccharide conjugates ( Fig.37B ), so it can be shown from the mouse data that the minimum length of the oligosaccharide required to effectively mimic the native antigen is a tetrasaccharide. Whole cells killed as detailed in Table 7 were screened in ELISA for recognition by the generated sera.
[0475] Example 10: Screening of derived rabbit serum with BSA-conjugates and LPS
[0476] All rabbits developed a good immune response to the conjugates as shown by their recognition of the BSA-oligosaccharide conjugates relative to pre-immune sera in ELISA ( Fig.38A Similarly, all rabbits developed a good immune response to the conjugate as shown by their recognition of LPS in ELISA relative to pre-immune sera ( Fig.38B All rabbits developed a strong response (endpoint titers in the 1:10,000 range) that recognized several different LPS molecules.
[0477] Example 11: Screening of Derived Mouse and Rabbit Sera and Killed Whole Cells
[0478] Whole cell ELISAs were performed on a panel of P. aeruginosa killed cells (Table 7), including wild-type strains, strains with mutations in genes thought to be associated with A-banding methylrhamnan, and strains of the serotypes most commonly encountered in clinical settings.
[0479] Table 7. List of cells screened in whole cell ELISA.
[0480] Species strain NRCC# Serotype detail source Pseudomonas aeruginosa PAO1 BAA-47 6678 5 wild type ATCC PAO1 6667 - PAO1(wzy::Gm) Lam lab PAO1 6668 - PAO1(wzy::Gm)(Δpa5457) Lam lab PAO1 6669 - PAO1(wzy::Gm)(Δpa5458) Lam lab PAO1 6670 - PAO1(wzy::Gm)(Δpa5459) Lam lab 5933 6954 1 33348 ATCC 5934 6955 2 33349 ATCC 5939 6956 6 33354 ATCC 5943 6957 10 33357 ATCC 5944 6958 11 33358 ATCC 170003 6959 16 33363 ATCC 5937 6960 5 33352 ATCC 001S4-1 6944 - Clinical isolates Sad lab 003S-20 6945 - Clinical isolates Sad lab 003E-9 6946 - Clinical isolates Sad lab 004S-3 6947 - Clinical isolates Sad lab 004E-8 6948 - Clinical isolates Sad lab 006S3-1 6949 - Clinical isolates Sad lab 006S4-1 6950 - Clinical isolates Sad lab 009S-7 6951 - Clinical isolates Sad lab 014S-1 6952 - Clinical isolates Sad lab 014E-31 6953 - Clinical isolates Sad lab Moraxella catarrhalis lgt2 / lgt4 6541 - Negative control Cox lab Neisseria meningitidis 8047lpt3 6263 - Negative control Cox lab
[0481] like Fig.39A As shown in , cells were recognized by pooled sera from immunized mice with the oligosaccharide vaccine they received. Again, sera from the trisaccharide conjugates produced a weaker response when compared to the clear responses elicited by the tetrasaccharide and pentasaccharide conjugates, indicating that the methylrhamnose tip epitope is visible in the context of whole cells and that the oligosaccharide conjugates are able to generate an immune response capable of recognizing this epitope.
[0482] After immunization, individual rabbit sera recognize cells, e.g. Fig.39B As shown, the methylrhamnose tip epitope is visible in the context of whole cells and that the oligosaccharide conjugates (tri-, tetra-, and penta-) are able to generate an immune response that recognizes this epitope. In addition, when rabbit sera were screened against a series of clinical isolates from our collection (Table 7), Fig.39C ), good cross-reactivity was again observed against most strains, further demonstrating the conservation of this epitope and the ability of the oligosaccharide-based conjugates to generate the desired immune response.
[0483] Consistent with earlier data with LPS and BSA conjugates, whole cell ELISA confirmed that mice require a tetrasaccharide as the minimum length of the oligosaccharide necessary to promote an appropriate response. However, rabbit-derived sera did not exhibit this same minimum length requirement, as all conjugates were able to elicit similar cross-reactive responses.
[0484] In summary, these results demonstrate that at least CRM conjugates of synthetic tetrasaccharides and pentasaccharides representing the methylrhamnan A-band tip epitope are able to elicit specific immune responses recognizing Pa wt LPS and whole cells representing the serotypes most frequently encountered in the clinical setting, illustrating their potential as viable alternatives to isolated antigens as vaccine immunogens.
[0485] The specific embodiments described herein are intended to be examples only. Those skilled in the art may make changes, modifications and variations to the specific embodiments. The scope of the claims should not be limited by the specific embodiments set forth herein, but should be interpreted in a manner consistent with the specification as a whole.
[0486] All publications, patents, and patent applications mentioned in this specification are indicative of the levels of skill of those skilled in the art to which this invention pertains and are incorporated herein by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0487] The present invention has thus been described, it will be apparent that the invention may be varied in many ways. Such variations should not be regarded as departing from the spirit and scope of the present invention, and it will be apparent to those skilled in the art that all such modifications are intended to be included within the scope of the appended claims.
[0488] References
[0489] The contents of each of the following references are incorporated herein by reference in their entirety.
[0490] 1.Plackett,B.,No money for new drugs,Nature 586(2020)S50-S52.
[0491] 2.Jansen,K.U.,Anderson,A.S.,The role of vaccines in fightingantimicrobial resistance,Hum.Vaccines Immunother.14(2018)2142-2149.
[0492] 3.Grimwood et al.,Vaccination against respiratory Pseudomonasaeruginosa infection,Hum.Vaccines Immunother.11(2015)14-20.
[0493] 4.Adlbrecht et al.,Efficacy,immunogenicity,and safety ofIC43recombinant Pseudomonas aeruginosa vaccine in mechanically ventilatedintensive care patients-a randomized clinical trial,Crit.Care,24(2020)74.
[0494] 5.Merakou,C.,Schaefers,M.M.,Priebe,G.P.,Progress toward the elusivePseudomonas aeruginosa vaccine,Surg.Infect.8(2018)757-768.
[0495] 6.V.L.Campodónico et al.,Efficacy of a conjugate vaccine containingpolymannuronic acid and flagellin against experimental Pseudomonas aeruginosalung infection in mice,Infect.Imun.79(2011)3455-3464.
[0496] 7.Hegerie et al.,Development of a broad spectrum glycoconjugatevaccine to prevent wound and disseminated infections with Klebsiellapneuoniae and Pseudomonas aeruginosa,PLOS ONE(2018)https: / / doi.org / 10.1371 / journal.pone.0203143.
[0497] 8.DiGiandomenico et al.,Identification of broadly protective humanantibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypicscreening.J Exp Med 209(2012)1273-1287
[0498] 9.DiGiandomenico et al.,A multifunctional bispecific antibodyprotects against Pseudomonas aeruginosa.Sci Transl Med 6(2014)262ra155
[0499] 10.Horn et al.,Preclinical in vitro and in vivo characterization ofthe fully human monoclonal IgM antibody KBPA101 specific for Pseudomonasaeruginosa serotype IATS-O11.(2010)Antimicrob.Ag.Chemother.54:2338-2344.
[0500] 11.Loos et al.,Pre-clinical and phase I safety data for anti-Pseudomonas aeruginosa human monoclonal antibody AR-105.(2019)Open ForumInfect.Dis.6:S307–S308.
[0501] 12.AstraZeneca.2019.AstraZeneca pipeline update.April 2020.https: / / www.astrazeneca.com / content / dam / az / PDF / 2020 / q12020 / Q1_2020_re sults_clinical_trials_appendix.pdf
[0502] 13.Patel et al.,An engineered bispecific DNA encoded IgG antibodyprotects against Pseudomonas aeruginosa in a pneumonia challenge model.(2017)Nat.Commun.8:637-648.
[0503] 14.Dasgupta et al.,Characterization of lipopolysaccharide-deficientmutants of Pseudomonas aeruginosa derived from serotypes 03,05,and06.Infect.Immun(1994)62:809-817
[0504] 15.Byrd et al.,Genetic and biochemical analyses of the Pseudomonasaeruginosa Psl exopolysaccharide reveal overlapping roles for polysaccharidesynthesis enzymes in Psl and LPS production.Mol.Microbiol.(2009)73:622-638
[0505] 16.Sadovskaya et al.,High-level antibiotic resistance in Pseudomonasaeruginosa biofilm:the ndvB gene is involved in the production of highlyglycerol-phosphorylated beta-(1->3)-glucans,which bindaminoglycosides.Glycobiology 20(2010)895-904.
[0506] 17.Knirel,Y.A.and Kocharova,N.A.,Structure and properties of thecommon polysaccharide antigen of the bacterium Pseudomonasaeruginosa.Biochemistry(Moscow)60(1995)1499-1507.
[0507] 18.Yokota et al.,Characterization of a polysaccharide component oflipopolysaccharide from Pseudomonas aeruginosa IID 1008(ATCC 27584)as D-rhamnan.Eur.J.Biochem.167(1987)203-209.
[0508] 19.Vinogradov et al.,Structures of lipopolysaccharides fromKlebsiella pneumoniae.Eluicidation of the structure of the linkage regionbetween core and polysaccharide O chain and identification of the residues atthe non-reducing termini of the O chains.J Biol Chem.(2002)277:25070-25081.
[0509] 20.Wang et al.,Biosynthesis of the Common Polysaccharide Antigen ofPseudomonas aeruginosa PAO1:Characterization and Role of GDP-D-Rhamnose:GlcNAc / GalNAc-Diphosphate-Lipidα1,3-D-Rhamnosyltransferase WbpZ.J.Bacteriol.(2015)197:2012-2019.
[0510] 21.Arsenault et al.,Structural studies on the polysaccharide portionof"A-band"lipopolysaccharide from a mutant(AK1401)of Pseudomonas aeruginosastrain PAO1.Can.J.Chem.69(1991)1273-1280
[0511] 22.Cox et al.,Investigating the candidacy of a capsularpolysaccharide-based glycoconjugate as a vaccine to combat Haemophilusinfluenzae type a disease:a vaccine solution for an unmet public healthneed.Vaccine(2017)35:6129-36.
[0512] 23.St.Michael et al.,Investigating the candidacy of the serotypespecific rhamnan polysaccharide based glycoconjugates to prevent diseasecaused by the dental pathogen Streptococcus mutans.Glycoconj.J.(2018)35:53-64.
[0513] 24.Cairns et al.,Development and characterisation of mouse monoclonalantibodies specific for Clostridiodes(Clostridium)difficile lipoteichoicacid,utilising synthetic molecules to define a minimal epitope.ACS Chem.Biol.(2020)15:1050-1058.
[0514] 25.Makarenko et al.,Immunological studies of an artificial antigenwith specificity of a common polysaccharide antigen of Pseudomonasaeruginosa.FEMS Imm.Med.Microbiol.(1993)7:251-256.
[0515] 26.Lam et al.,Occurrence of a common lipopolysaccharide antigen instandard and clinical strains of Pseudomonas aeruginosa.(1989)J.Clin.Microbiol.27:962–967.
[0516] 27.Richard et al.,Antibody binding to the O-specific antigen ofPseudomonas aeruginosa O6 inhibits cell growth.Antimrob.Ag.Chemother.(2020)64:e02168-19
[0517] 28.Zunk,M.and Kiefel,M.J.,An efficient synthesis of selectivelyfunctionalized d-rhamnose derivatives,Tetrahedron Lett.,52(2011)1296-1299.
[0518] 29.Fauréet al.,Practical synthesis of valuable d-rhamnoside buildingblocks for oligosaccharide synthesis,Tetrahedron.Lett.48(2007)2385-2388.
[0519] 30.Seepersaud et al.,Ceric ammonium nitrate / acetic anhydride:Atunable system for the O-acetylation and mononitration of diversely protectedcarbohydates,Synth.Commun.47(2017)853-871.
[0520] 31.Blattner et al.,Syntheses of oligomannosides in solution and on asoluble polymer support:a comparison,Carbohydr.Res.341(2006)299-321.
[0521] 32.Nagashima,N.and Ohno,M.,An efficient O-monoalkylation of dimethyll-tartrate via O-stannylene acetal with alkyl halides in the presence ofcesium fluoride,Chem.Lett.,16(1987)141-144.
[0522] 33.Leontein,K.and J.,Determination of the absoluteconfiguration of sugars by gas-liquid chromatography of their acetylated 2-octyl glycosides,in:J.N.BeMiller,R.L.Whistler,D.H.Shaw(Eds.),Methods inCarbohydrate Chemistry,Stockholm,John Wiley&Sons,Inc.,1993,pp.87-89.
[0523] 34.Wang,L.and Lowary,T.L.,Synthesis of rhamnolipid derivativescontaining ester isoteres,Org.Lett.22(2020)9633-9637.
[0524] 35.Domon,B.and Costello,C.E.,A systematic nomenclature forcarbohydrate fragments in FAB-MS / MS spectra of glycoconjugates,GlycoconjugateJ,5(1988)397-409.
[0525] 36.Dass,C.,Fundamentals of Contemporary Mass Spectrometry,Hoboken,NewJersey,John Wiley&Sons,Inc.,2007,pp.17-26.
[0526] 37.Crawford,C.J.and Oscarson,S.,Convergent total synthesis ofCryptococcus neoformans serotype B capsule repeating motif,Carbohydr.Res.497(2020),https: / / doi.org / 10.1016 / j.carres.
[0527] 38.Qin et al.,Chemical synthesis of Pseudomonas aeruginosa O11 O-antigen trisaccharide based on neighboring electron-donating effect,J.Carbohydr.Chem.39(2020)374-397.
[0528] 39.X.Zhang,D.Wang,G.Jin,L.Wang,Z.Guo,G.Gu,Synthesis of atetrasaccharide repeating unit of the exopolysaccharide from Burkholderiamultivorans,J.Carb.Chem.36(2017)189-204.
[0529] 40.D.Wang,W.Zhuge,Z.Guo,G.Gu,Synthesis of a disaccharide repeatingunit of the O-antigen from Burkholderia ambifaria and its oligomers,Carb.Res.442(2017)41-51.
[0530] 41.M.P.Jamshidi,C.Cairns,S.Chong,F.St.Micheal,E.V.Vinogradov,A.D.Cox,J.Sauvageau,Synthesis and Immunogenicity of a Methyl Rhamnan PentasaccharideConjugate from Pseudomonas aeruginosa A-Band Polysaccharide,ACS Infect.Dis.8(2022)1347-1355.
[0531] 42.Munneke S,Dangerfield EM,Stocker BL,Timmer MSM.The versatility ofN-alkyl-methoxyamine bi-functional linkers for the preparation ofglycoconjugates.Glycoconj J.2017 Oct;34(5):633-642.doi:10.1007 / s10719-017-9785-4.Epub 2017 Jul 19.PMID:28725972.
[0532] 43.Bethell et al.,1979,J.Biol.Chem.254:2572-4;Hearn et al.,1981,J.Chromatogr.218:509-18.
Claims
1. An antigenic compound comprising an oligosaccharide portion of formula A: α-Rha3OMe(-4α-Rha3OMe) n - Formula A wherein n is 1-5, preferably 2-4, and wherein the 2-position in each Rha3OMe sugar moiety is independently substituted with -OAc or -OH.
2. The antigenic compound according to claim 1, which has the formula A1: α-Rha3OMe(-4α-Rha3OMe) n -X Formula A1 in n is 1-5, and X is -H or -(4α-Man3OMe) m - a connecting handle; and m is 0, 1 or 2, preferably 0 or 1; wherein the 2-position in each Rha3OMe sugar moiety is independently substituted with -OAc or -OH.
3. The antigenic compound of claim 2, wherein when m is 1 or 2, the linker is 2-glyceraldehyde, wherein when m is 0, the linker is -(CH2) z NH 2 , and wherein z is an integer selected from the group consisting of 1-5.
4. The compound according to claim 1, selected from the group consisting of: ·α-D-Rha3OMe-4-(α-D-Rha3OMe-4) 4 -4-α-D-Man3OMe-2-glyceraldehyde-1d(OS2); ·3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside (pentasaccharide); ·3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside (tetrasaccharide) ·3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside-(1→4)-3-O-methyl-α-D-rhamnopyranoside (trisaccharide) 5. The antigenic compound according to any one of claims 1 to 4, which further comprises a linker for attachment to a carrier protein and has formula A2: α-Rha3OMe(-4α-Rha3OMe) n -X-Connector Type A2 in n is 1-5, and X is -(4α-Man3OMe) m -(Connecting handle) p -; m is 0, 1 or 2, preferably 0 or 1; and p is 0 or 1, wherein the 2-position in each Rha3OMe sugar moiety is independently substituted with -OAc or -OH.
6. A conjugate comprising the compound according to any one of claims 1 to 5 conjugated to a carrier protein.
7. The conjugate of claim 6, wherein the carrier protein comprises CRM197, tetanus toxoid (TT), Pseudomonas aeruginosa protein, human serum albumin (HSA), bovine serum albumin (BSA), diphtheria toxin B fragment (DTFB), DTFB C8, diphtheria toxoid (DT), C fragment of TT, pertussis toxoid, cholera toxoid, Escherichia coli LT, Escherichia coli ST, or exotoxin from Pseudomonas aeruginosa.
8. A pharmaceutical composition comprising: A compound according to any one of claims 1 to 5 or a conjugate according to claim 6 or 7; and Pharmaceutically acceptable diluents, adjuvants, carriers or excipients.
9. A vaccine comprising the compound according to any one of claims 1 to 5, the conjugate according to any one of claims 6 to 7, or the pharmaceutical composition according to claim 8.
10. A method of enhancing an immune response in a subject, comprising administering to the subject: a compound according to any one of claims 1 to 5, a conjugate according to any one of claims 6 to 7, a pharmaceutical composition according to claim 8, or a vaccine according to claim 9.
11. A method for preventing Pseudomonas aeruginosa infection in a subject, the method comprising administering to the subject: a compound according to any one of claims 1 to 5, a conjugate according to any one of claims 6 to 7, a pharmaceutical composition according to claim 8, or a vaccine according to claim 9.
12. The compound according to any one of claims 1 to 5, the conjugate according to any one of claims 6 to 7, the pharmaceutical composition according to claim 8, or the vaccine according to claim 9 for use in preventing Pseudomonas aeruginosa infection.
13. An antibody or antigen-binding fragment thereof that selectively binds to: The compound according to any one of claims 1 to 5, The conjugate according to any one of claims 6 to 7, LPS of Pseudomonas aeruginosa, and / or Pseudomonas aeruginosa cells.
14. An antibody or antigen-binding fragment thereof that selectively binds to the isolated oxidized A-band terminal epitope antigen (OS2) of the formula: α-D-Rha3OMe-4-(α-D-Rha3OMe-4) 4 -4-α-D-Man3OMe-2-glyceraldehyde-1d(OS2).
15. The antibody or antigen-binding fragment thereof according to claim 13 or 14, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.
16. The antibody or antigen-binding fragment thereof according to any one of claims 13 to 15, which is a chimeric or humanized antibody.
17. The antibody or antigen-binding fragment thereof according to any one of claims 13 to 16, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a variable heavy chain CDR1, a variable heavy chain CDR2 and a variable heavy chain CDR3, wherein the variable heavy chain CDR1 comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 10, and SEQ ID NO: 19; wherein the variable heavy chain CDR2 comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 11, and SEQ ID NO: 20; and Wherein the variable heavy chain CDR3 comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, SEQ ID NO:12 and SEQ ID NO:
21.
18. The antibody or antigen-binding fragment thereof according to claim 17, further comprising a light chain variable region, wherein the light chain variable region comprises a variable light chain CDR1, a variable light chain CDR2 and a variable light chain CDR3, wherein the variable light chain CDR1 comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:6, SEQ ID NO:15, and SEQ ID NO:24; wherein the variable light chain CDR2 comprises an amino acid sequence selected from the group consisting of: GTS and RVS; and wherein the variable light chain CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:16 and SEQ ID NO:
25.
19. The antibody or antigen-binding fragment thereof according to any one of claims 13 to 16, comprising a combination of a heavy chain variable region (VH) and a light chain variable region (VL), wherein the combination is selected from the group consisting of: a VH comprising the amino acid sequence of SEQ ID NO: 4 and a VL comprising the amino acid sequence of SEQ ID NO: 8; a VH comprising the amino acid sequence of SEQ ID NO: 13 and a VL comprising the amino acid sequence of SEQ ID NO: 17; and A VH comprising the amino acid sequence of SEQ ID NO:22 and a VL comprising the amino acid sequence of SEQ ID NO:
26.
20. The antibody or antigen-binding fragment thereof according to any one of claims 13 to 19 for use in treating Pseudomonas aeruginosa infection.
21. The antibody or antigen-binding fragment thereof according to any one of claims 13 to 19 for use in diagnosing Pseudomonas aeruginosa infection.
22. A method for treating a Pseudomonas aeruginosa infection, the method comprising administering to a subject the antibody or antigen-binding fragment thereof according to any one of claims 13 to 19.
23. A method for diagnosing a Pseudomonas aeruginosa bacterial infection in an animal, preferably a human, comprising contacting a test sample with the antibody or antigen-binding fragment thereof according to any one of claims 13 to 19, and detecting specific binding thereto.
24. A synthetic method for preparing a compound of formula A1 according to claim 2, wherein m is 0, said method include: Deprotecting the anomeric portion of the 3-O-methylated rhamnopyranoside to form 3-O-methylated rhamnopyranose; Acetylation of 3-O-methylated rhamnopyranose to form acetylated 3-O-methylated rhamnopyranoside; Partially deprotecting the O-4 of the acetylated 3-O-methylated rhamnopyranoside to form a deprotected acetylated 3-O-methylated rhamnopyranoside; · coupling the O-4 deprotected acetylated 3-O-methylated rhamnopyranoside to form the acetylated 3-O-methylated oligosaccharide; deprotecting the O-4 of the acetylated 3-O-methylated oligosaccharide to form an O-4 deprotected acetylated 3-O-methylated oligosaccharide; and • Deacetylation of the partially deprotected acetylated 3-O-methylated oligosaccharide to form a compound of formula A1.
25. A synthetic method for preparing a compound of formula A1 according to claim 2, wherein X is a linker handle, said method The following steps are involved: glycosylation of an activated O-3 methylated rhamnopyranoside intermediate at 1-O with a linker handle comprising a protected amine, wherein the activated monorhamnopyranoside intermediate comprises a protecting group at glycosylation site 4-O, and forming a protected 1-O glycoside intermediate; Removal of the protecting group from 4-O and formation of a deprotected 1-O glycoside intermediate; and coupling the deprotected 1-O glycoside intermediate to an activated O-3 methylated rhamnopyranoside intermediate, wherein the activated rhamnopyranoside intermediate comprises a protecting group at 4-O, and forming a protected methylated disaccharide, trisaccharide, tetrasaccharide or pentasaccharide; and removing all protecting groups from a protected disaccharide, trisaccharide, tetrasaccharide or pentasaccharide.
Citation Information
Patent Citations
Uronium salt conjugate vaccines
WO1998042721A1
